04-13-01 PCT

JC17 Rec'd PCT/PTO 11 APR 2001



| FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE<br>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 | | ATTORNEY'S DOCKET NUMBER<br>PF-0619 USN<br>U.S. APPLICATION NO (If known, see 37 CFR 1.5)<br>TO BE ASSIGNED 09/807452 |
|---|---|---|
| INTERNATIONAL APPLICATION NO<br>PCT/US99/24511 | INTERNATIONAL FILING DATE<br>19 October 1999 | PRIORITY DATE CLAIMED<br>20 October 1998 |

TITLE OF INVENTION
**PROLIFERATION AND APOPTOSIS RELATED PROTEINS**

APPLICANT(S) FOR DO/EO/US
**INCYTE PHARMACEUTICALS, INC.; TANG, Y. Tom; YUE, Henry; HILLMAN, Jennifer L.; GUEGLER, Karl J.; CORLEY, Neil C.; LAL, Preeti; AZIMZAI, Yalda; BAUGHN, Mariah R.; JUNMING, Yang; SHIH, Leo L.**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is the **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to promptly begin national examination procedures (35 U.S.C. 371 (f)).
4. ☐ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. ☐ is attached hereto (required only if not communicated by the International Bureau)
   b. ☐ has been communicated by the International Bureau.
   c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C 371(c)(3))
   a. ☐ are attached hereto (required only if not communicated by the International Bureau).
   b. ☐ have been communicated by the International Bureau
   c ☐ have not been made, however, the time limit for making such amendments has NOT expired.
   d. ☒ have not been made and will not be made
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C 371(c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11 to 16 below concern document(s) or information included:**

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.27 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
    ☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:

1) Transmittal Letter (2 pp, in duplicate)
2) Return Postcard
3) Express Mail Label No.: **EL 856 113 274 US**

JC02 Rec'd PCT/PTO 11 APR 2001

| U.S. APPLICATION NO (if known, see 37 CFR 1.5) TO BE ASSIGNED | INTERNATIONAL APPLICATION NO PCT/US99/24511 | ATTORNEY'S DOCKET NUMBER PF-0619 USN |
|---|---|---|

09/807452

17. ☒ The following fees are submitted:

**BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5):**

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....$1000 00

☐International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..$860.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... $710.00

☒**International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....$690.00**

☐International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)..... ....$100.00

| | | | | | |
|---|---|---|---|---|---|
| **ENTER APPROPRIATE BASIC FEE AMOUNT =** | | | | $690.00 | |
| Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)). | | | | $ | |
| CLAIMS | NUMBER FILED | NUMBER EXTRA | RATE | | |
| Total Claims | 20 - | 0 | X **$ 18.00** | $ | |
| Independent Claims | 2 = | 0 | X **$ 80.00** | $ | |
| MULTIPLE DEPENDENT CLAIM(S) (if applicable) | | | + **$270.00** | $ | |
| **TOTAL OF ABOVE CALCULATIONS =** | | | | $690.00 | |
| ☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. | | | | $ | |
| **SUBTOTAL =** | | | | $690.00 | |
| Processing fee of **$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1492(f)). + | | | | $ | |
| **TOTAL NATIONAL FEE =** | | | | $690.00 | |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by the appropriate cover sheet (37 CFR 3.28, 3.31). **$40.00** per property + | | | | $ | |
| **TOTAL FEES ENCLOSED =** | | | | $690.00 | |
| | | | | Amount to be Refunded | $ |
| | | | | Charged | $ |

a. ☐ A check in the amount of $_____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 09-0108 in the amount of $ 690.00 to cover the above fees.

c. ☐ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

INCYTE GENOMICS, INC.
3160 Porter Drive
Palo Alto, CA 94304

SIGNATURE

NAME: Diana Hamlet-Cox

REGISTRATION NUMBER 33,302

DATE: 11 April 2001

# PROLIFERATION AND APOPTOSIS RELATED PROTEINS

## TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of proliferation and apoptosis related proteins and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, immunological, and reproductive disorders.

## BACKGROUND OF THE INVENTION

Tissue growth involves complex and ordered patterns of cell proliferation, cell differentiation, and regulated cell death (apoptosis). Cell proliferation and apoptosis are regulated to maintain both the number and the spatial organization of cells. This regulation depends on appropriate expression of proteins which control cell cycle progression in response to extracellular signals, such as growth factors and other mitogens, and intracellular cues, such as DNA damage or nutrient starvation. Molecules which directly or indirectly modulate cell cycle progression fall into several categories, including growth factors and their receptors, second messenger and signal transduction proteins, oncogene products, tumor-suppressor proteins, and mitosis-promoting factors. Cancers are characterized by continuous or uncontrolled cell proliferation. Some cancers are associated with suppression of normal apoptotic cell death.

Growth Factors and Signal Transduction Machinery

Growth factors are typically large, secreted polypeptides that act on cells in their local environment to promote cell proliferation. Growth factors bind to and activate specific cell surface receptors that initiate intracellular signal transduction cascades. Many growth factor receptors are classified as receptor tyrosine kinases that undergo autophosphorylation upon ligand binding. Autophosphorylation enables the receptor to interact with signal transduction proteins such as SH2 or SH3 (Src homology regions 2 or 3) domain-containing proteins. Other proteins that act downstream of growth factor receptors contain unique signaling domains such as the SPRY (Sp1a and ryanodine receptor) domain. (See, for example, Schultz, J. et al. (1998) Proc. Natl. Acad. Sci. USA 95:5857-5864.) These proteins then modulate the activity state of small G-proteins, such as Ras, Rab, and Rho, along with GTPase activating proteins (GAPs), guanine nucleotide releasing proteins (GNRPs), and other guanine nucleotide exchange factors. Small G proteins act as molecular switches that turn on mitogen-activated protein kinase (MAP kinase) cascades. MAP kinase activates transcription of the early-response genes discussed below.

Most growth factors also have a multitude of other actions besides the regulation of cell growth and division: they can control the proliferation, survival, differentiation, migration, or function

of cells depending on the circumstance. For example, epidermal growth factor (EGF) protects gastric mucosa against injury and accelerates ulcer healing by stimulating cell migration and proliferation. EGF binds the transmembrane protein tyrosine kinase EGF-R to trigger a series of events that results in activation of the Ras/Raf/MAP kinase pathway by the GTP-binding protein Ras. Other pathways potentially activated by EGF include the phosphatidylinositol pathway and the JAK/STAT signaling pathway (Tarnawski, A.S. et al. (1998) J. Clin. Gastroenterol. 27:S12-S20).

In addition to growth factors, small signaling peptides and hormones also influence cell proliferation. These molecules bind primarily to another class of receptor, the trimeric G-protein coupled receptor (GPCR), found predominantly on the surface of immune, neuronal, and neuroendocrine cells. Upon ligand binding, the GPCR activates a trimeric G protein which in turn triggers increased levels of intracellular second messengers such as phospholipase C, $Ca^{2+}$, and cyclic AMP. Most GPCR-mediated signaling pathways indirectly promote cell proliferation by causing the secretion or breakdown of other signaling molecules that have direct mitogenic effects (Smith, A. et al. (1994) Cell 76:959-962).

Protein kinase C (PKC) plays a central role in the control of proliferation and differentiation of various cell types by mediating the signal transduction response to hormones and growth factors. The PKC family of serine/threonine kinases includes twelve different isoforms which have similar catalytic domains at their C-termini, but differ in their N-terminal regulatory domains. Since most cells express multiple PKC isoforms, the specificity of each enzyme for its substrate is achieved by targeting individual isoenzymes to a select location in the cell, either constitutively or upon cell stimulation. A variety of PKC-binding proteins and lipids have been identified that may function to compartmentalize PKC isoenzymes, including RACK1, serum deprivation response (sdr) protein, and SRBC (sdr-related gene product that binds C-kinase). Interestingly, both sdr and SRBC appear to provide localization of activated PKC to caveolae, but each has specificity for a different isoenzyme; sdr interacts specifically with PKCα and SRBC interacts with PKCδ. Both sdr and SRBC are induced during stages of growth arrest, and were originally isolated from serum-deprived cultured cells. Thus, sdr and SRBC appear to be important for targeting activated PKC isoenzymes to subcellular signaling sites important in growth control. (Mineo, C. et al. (1998) J. Cell Biol. 141:601-610; and Izumi, Y. et al. (1997) J. Biol. Chem. 272:7381-7389.)

Oncogenes

Oncogenes (i.e. "cancer-causing genes") are involved in the reception and transduction of growth factor signals and in the modulation of gene expression in response to these signals. For example, stimulation of a cell by growth factor activates two sets of genes, the early-response genes and the delayed-response genes. Early-response gene products include myc, fos, and jun, all of

which encode gene regulatory proteins. These regulatory proteins activate the transcription of the delayed-response genes which encode proteins directly involved in cell cycle progression, such as the cyclins and cyclin dependent kinase discussed below. Additional oncogene products which directly regulate gene expression include the Rel transcription factor, the Ret zinc finger protein, and the Tre oncoprotein. (See, for example, Cao, T. et al. (1998) J. Cell Sci. 111:1319-1329; and Nakamura, T. et al. (1992) Oncogene 7:733-741.) Some conserved regions of oncogenes have been identified, such as the C3HC4 RING finger motif. Mutations in the C3HC4 RING finger domain of the Bmi-1 oncoprotein, for example, block lymphoma induction in mice (Hemenway, C.S. (1998) Oncogene 16:2541-2547). Apoptosis inhibition motifs have also been identified, such as the BIR repeat implicated in the activity of the IAP (Inhibitor of Apoptosis) family. Mutations or chromosomal translocations which result in hyperactivation of oncogenes result in uncontrolled cell proliferation.

Tumor Suppressors

Tumor suppressor genes are involved in inhibition of cell proliferation. Mutations which decrease the activity of tumor suppressor genes result in increased cell proliferation. In humans and other mammals, tumor suppressors include the retinoblastoma (Rb) and p53 proteins. Tumor suppressors have also been discovered in lower animals such as Drosophila, in which the Discs-Large (Dlg) and Hyperplastic Discs (Hyd) proteins inhibit hyperplasia of undifferentiated epithelial cells in developing imaginal discs. (See, for example, Mansfield, E. et al. (1994) Dev. Biol. 165:507-526.) The importance of tumor suppressor genes and oncogenes in the development of cancer is demonstrated by the fact that about 75% of coloreetal cancers have inactivating mutations in the p53 gene and about 50% have a hyper-activating mutation in a ras family oncogene.

Tumor supressor genes often act as "gatekeepers" (Kinzler, K.W. and Vogelstein, B. (1996) Cell 87:159-170). Normally, the gatekeeper is responsible for maintaining a balance of cell division, growth arrest, and death. External signals may activate or inactivate the gatekeeper, or alter its location within the cell. In some cases, inactivation of the gatekeeper is necessary for cell proliferation, and activation is necessary for cell growth arrest and differentiation. In other cases, the situation is reversed. Proteins which interact with the gatekeeper modify its activity or intracellular location to provide the appropriate response to external signals at any stage in the cell's development.

An example of a gatekeeper protein is the adenomatous polyposis coli (APC) protein. Though APC is expressed ubiquitously, it appears to function as a gatekeeper in colorectal cells. Mutations in the APC protein are linked to familial and sporadic forms of colon cancer. All of these mutations involve truncations in the APC C-terminus, which serves as a binding site for several proteins, including EB1, RP1, and the tumor suppressor protein Dlg. The interactions between APC and these binding proteins may be important for localizing or regulating APC activity. For example,

EB1 appears to link APC to microtubules, and a defect in chromosome segregation has been implicated as an early event in colorectal tumorigenesis (Berreuta, L. (1998) Proc. Natl. Acad. Sci. USA 95:10596-10601; and Renner, C. et al. (1997) J. Immunol. 159:1276-1283).

Another example of a gatekeeper is the E2F transcription factor, which can function either as a positive regulator of cell cycle progression or as a suppressor of cell proliferation, depending on the tissue. The balance of cell division over growth arrest and differentiation appears to involve proteins which interact with and modulate E2F. These proteins include the Rb tumor suppressor protein and NPDC-1 (neural proliferation, differentiation, and control). Rb acts to repress transcriptional activity of E2F, leading to differentiation or apoptosis in the responding cell. NPDC-1 is a neural specific gene expressed in growth arrested and differentiated cells. The NPDC-1 gene product, npdef-1, interacts with E2F to down-regulate cell proliferation (Dupont, E. et al. (1998) J. Neurosci. Res. 51:257-267).

Cell Cycle Machinery

The molecular machinery which drives the cell cycle in response to mitogens and growth factors has been extensively studied in model systems such as budding yeast, fission yeast, and the African clawed frog, Xenopus. Essentially, the cell cycle is comprised of four successive phases: G1, S (DNA synthesis), G2, and M (mitosis). Cells which exit the cell cycle enter a quiescent phase called G0. Studies in yeast have shown that exit from S and M phases is driven by the anaphase-promoting complex, an assembly of proteins that degrades cyclins via the ubiquitin-mediated protein degradation pathway. (See, for example, Kominami, K. et al. (1998) EMBO J. 17:5388-5399.) Other non-kinase proteins, such as the Zer1p RNA splicing protein in fission yeast, are important for exit of the cell from G0 and entry into G1 or G2. (See, for example, Urushiyama, S. et al. (1997) Genetics 147:101-115.)

Several cell cycle transitions, including the entry and exit of a cell from mitosis, are dependent upon the activation and inhibition of cyclin-dependent kinases (Cdks). The Cdks are composed of a kinase subunit, Cdk, and an activating subunit, cyclin, in a complex that is subject to many levels of regulation. Cyclins bind and activate cyclin-dependent protein kinases which then phosphorylate and activate selected proteins involved in the mitotic process. The Cdk-cyclin complex is both activated and inhibited by phosphorylation. In addition, the Cdk-cyclin complex is regulated by targeted degradation involving molecules such as CDC4 and CDC53. Other proteins mediate entry into or progression through mitosis. For example, Berry and Gould recently identified a novel, 142 amino acid protein from the yeast S. pombe, termed dmp1p, that is required for proper spindle formation and entry into mitosis, but does not interact with cyclin-type proteins (Berry L.D. and Gould K.L. (1997) J. Cell Biol. 137:1337-1354). Dim1p appears to be evolutionarily conserved,

since a human homolog has recently been described (Larin D., et al. (1997) GI 2565275).

Apoptosis Machinery

Apoptosis is the genetically controlled process by which unneeded or defective cells undergo programmed cell death. Selective elimination of cells is as important for morphogenesis and tissue remodeling as is cell proliferation and differentiation. Lack of apoptosis may result in hyperplasia and other disorders associated with increased cell proliferation. Apoptosis is also a critical component of the immune response. Immune cells such as cytotoxic T-cells and natural killer cells prevent the spread of disease by inducing apoptosis in tumor cells and virus-infected cells. In addition, immune cells that fail to distinguish self molecules from foreign molecules must be eliminated by apoptosis to avoid an autoimmune response.

Apoptotic cells undergo distinct morphological changes. Hallmarks of apoptosis include cell shrinkage, nuclear and cytoplasmic condensation, and alterations in plasma membrane topology. Biochemically, apoptotic cells are characterized by increased intracellular calcium concentration, fragmentation of chromosomal DNA, and expression of novel cell surface components.

The molecular mechanisms of apoptosis are highly conserved, and many of the key protein regulators and effectors of apoptosis have been identified. Apoptosis generally proceeds in response to a signal which is transduced intracellularly and results in altered patterns of gene expression and protein activity. Signaling molecules such as hormones and cytokines are known both to stimulate and to inhibit apoptosis through interactions with cell surface receptors. Transcription factors also play an important role in the onset of apoptosis. A number of downstream effector molecules, particularly proteases such as the cysteine proteases called caspases, have been implicated in the degradation of cellular components and the proteolytic activation of other apoptotic effectors.

The Fas/Apo-1 receptor (FAS) is a member of the tumor necrosis factor-receptor family. Upon binding its ligand (Fas ligand), the membrane-spanning FAS induces apoptosis by recruiting several cytoplasmic proteins that transmit the death signal. Chu et al. isolated one such protein from mice, termed FAS-associated protein factor 1 (FAF1), and demonstrated that expression of FAF1 in L cells potentiated FAS-induced apoptosis (Chu, K. et al. (1995) Proc. Natl. Acad. Sci. USA 92:11894-11898). Subsequently, FAS-associated factors have been isolated from numerous other species, including quail and fly (Frohlich, T., et al. (1998) J. Cell Sci. 111:2353-63; and Lukacsovich, T. et al. (1998) GI 3688609).

Fragmentation of chromosomal DNA is one of the hallmarks of apoptosis. DNA fragmentation factor (DFF) is a protein composed of two subunits, a 40-kDa, caspase-activated nuclease termed DFF40/CAD, and its 45-kDa inhibitor DFF45/ICAD. Two mouse homologs of DFF45/ICAD, termed CIDE-A and CIDE-B, have recently been described (Inohara, N. et al.(1998)

EMBO J. 17:2526-2533). CIDE-A and CIDE-B expression in mammalian cells activated apoptosis, while expression of CIDE-A alone induced DNA fragmentation. In addition, FAS-mediated apoptosis was enhanced by CIDE-A and CIDE-B, further implicating these proteins as effectors that mediate apoptosis.

Cancers are characterized by inappropriate cell proliferation, which may be due to uncontrolled cell growth or inadequate apoptosis. Strategies for treatment may involve either reestablishing control over cell cycle progression, or selectively stimulating apoptosis in cancerous cells (Nigg, E.A. (1995) BioEssays 17:471-480).

Immunological defenses against cancer include induction of apoptosis in mutant cells by tumor suppressors, and the recognition of tumor antigens by T lymphocytes. Response to mitogenic stresses is frequently controlled at the level of transcription and is coordinated by various transcription factors. The Rel/NF-kappa B family of vertebrate transcription factors, for example, plays a pivotal role in inflammatory and immune responses to radiation. The NF-kappa B family includes p50, p52, RelA, RelB, and cRel and other DNA-binding proteins. The p52 protein induces apoptosis, upregulates transcription factor c-Jun, and activates c-Jun N-terminal kinase 1 (JNK1) (Sun, L. et al. (1998) Gene 208:157-166). Most NF-kappa B proteins form DNA-binding homodimers or heterodimers. Dimerization of many transcription factors is mediated by a conserved sequence known as the bZIP domain, characterised by a basic region followed by a leucine zipper.

The discovery of new proliferation and apoptosis related proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative, immunological, and reproductive disorders.

## SUMMARY OF THE INVENTION

The invention features substantially purified polypeptides, proliferation and apoptosis related proteins, referred to collectively as "PROAP" and individually as "PROAP-1," "PROAP-2," "PROAP-3," "PROAP-4," "PROAP-5," "PROAP-6" "PROAP-7," "PROAP-8," "PROAP-9," "PROAP-10," "PROAP-11," "PROAP-12," "PROAP-13," "PROAP-14," "PROAP-15," "PROAP-16," "PROAP-17," "PROAP-18," and "PROAP-19." In one aspect, the invention provides a substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19 and fragments thereof. The invention also includes a polypeptide comprising an amino acid sequence that differs by one or more conservative amino acid substitutions from an amino acid sequence selected from the group consisting of SEQ ID NO:1-19.

The invention further provides a substantially purified variant having at least 90% amino acid identity to at least one of the amino acid sequences selected from the group consisting of SEQ ID

NO:1-19 and fragments thereof. The invention also provides an isolated and purified polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19 and fragments thereof. The invention also includes an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19 and fragments thereof.

Additionally, the invention provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19 and fragments thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1-19 and fragments thereof.

The invention also provides a method for detecting a polynucleotide in a sample containing nucleic acids, the method comprising the steps of: (a) hybridizing the complement of the polynucleotide sequence to at least one of the polynucleotides of the sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide in the sample. In one aspect, the method further comprises amplifying the polynucleotide prior to hybridization.

The invention also provides an isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:20-38 and fragments thereof. The invention further provides an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide sequence selected from the group consisting of SEQ ID NO:20-38 and fragments thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:20-38 and fragments thereof.

The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19. In another aspect, the expression vector is contained within a host cell.

The invention also provides a method for producing a polypeptide, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing a polynucleotide of the invention under conditions suitable for the expression of the polypeptide; and (b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-19 and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention further includes a purified antibody which binds to a polypeptide selected from the group consisting of SEQ ID NO:1-19 and fragments thereof. The invention also provides a purified agonist and a purified antagonist to the polypeptide.

The invention also provides a method for treating or preventing a disorder associated with decreased expression or activity of PROAP, the method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-19 and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for treating or preventing a disorder associated with increased expression or activity of PROAP, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-19 and fragments thereof.

## BRIEF DESCRIPTION OF THE FIGURES AND TABLES

Figures 1A and 1B show the amino acid sequence alignment between PROAP-1 (Incyte ID number 1342011; SEQ ID NO:1) and mouse npdef-1 (GI 452276; SEQ ID NO:39).

Figures 2A and 2B show the amino acid sequence alignment between PROAP-2 (Incyte ID number 1880041; SEQ ID NO:2) and human EB1 (GI 998357, SEQ ID NO:40).

Figure 3 shows the amino acid sequence alignment between PROAP-3 (Incyte ID number 3201881; SEQ ID NO:3) and mouse serum deprivation response (sdr) protein (GI 455719; SEQ ID NO:41).

Figure 4 shows the amino acid sequence alignment between PROAP-13 (Incyte ID number 1438978; SEQ ID NO:13) and human dim1p homolog (GI 2565275; SEQ ID NO:42).

Figures 5A and 5B show the amino acid sequence alignment between PROAP-14 (Incyte ID number 2024773; SEQ ID NO:14) and FAS-associated factor from Drosophila melanogaster (GI 3688609; SEQ ID NO:43).

Figure 6 shows the amino acid sequence alignment between PROAP-15 (Incyte ID number 3869790; SEQ ID NO:15) and cell death activator CIDE-B from Mus musculus (GI 3114594; SEQ ID NO:44).

The above alignments were produced using the multisequence alignment program of LASERGENE software (DNASTAR, Madison WI).

Table 1 shows polypeptide and nucleotide sequence identification numbers (SEQ ID NOs),

clone identification numbers (clone IDs), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding PROAP.

Table 2 shows features of each polypeptide sequence, including potential motifs, homologous sequences, and methods and algorithms used for identification of PROAP.

Table 3 shows selected fragments of each nucleic acid sequence; the tissue-specific expression patterns of each nucleic acid sequence as determined by northern analysis; diseases, disorders, or conditions associated with these tissues; and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which cDNA clones encoding PROAP were isolated.

Table 5 shows the tools, programs, and algorithms used to analyze PROAP, along with applicable descriptions, references, and threshold parameters.

## DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

### DEFINITIONS

"PROAP" refers to the amino acid sequences of substantially purified PROAP obtained from

any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of PROAP. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of PROAP either by directly interacting with PROAP or by acting on components of the biological pathway in which PROAP participates.

An "allelic variant" is an alternative form of the gene encoding PROAP. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding PROAP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as PROAP or a polypeptide with at least one functional characteristic of PROAP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding PROAP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding PROAP. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent PROAP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of PROAP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein

molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of PROAP. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of PROAP either by directly interacting with PROAP or by acting on components of the biological pathway in which PROAP participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, $F(ab')_2$, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind PROAP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition containing a nucleic acid sequence which is complementary to the "sense" strand of a specific nucleic acid sequence. Antisense molecules may be produced by any method including synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and to block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic PROAP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" and "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence "5' A-G-T 3'" bonds to the complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acid strands, and in the design and use of peptide nucleic acid (PNA) molecules.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding PROAP or fragments of PROAP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, extended using the XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of one or more Incyte Clones and, in some cases, one or more public domain ESTs, using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that, when made, least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

| Original Residue | Conservative Substitution |
|---|---|
| Ala | Gly, Ser |
| Arg | His, Lys |
| Asn | Asp, Gln, His |
| Asp | Asn, Glu |
| Cys | Ala, Ser |
| Gln | Asn, Glu, His |
| Glu | Asp, Gln, His |
| Gly | Ala |

| | |
|---|---|
| His | Asn, Arg, Gln, Glu |
| Ile | Leu, Val |
| Leu | Ile, Val |
| Lys | Arg, Gln, Glu |
| Met | Leu, Ile |
| Phe | His, Met, Leu, Trp, Tyr |
| Ser | Cys, Thr |
| Thr | Ser, Val |
| Trp | Phe, Tyr |
| Tyr | His, Phe, Trp |
| Val | Ile, Leu, Thr |

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "fragment" is a unique portion of PROAP or the polynucleotide encoding PROAP which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50% of a polypeptide) as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:20-38 comprises a region of unique polynucleotide sequence that

specifically identifies SEQ ID NO:20-38, for example, as distinct from any other sequence in the same genome. A fragment of SEQ ID NO:20-38 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:20-38 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:20-38 and the region of SEQ ID NO:20-38 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-19 is encoded by a fragment of SEQ ID NO:20-38. A fragment of SEQ ID NO:1-19 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-19. For example, a fragment of SEQ ID NO:1-19 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-19. The precise length of a fragment of SEQ ID NO:1-19 and the region of SEQ ID NO:1-19 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

The term "similarity" refers to a degree of complementarity. There may be partial similarity or complete similarity. The word "identity" may substitute for the word "similarity." A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced stringency. A substantially similar sequence or hybridization probe will compete for and inhibit the binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the substantially similar sequence or probe will not hybridize to the second non-complementary target sequence.

The phrases "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default

parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequence pairs.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorf/bl2.html. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such default parameters may be, for example:

*Matrix: BLOSUM62*
*Reward for match: 1*
*Penalty for mismatch: -2*
*Open Gap: 5 and Extension Gap: 2 penalties*
*Gap x drop-off: 50*
*Expect: 10*
*Word Size: 11*
*Filter: on*

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length

supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the hydrophobicity and acidity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) with blastp set at default parameters. Such default parameters may be, for example:

*Matrix: BLOSUM62*

*Open Gap: 11 and Extension Gap: 1 penalties*

*Gap x drop-off: 50*

*Expect: 10*

*Word Size: 3*

*Filter: on*

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be

used to describe a length over which percentage identity may be measured.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance.

The term "humanized antibody" refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of identity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 μg/ml denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Generally, such wash temperatures are selected to be about 5°C to 20°C lower than the thermal melting point ($T_m$) for the specific sequence at a defined ionic strength and pH. The $T_m$ is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating $T_m$ and conditions for nucleic acid hybridization are well known and can be found in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, denatured salmon sperm DNA at about 100-200 μg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular

circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., $C_0t$ or $R_0t$ analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

The term "microarray" refers to an arrangement of distinct polynucleotides on a substrate.

The terms "element" and "array element" in a microarray context, refer to hybridizable polynucleotides arranged on the surface of a substrate.

The term "modulate" refers to a change in the activity of PROAP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of PROAP.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition.

PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Probe" refers to nucleic acid sequences encoding PROAP, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel et al.,1987, Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis et al., 1990, PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA)

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the

selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding PROAP, or fragments thereof, or PROAP itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

"Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The

presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

## THE INVENTION

The invention is based on the discovery of new human proliferation and apoptosis related proteins (PROAP), the polynucleotides encoding PROAP, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, immunological, and reproductive disorders.

Table 1 lists the Incyte clones used to assemble full length nucleotide sequences encoding PROAP. Columns 1 and 2 show the sequence identification numbers (SEQ ID NOs) of the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone IDs of the Incyte clones in which nucleic acids encoding each PROAP were identified, and column 4 shows the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones and their corresponding cDNA libraries. Clones for which cDNA libraries are not indicated were derived from pooled cDNA libraries. The Incyte clones in column 5 were used to assemble the consensus nucleotide sequence of each PROAP and are useful as fragments in hybridization technologies.

The columns of Table 2 show various properties of each of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each polypeptide; column 3 shows potential phosphorylation sites; column 4 shows potential glycosylation sites; column 5 shows the amino acid residues comprising signature sequences and motifs; column 6 shows homologous sequences as identified by BLAST analysis; and column 7 shows analytical methods used to identify each polypeptide through sequence homology and protein motifs.

As shown in Figures 1A and 1B, PROAP-1 has chemical and structural similarity with mouse npdef-1 (GI 452276; SEQ ID NO:39). In particular, PROAP-1 and npdef-1 share 66% identity and have similar isoelectric points (7.5 and 7.2, respectively). As shown in Figures 2A and 2B, PROAP-2 has chemical and structural similarity with human EB1 (GI 998357; SEQ ID NO:40). In particular, PROAP-2 and EB1 share 64% identity and have similar isoelectric points (5.3 and 4.9, respectively). As shown in Figure 3, PROAP-3 has chemical and structural similarity with mouse serum deprivation response (sdr) protein (GI 455719; SEQ ID NO:41). In particular, PROAP-3 is 86% identitical to sdr

from residue M1 through V239 on sdr. As shown in Figure 4, PROAP-13 has chemical and structural similarity with human dim1p homolog (GI 2565275; SEQ ID NO:42). In particular, PROAP-13 and Dim1p share 36% identity. As shown in Figures 5A and 5B, PROAP-14 has chemical and structural similarity with Fly FAS-associated factor (FFAF) from D. melanogaster (GI 3688609; SEQ ID NO:43). In particular, PROAP-14 and FFAF share 40% identity. As shown in Figure 6, PROAP-15 has chemical and structural similarity with cell death activator CIDE-B from M. musculus (GI 3114594; SEQ ID NO:44). In particular, PROAP-15 and CIDE-B share 83% identity.

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding PROAP. The first column of Table 3 lists the nucleotide SEQ ID NOs. Column 2 lists fragments of the nucleotide sequences of column 1. These fragments are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:20-38 and to distinguish between SEQ ID NO:20-38 and related polynucleotide sequences. The polypeptides encoded by these fragments are useful, for example, as immunogenic peptides. Column 3 lists tissue categories which express PROAP as a fraction of total tissues expressing PROAP. Column 4 lists diseases, disorders, or conditions associated with those tissues expressing PROAP as a fraction of total tissues expressing PROAP. Column 5 lists the vectors used to subclone each cDNA library. Of particular note is the expression of SEQ ID NO:20 in reproductive, nervous, and cardiovascular tissues, of SEQ ID NO:21 in nervous tissue, of SEQ ID NO:22 in reproductive and gastrointestinal tissues, of SEQ ID NO:28, which is detected exclusively in a cDNA library derived from tibia meniscus tissue, of SEQ ID NO:30, which is detected exclusively in a cDNA library derived from diseased liver, of SEQ ID NO:32 in brain tumor-associated tissues, of SEQ ID NO:33 in tumors of the breast and brain, and of SEQ ID NO:34 in tumors of the breast and testicle.

The columns of Table 4 show descriptions of the tissues used to construct the cDNA libraries from which cDNA clones encoding PROAP were isolated. Column 1 references the nucleotide SEQ ID NOs, column 2 shows the cDNA libraries from which these clones were isolated, and column 3 shows the tissue origins and other descriptive information relevant to the cDNA libraries in column 2.

The invention also encompasses PROAP variants. A preferred PROAP variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the PROAP amino acid sequence, and which contains at least one functional or structural characteristic of PROAP.

The invention also encompasses polynucleotides which encode PROAP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:20-38, which encodes PROAP.

The invention also encompasses a variant of a polynucleotide sequence encoding PROAP. In

particular, such a variant polynucleotide sequence will have at least about 80%, or alternatively at least about 90%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding PROAP. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:20-38 which has at least about 80%, or alternatively at least about 90%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:20-38. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of PROAP.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding PROAP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring PROAP, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode PROAP and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring PROAP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding PROAP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding PROAP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode PROAP and PROAP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding PROAP or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:20-38 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and

S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol. 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Perkin-Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Perkin-Elmer). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Perkin-Elmer), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding PROAP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed

using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode PROAP may be cloned in recombinant DNA molecules that direct expression of PROAP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express PROAP.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter PROAP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

In another embodiment, sequences encoding PROAP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, PROAP itself or a fragment thereof may be synthesized using chemical methods. For

example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of PROAP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY.)

In order to express a biologically active PROAP, the nucleotide sequences encoding PROAP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding PROAP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding PROAP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding PROAP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding PROAP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences

encoding PROAP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding PROAP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding PROAP can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding PROAP into the vector's multiple cloning site disrupts the *lac*Z gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of PROAP are needed, e.g. for the production of antibodies, vectors which direct high level expression of PROAP may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of PROAP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.)

Plant systems may also be used for expression of PROAP. Transcription of sequences encoding PROAP may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding PROAP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses PROAP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of PROAP in cell lines is preferred. For example, sequences encoding PROAP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk*$^-$ and *aprt*$^-$ cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), ß glucuronidase and its substrate ß-glucuronide, or luciferase and its substrate

luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding PROAP is inserted within a marker gene sequence, transformed cells containing sequences encoding PROAP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding PROAP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding PROAP and that express PROAP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of PROAP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on PROAP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding PROAP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding PROAP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega

(Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding PROAP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode PROAP may be designed to contain signal sequences which direct secretion of PROAP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding PROAP may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric PROAP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of PROAP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the PROAP encoding sequence and the heterologous protein sequence, so that PROAP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10).

A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled PROAP may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, $^{35}$S-methionine.

Fragments of PROAP may be produced not only by recombinant means, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, supra, pp. 55-60.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the ABI 431A peptide synthesizer (Perkin-Elmer). Various fragments of PROAP may be synthesized separately and then combined to produce the full length molecule.

**THERAPEUTICS**

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of PROAP and proliferation and apoptosis related proteins. In addition, the expression of PROAP is closely associated with cancer, inflammation, and proliferating, reproductive, and developmental tissues. Therefore, PROAP appears to play a role in cell proliferative, immunological, and reproductive disorders. In the treatment of disorders associated with increased PROAP expression or activity, it is desirable to decrease the expression or activity of PROAP. In the treatment of disorders associated with decreased PROAP expression or activity, it is desirable to increase the expression or activity of PROAP.

Therefore, in one embodiment, PROAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PROAP. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, a cancer of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an immunological disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-

candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, a complication of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and a reproductive disorder such as disorders of prolactin production, infertility, including tubal disease, ovulatory defects, and endometriosis, disruptions of the estrous cycle, disruptions of the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, endometrial and ovarian tumors, uterine fibroids, autoimmune disorders, ectopic pregnancies, and teratogenesis; cancer of the breast, fibrocystic breast disease, and galactorrhea; disruptions of spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the male breast, and gynecomastia.

In another embodiment, a vector capable of expressing PROAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PROAP including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified PROAP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PROAP including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of PROAP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PROAP including, but not limited to, those listed above.

In a further embodiment, an antagonist of PROAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of PROAP. Examples of such disorders include, but are not limited to, those cell proliferative, immunological, and reproductive disorders described above. In one aspect, an antibody which specifically binds PROAP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express PROAP.

In an additional embodiment, a vector expressing the complement of the polynucleotide

encoding PROAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of PROAP including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of PROAP may be produced using methods which are generally known in the art. In particular, purified PROAP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind PROAP. Antibodies to PROAP may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with PROAP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to PROAP have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of PROAP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to PROAP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J.

Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce PROAP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for PROAP may also be generated. For example, such fragments include, but are not limited to, $F(ab')_2$ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between PROAP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering PROAP epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for PROAP. Affinity is expressed as an association constant, $K_a$, which is defined as the molar concentration of PROAP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The $K_a$ determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple PROAP epitopes, represents the average affinity, or avidity, of the antibodies

for PROAP. The $K_a$ determined for a preparation of monoclonal antibodies, which are monospecific for a particular PROAP epitope, represents a true measure of affinity. High-affinity antibody preparations with $K_a$ ranging from about $10^9$ to $10^{12}$ L/mole are preferred for use in immunoassays in which the PROAP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with $K_a$ ranging from about $10^6$ to $10^7$ L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of PROAP, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington, DC; Liddell, J.E. and Cryer, A. (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of PROAP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding PROAP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding PROAP may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding PROAP. Thus, complementary molecules or fragments may be used to modulate PROAP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding PROAP.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences complementary to the polynucleotides encoding PROAP. (See, e.g., Sambrook, supra; Ausubel, 1995, supra.)

Genes encoding PROAP can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or fragment thereof, encoding PROAP. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules

until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding PROAP. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may be employed. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding PROAP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding PROAP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of PROAP, antibodies to PROAP, and mimetics, agonists, antagonists, or inhibitors of PROAP. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acids. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of PROAP, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example PROAP or fragments thereof, antibodies of PROAP, and agonists, antagonists or inhibitors of PROAP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the $ED_{50}$ (the dose therapeutically effective in 50% of the population) or $LD_{50}$ (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the $LD_{50}/ED_{50}$ ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the $ED_{50}$ with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 $\mu$g to 100,000 $\mu$g, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

**DIAGNOSTICS**

In another embodiment, antibodies which specifically bind PROAP may be used for the diagnosis of disorders characterized by expression of PROAP, or in assays to monitor patients being treated with PROAP or agonists, antagonists, or inhibitors of PROAP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for PROAP include methods which utilize the antibody and a label to detect PROAP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring PROAP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of PROAP expression. Normal or standard values for PROAP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibody to PROAP under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of PROAP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding PROAP may be used

for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of PROAP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of PROAP, and to monitor regulation of PROAP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding PROAP or closely related molecules may be used to identify nucleic acid sequences which encode PROAP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding PROAP, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the PROAP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:20-38 or from genomic sequences including promoters, enhancers, and introns of the PROAP gene.

Means for producing specific hybridization probes for DNAs encoding PROAP include the cloning of polynucleotide sequences encoding PROAP or PROAP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as $^{32}P$ or $^{35}S$, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding PROAP may be used for the diagnosis of disorders associated with expression of PROAP. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, a cancer of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an immunological disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis,

autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, a complication of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and a reproductive disorder such as disorders of prolactin production, infertility, including tubal disease, ovulatory defects, and endometriosis, disruptions of the estrous cycle, disruptions of the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, endometrial and ovarian tumors, uterine fibroids, autoimmune disorders, ectopic pregnancies, and teratogenesis; cancer of the breast, fibrocystic breast disease, and galactorrhea; disruptions of spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the male breast, and gynecomastia. The polynucleotide sequences encoding PROAP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered PROAP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding PROAP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding PROAP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding PROAP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of PROAP, a normal or standard profile for expression is established. This may be accomplished by

combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding PROAP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding PROAP may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding PROAP, or a fragment of a polynucleotide complementary to the polynucleotide encoding PROAP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

Methods which may also be used to quantify the expression of PROAP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray

can be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No 5,605,662.)

In another embodiment of the invention, nucleic acid sequences encoding PROAP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding PROAP on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the subject invention

may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, PROAP, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between PROAP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with PROAP, or fragments thereof, and washed. Bound PROAP is then detected by methods well known in the art. Purified PROAP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding PROAP specifically compete with a test compound for binding PROAP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PROAP.

In additional embodiments, the nucleotide sequences which encode PROAP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. No. [Atty Docket No. PF-0619 P, filed October 20, 1998] U.S. Ser. No. 60/118,559, U.S. Ser. No. [Atty Docket No. PF-0670 P, filed February 11, 1999], and U.S. Ser. No. 60/154,336 are hereby expressly incorporated by reference.

## EXAMPLES

### I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), or pINCY (Incyte Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5α, DH10B, or ElectroMAX DH10B from Life Technologies.

### II. Isolation of cDNA Clones

Plasmids were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit

from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

**III. Sequencing and Analysis**

cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Perkin-Elmer) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Perkin-Elmer) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example V.

The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the tools, programs, and algorithms used and provides applicable descriptions, references, and threshold parameters. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments were generated using the default parameters specified by the clustal algorithm as incorporated into the MEGALIGN multisequence

alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programing, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and PFAM to acquire annotation using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene families. (See, e.g., Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:20-38. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

**IV. Northern Analysis**

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\%\ \text{sequence identity} \times \%\ \text{maximum BLAST score}}{100}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact

within a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding PROAP occurred. Analysis involved the categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation/trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories. Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

**V. Extension of PROAP Encoding Polynucleotides**

The full length nucleic acid sequences of SEQ ID NO:20-38 were produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing $Mg^{2+}$, $(NH_4)_2SO_4$, and β-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 µl PICOGREEN

quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μl to 10 μl aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells were selected on antibiotic-containing media, individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

In like manner, the nucleotide sequences of SEQ ID NO:20-38 are used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

**VI. Labeling and Use of Individual Hybridization Probes**

Hybridization probes derived from SEQ ID NO:20-38 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06

software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 $\mu$Ci of [$\gamma$-$^{32}$P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing $10^7$ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

**VII. Microarrays**

A chemical coupling procedure and an ink jet device can be used to synthesize array elements on the surface of a substrate. (See, e.g., Baldeschweiler, supra.) An array analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of complementarity and the relative abundance of each probe which hybridizes to an element on the microarray may be assessed through analysis of the scanned images.

Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise the elements of the microarray. Fragments suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). Full-length cDNAs, ESTs, or fragments thereof corresponding to one of the nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking followed by thermal and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645.) Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

## VIII. Complementary Polynucleotides

Sequences complementary to the PROAP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring PROAP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of PROAP. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the PROAP-encoding transcript.

## IX. Expression of PROAP

Expression and purification of PROAP is achieved using bacterial or virus-based expression systems. For expression of PROAP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express PROAP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of PROAP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding PROAP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, PROAP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from

PROAP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified PROAP obtained by these methods can be used directly in the following activity assay.

**X. Demonstration of PROAP Activity**

An assay for PROAP activity measures cell proliferation as the amount of newly initiated DNA synthesis in Swiss mouse 3T3 cells. A plasmid containing polynucleotides encoding PROAP is transfected into quiescent 3T3 cultured cells using methods well known in the art. The transiently transfected cells are then incubated in the presence of [$^3$H]thymidine, a radioactive DNA precursor. Where applicable, varying amounts of PROAP ligand are added to the transfected cells. Incorporation of [$^3$H]thymidine into acid-precipitable DNA is measured over an appropriate time interval, and the amount incorporated is directly proportional to the amount of newly synthesized DNA.

An alternative assay for PROAP activity measures the induction of apoptosis when PROAP is expressed at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies, Gaithersburg, MD) and pCR 3.1 (Invitrogen, Carlsbad, CA, both of which contain the cytomegalovirus promoter. 5-10 $\mu$g of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2 $\mu$g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP) (Clontech, Palo Alto, CA), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate their apoptotic state. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane

composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface.

Alternatively, PROAP activity may be measured by the induction of growth arrest when PROAP is expressed at physiologically elevated levels in transformed mammalian cell lines. PROAP cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression, and these constructs are stably transfected into a transformed cell line, such as NIH 3T6 or C6, using methods known in the art. An additional plasmid, containing sequences which encode a selectable marker, such as hygromycin resistance, are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Cells expressing PROAP are compared with control cells, either non-transfected or transfected with vector alone, for characteristics associated with growth arrest. Such characteristics can include, but are not limited to, a reduction in [$^3$H]-thymidine incorporation into newly synthesized DNA, lower doubling and generation times, and decreased culture saturation density.

Alternatively, an assay for PROAP activity uses radiolabeled nucleotides, such as [$\alpha^{32}$P]ATP, to measure either the incorporation of radiolabel into DNA during DNA synthesis, or fragmentation of DNA that accompanies apoptosis. Mammalian cells are transfected with plasmid containing cDNA encoding PROAP by methods well known in the art. Cells are then incubated with radiolabeled nucleotide for various lengths of time. Chromosomal DNA is collected, and radioactivity detected using a scintillation counter. Incorporation of radiolabel into chromosomal DNA is proportional to the degree of stimulation of the cell cycle. To determine if PROAP promotes apoptosis, chromosomal DNA is collected as above, and analyzed using polyacrylamide gel electrophoresis, by methods well known in the art. Fragmentation of DNA is quantified by comparison to untransfected control cells, and is proportional to the apoptotic activity of PROAP.

**XI. Functional Assays**

PROAP function is assessed by expressing the sequences encoding PROAP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 $\mu$g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 $\mu$g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein

provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of PROAP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding PROAP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding PROAP and other genes of interest can be analyzed by northern analysis or microarray techniques.

**XII. Production of PROAP Specific Antibodies**

PROAP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the PROAP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-

KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-PROAP activity by, for example, binding the peptide or PROAP to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

**XIII. Purification of Naturally Occurring PROAP Using Specific Antibodies**

Naturally occurring or recombinant PROAP is substantially purified by immunoaffinity chromatography using antibodies specific for PROAP. An immunoaffinity column is constructed by covalently coupling anti-PROAP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing PROAP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of PROAP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/PROAP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and PROAP is collected.

**XIV. Identification of Molecules Which Interact with PROAP**

PROAP, or biologically active fragments thereof, are labeled with $^{125}$I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled PROAP, washed, and any wells with labeled PROAP complex are assayed. Data obtained using different concentrations of PROAP are used to calculate values for the number, affinity, and association of PROAP with the candidate molecules.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

| Polypeptide SEQ ID NO: | Nucleotide SEQ ID NO: | Clone ID | Library | Fragments |
|---|---|---|---|---|
| 1 | 20 | 1342011 | COLNTUT03 | 1291596H1 (BRAINOT11), 485081X18 (HNT2RAT01), 671427H1 (CRBLNOT01), 1352964T6 (LATRTUT02), 1342011H1 (COLNTUT03), 1444182R1 (THRYNOT03), 1444182F1 (THRYNOT03) |
| 2 | 21 | 1880041 | LEUKNOT03 | 3470287H1 (BRAINOT01), 1832158R6 (BRAINON01), 2288712H1 (BRAINON01), 1384536F1 (BRAITUT08), 1880041H1 (LEUKNOT03) |
| 3 | 22 | 3201881 | PENCNOT02 | 3201881H1 (PENCNOT02), 2520087F6 (BRAITUT21), 352438X15 (LVENNOT01) |
| 4 | 23 | 939000 | CERVNOT01 | 110900F1 (PITUNOT01), 548840F1 (BEPINOT01), 939000H1 (CERVNOT01), 939000X12 (CERVNOT01), 1271295F6 (TESTTUT02), 2122589F6 (BRSTNOT07), 3618041H1 (BPIPNOT01), SXAA02479D1, SXAA01641D1, SXAA02385F1 |
| 5 | 24 | 2125677 | BRSTNOT07 | 368085R1 (SYNORAT01), 392816H1 (TMLR2DT01), 518806R6 (MMLRITT01), 1271911H1 (TESTTUT02), 1822315X314D1 (GBLATUT01), 1858290F6 (PROSNOT18), 2125677H1 (BRSTNOT07), 2293815H1 (BRAINON01), 2573443R6 (HIPOAZT01), 2764062H1 (BRSTNOT12), 2820044T6 (TLYMNOT03), 3428001H1 (BRSTNOR01), 3687264H1 (HEAANOT01), 3765525H1 (BRSTNOT24), 4590195H1 (MASTTXT01) |
| 6 | 25 | 2603810 | LUNGTUT07 | 013535R1 (THP1PLB01), 267329R1 (HNT2NOT01), 1453513F1 (PENITUT01), 1556582F6 (BLADTUT04), 2603810H1 (LUNGTUT07) |
| 7 | 26 | 2715761 | THYRNOT09 | 2715761H1 (THYRNOT09), 2993353F6 (KIDNFET02), SBLA03719F1 |

Table 1 (cont.)

| Polypeptide SEQ ID NO: | Nucleotide SEQ ID NO: | Clone ID | Library | Fragments |
|---|---|---|---|---|
| 8 | 27 | 3255641 | OVARTUN01 | 516590H1 (MMLR1DT01), 1921460R6 (BRSTTUT01), 2824323F6 (ADRETUT06), 3255641H1 (OVARTUN01), 3255641R6 (OVARTUN01), SBXA03995D1 |
| 9 | 28 | 3620391 | MENTNOT01 | 1556171H1 (BLADTUT04), 3620391H1 (MENTNOT01) |
| 10 | 29 | 3969860 | PROSTUT10 | 3969860H1 (PROSTUT10), 4275630F6 (PROSTMT01), 4275630T6 (PROSTMT01), 4403647F6 (PROSDIT01) |
| 11 | 30 | 4286006 | LIVRDIR01 | 4286006F6 (LIVRDIR01), 4286006H1 (LIVRDIR01) |
| 12 | 31 | 4325626 | TLYMUNT01 | 841543R1 (PROSTUT05), 841543X53 (PROSTUT05), 1752767F6 (LIVRTUT01), 2994209T6 (KIDNFET02), 3053308H1 (LNODNOT08), 4325626H1 (TLYMUNT01), 5209052H1 (BRAFNOT02) |
| 13 | 32 | 1438978 | PANCNOT08 | 834140H1 (PROSNOT07), 1438978F6 (PANCNOT08), 4074639H1 (PANCNOT19) |
| 14 | 33 | 2024773 | KERANOT02 | 782716R1 (MYOMNOT01), 980866R1 (TONGTUT), 1995464T6 (BRSTTUT03), 2024773H1 (KERANOT02), 2106331F6 (BRAITUT03), 3333150H1 (BRAIFET01) |
| 15 | 34 | 3869790 | BMARNOT03 | 359792R6 (SYNORAB01), 1535116T1 (SPLNNOT04), 2587946F6 (BRAITUT22), 3869790H1 (BMARNOT03) |
| 16 | 35 | 001273 | U937NOT01 | 001273H1 (U937NOT01), 1528039F1 (UCMCL5T01), 1526245F6 (UCMCL5T01), 899008R6 (BRSTTUT03), 022308F1 (ADENINB01) |

# Table 1 (cont.)

| Polypeptide SEQ ID NO: | Nucleotide SEQ ID NO: | Clone ID | Library | Fragments |
|---|---|---|---|---|
| 17 | 36 | 411831 | BRSTNOT01 | 411831H1 (BRSTNOT01), 1232212F1 (LUNGFET03), 1997123R6 (BRSTTUT03), 001732H1 (U937NOT01), 414405T6 (BRSTNOT01), 781412R1 (MYOMNOT01), SADC11822F1 |
| 18 | 37 | 1520835 | BLADTUT04 | 1419118F6 (KIDNNOT09), 1520835F1 and 1520835H1 (BLADTUT04), 1529102F6 (UCMC_5TO1), 3842242F6 (DENDNOT01) |
| 19 | 38 | 1902803 | OVARNOT07 | 180897F1 (PLACNOB01), 491345H1 (HNT2AGT01), 927993R1 (BRAINOT04), 1902803H1 (OVARNOT07), 421747SH1 (ADRENOT15) |

Table 2

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Identification | Analytical Methods |
|---|---|---|---|---|---|---|
| 1 | 334 | S122 T60 S192<br>S203 S204 S218<br>S89 S118 S226 | N190 | | Mouse npdc-1 (g452276) | BLAST |
| 2 | 281 | S120 S44 S180<br>S245 S284 S285<br>T295 S143 T225<br>T232 | | | Human EB1 (g998357) | BLAST |
| 3 | 237 | S16 T33 S149<br>S172 S190 Y119 | N14 N25 N31<br>N147 | | Mouse serum deprivation response protein (sdr) (g455719) | BLAST |
| 4 | 941 | T542 T858 T30<br>T55 T76 T153<br>S159 T198 T249<br>T266 S300 T432<br>S653 S750 T29<br>S315 T322 T357<br>S372 S403 T462<br>S493 S572 T674<br>S681 S783 S853<br>T867 Y131 Y658 | N74 N196 | | TPR protein (Zerip) (g1209191) | MOTIFS<br>BLAST |

Table 2 (cont.)

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Identification | Analytical Methods |
|---|---|---|---|---|---|---|
| 5 | 918 | T19 T94 S469 T2<br>S44 T82 S107<br>T120 S257 T276<br>T399 S475 S579<br>S605 S708 S715<br>S785 T790 S814<br>S835 S841 S8<br>S22 S29 S60<br>S198 S251 S285<br>T374 S556 S589<br>S602 T634 S697<br>T843 T872 S897 | N116 | Polyadenylate binding (PABP) protein domain:<br>P87-D126<br>F139-G185<br>R492-I568<br>HECT (ubiquitin tranpferase) domain:<br>S705-V918 | Drosophila hyper-plastic discs (HYD) protein (g2673887) | MOTIFS<br>BLAST<br>PFAM<br>BLOCKS |
| 6 | 324 | S140 S191 S273<br>T287 S226 | | Mitochondrial energy transfer protein signature:<br>P141-L149<br>Transmembrane domains:<br>V106-I324<br>A13-R53 | Similar to human growth arrest inducible gene product (g1707054) | MOTIFS<br>BLAST<br>HMM |
| 7 | 185 | T72 T73 T132<br>T21 T160 T174<br>S35 S95 | | | APC10 (Anaphase promoting complex) (g3402134) | MOTIFS<br>BLAST |

Table 2 (cont.)

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Identification | Analytical Methods |
|---|---|---|---|---|---|---|
| 8 | 445 | T281 S32 S118 S135 S177 S416 T418 T81 T186 T203 S262 S302 T335 T346 | N300 N414 | Rhodopsin-like GPCR fingerprint: F282-L306<br>Transmembrane domains: I147-Y166 S357-Y373 | Mitogen-induced protein (g2290726) | MOTIFS BLAST PRINTS HMM |
| 9 | 73 | T55 T15 S25 S28 T50 | N34 | | Cyclin E (g1262821) | MOTIFS BLAST |
| 10 | 288 | T159 T161 S190 S228 S245 S56 S117 S120 S143 S190 T240 | N226 | SPRY domain: E132-W153 C148-M273<br>C3HC4 zinc finger: C11-Q39 | RET finger protein-like 1, long variant (g3417312) | MOTIFS BLAST PFAM BLOCKS |
| 11 | 98 | T61 S22 Y57 Y69 Y90 | N59 | SH3 domain: A46-E64 | Melanoma inhibitor protein homolog (g1778171) | MOTIFS BLAST BLOCKS PRINTS |

Table 2 (cont.)

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Identification | Analytical Methods |
|---|---|---|---|---|---|---|
| 12 | 549 | S139 T313 T351 T61 T460 S484 T511 S73 S90 S91 T152 S216 T282 T315 S346 S446 Y99 | | Probable rabGAP domain: A98-T315 | TRE oncogene product (g37330) | MOTIFS BLAST PFAM |
| 13 | 95 | T9 S10 S20 T48 | | | Human dim2p homolog (g2565275) | BLAST |
| 14 | 445 | T14 T24 T109 S142 T213 T244 S275 Y297 S300 S355 S361 S372 S393 T425 T432 | N269 N284 N370 | | Fly FAS-associated factor (FFAF) (g3688609) | BLAST |
| 15 | 219 | T46 T55 T82 T199 | N18 | | Cell death activator CIDE-B (g3114594) | BLAST |
| 16 | 439 | T27 T32 S75 S123 S347 T381 T404 T263 Y231 Y294 | | Signal peptide: M1-A28 | p52 apoptotic protein (g2599942) | MOTIFS BLAST HMM |

Table 2 (cont.)

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Identification | Analytical Methods |
|---|---|---|---|---|---|---|
| 17 | 526 | S383 S470 S69<br>S78 S137 T273<br>T274 S342 S432<br>T453 S231 T285<br>T290 S342 T360<br>T407 S423 S436<br>S460 S508 | N217 N229 | bZIP transcription factor:<br>K84-R398<br>Cyclin cell cycle division protein:<br>A224-I250<br>Signal peptide:<br>M1-S25 | cyclin ania-6a gi5453421 [Mus musculus] | MOTIFS<br>BLAST<br>BLOCKS<br>HMM |
| 18 | 298 | T63 S93 S165<br>S212 S220 S6<br>T44 S133 T203<br>T251 | | C3HC4 type Zn finger:<br>C267-A276<br>apoptosis inhibitor:<br>R30-L155 | putative apoptosis inhibitor (g2957175) | MOTIFS<br>PFAM<br>PROFILESCAN<br>BLAST |
| 19 | 249 | S57 S119 T134<br>S150 T167 S205<br>S52 S125 T230<br>Y121 | | PHD finger:<br>P196-E245 | candidate tumor suppressor (g2829208) | MOTIFS<br>BLAST<br>PFAM |

# Table 3

| Polynucleotide SEQ ID NO: | Selected Fragments | Tissue Expression (Fraction of Total) | Disease or Condition (Fraction of Total) | Vector |
|---|---|---|---|---|
| 20 | 518-568 | | Cell Proliferation (0.660)<br>Inflammation/Trauma (0.270) | pINCY |
| 21 | 613-693 | | Cell Proliferation (0.560) | pINCY |
| 22 | 949-984 | | Cell Proliferation (0.560) | pINCY |
| 23 | 811-855<br>1297-1341 | Reproductive (0.287)<br>Nervous (0.181)<br>Hematopoietic/Immune (0.138) | Cancer (0.487)<br>Inflammation (0.250)<br>Cell Proliferation (0.181) | PSPORT1 |
| 24 | 275-322<br>1955-1999 | Reproductive (0.279)<br>Nervous (0.174)<br>Hematopoietic/Immune (0.116) | Cancer (0.419)<br>Inflammation (0.267)<br>Cell Proliferation (0.174) | pINCY |
| 25 | 322-351 | Reproductive (0.306)<br>Cardiovascular (0.105)<br>Hematopoietic/Immune (0.105) | Cancer (0.484)<br>Inflammation (0.290)<br>Cell Proliferation (0.234) | pINCY |
| 26 | 658-702 | Reproductive (0.444)<br>Developmental (0.111)<br>Hematopoietic/Immune (0.111) | Cancer (0.500)<br>Inflammation (0.333)<br>Cell Proliferation (0.167) | pINCY |
| 27 | 172-216<br>604-648 | Reproductive (0.256)<br>Nervous (0.186)<br>Hematopoietic/Immune (0.163) | Cancer (0.349)<br>Inflammation (0.302)<br>Trauma (0.116) | PSPORT1 |
| 28 | 58-102 | Musculoskeletal (1.000) | Cancer (1.000) | pINCY |

Table 3 (cont.)

| Polynucleotide SEQ ID NO: | Selected Fragments | Tissue Expression (Fraction of Total) | Disease or Condition (Fraction of Total) | Vector |
|---|---|---|---|---|
| 29 | 217-246<br>433-477 | Reproductive (0.455)<br>Nervous (0.273)<br>Cardiovascular (0.091) | Cancer (0.455)<br>Cell Proliferation (0.182)<br>Trauma (0.182) | pINCY |
| 30 | 257-301 | Gastrointestinal (1.000) | Inflammation (1.000) | pINCY |
| 31 | 219-263<br>1569-1613 | Gastrointestinal (0.245)<br>Nervous (0.245)<br>Reproductive (0.245) | Cancer (0.490)<br>Inflammation (0.265)<br>Cell Proliferation (0.143) | pINCY |
| 32 | 585-629 | Nervous (0.390)<br>Reproductive (0.150) | Cancer and Cell Proliferation (0.690) | |
| 33 | 381-425 | Reproductive (0.310)<br>Nervous (0.150) | Cancer and Cell Proliferation (0.650) | |
| 34 | 133-177 | Reproductive (0.330) | Cancer (0.440) | |
| 35 | 110-154 | Reproductive (0.282)<br>Hematopoietic/Immune (0.256)<br>Cardiovascular (0.154) | Cancer (0.462)<br>Inflammation (0.256)<br>Fetal (0.179) | PBLUESCRIPT |
| 36 | 164-208 | Reproductive (0.236)<br>Gastrointestinal (0.181)<br>Hematopoietic/Immune (0.153) | Cancer (0.486)<br>Inflammation (0.264)<br>Fetal (0.125) | PBLUESCRIPT |

Table 3 (cont.)

| Polynucleotide SEQ ID NO: | Selected Fragments | Tissue Expression (Fraction of Total) | Disease or Condition (Fraction of Total) | Vector |
|---|---|---|---|---|
| 37 | 272-316 | Developmental (0.429)<br>Hematopoietic/Immune (0.286)<br>Reproductive (0.143)<br>Urologic (0.143) | Fetal (0.571)<br>Cancer (0.286)<br>Inflammation (0.143) | pINCY |
| 38 | 782-826 | Reproductive (0.253)<br>Nervous (0.176)<br>Urologic (0.121) | Cancer (0.440)<br>Inflammation (0.242)<br>Fetal (0.231) | pINCY |

Table 4

| Polynucleotide SEQ ID NO: | Library | Library Comment |
|---|---|---|
| 20 | COLNTUT03 | This library was constructed using RNA isolated from colon tumor tissue obtained from the sigmoid colon of a 62-year-old Caucasian male during a sigmoidectomy and permanent colostomy. Pathology indicated invasive grade 2 adenocarcinoma. One lymph node contained metastasis with extranodal extension. Patient history included hyperlipidemia, cataract disorder, and dermatitis. Family history included benign hypertension, atherosclerotic coronary artery disease, hyperlipidemia, breast cancer, and prostate cancer. |
| 21 | LEUKNOT03 | This library was constructed using RNA isolated from white blood cells of a 27-year-old female with blood type A+. The donor tested negative for cytomegalovirus (CMV). |
| 22 | PENCNOT02 | This library was constructed using RNA isolated from penis right corpus cavernosum tissue. |
| 23 | CERVNOT01 | This library was constructed using RNA isolated from uterine cervical tissue of a 35-year-old Caucasian female during a vaginal hysterectomy with dilation and curettage. Pathology indicated mild chronic cervicitis. Family history included atherosclerotic coronary artery disease and type II diabetes. |
| 24 | BRSTNOT07 | This library was constructed using RNA isolated from diseased breast tissue removed from a 43-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated mildly proliferative fibrocystic changes with epithelial hyperplasia, papillomatosis, and duct ectasia. Pathology for the associated tumor tissue indicated invasive grade 4, nuclear grade 3 mammary adenocarcinoma with extensive comedo necrosis. Family history included epilepsy, cardiovascular disease, and type II diabetes. |

# Table 4 (cont.)

| Polynucleotide SEQ ID NO: | Library | Library Comment |
|---|---|---|
| 25 | LUNGTUT07 | This library was constructed using RNA isolated from lung tumor tissue removed from the upper lobe of a 50-year-old Caucasian male during segmental lung resection. Pathology indicated an invasive grade 4 squamous cell adenocarcinoma. Patient history included tobacco use. Family history included skin cancer. |
| 26 | THYRNOT09 | This library was constructed using RNA isolated from diseased thyroid tissue removed from an 18-year-old Caucasian female during a unilateral thyroid lobectomy and regional lymph node excision. Pathology indicated adenomatous goiter associated with a follicular adenoma of the thyroid. Family history included thyroid cancer. |
| 27 | OVARTUN01 | This normalized library was constructed from 5.36 million independent clones obtained from an ovarian tumor library. RNA was isolated from tumor tissue removed from the left ovary of a 58-year-old Caucasian female during a total abdominal hysterectomy, removal of a single ovary, and inguinal hernia repair. Pathology indicated metastatic grade 3 adenocarcinoma of colonic origin, forming a partially cystic and necrotic tumor mass in the left ovary and a nodule in the left mesovarium. A single intramural leiomyoma was identified in the myometrium. The cervix showed mild chronic cystic cervicitis. Patient history included benign hypertension, follicular ovarian cyst, colon cancer, benign colon neoplasm, and osteoarthritis. Family history included emphysema, myocardial infarction, atherosclerotic coronary artery disease, benign hypertension, hyperlipidemia, and primary tuberculous complex. The normalization and hybridization conditions were adapted from Soares et al. (PNAS (1994) 91:9228) and Bonaldo et al. (Genome Research (1996) 6:791). |

# Table 4 (cont.)

| Polynucleotide SEQ ID NO: | Library | Library Comment |
|---|---|---|
| 28 | MENTNOT01 | This library was constructed using RNA isolated from left tibial meniscus tissue removed from a 16-year-old Caucasian male during a partial left tibial ostectomy with free skin graft. Pathology for the associated tumor indicated metastatic alveolar rhabdomyosarcoma. Patient history included an abnormality of the red blood cells. Family history included osteoarthritis. |
| 29 | PROSTUT10 | This library was constructed using RNA isolated from prostatic tumor tissue removed from a 66-year-old Caucasian male during radical prostatectomy and regional lymph node excision. Pathology indicated an adenocarcinoma (Gleason grade 2+3) and adenofibromatous hyperplasia. The patient presented with elevated prostate specific antigen (PSA). Family history included prostate cancer and secondary bone cancer. |
| 30 | LIVRDIR01 | This library was constructed using RNA isolated from diseased liver tissue removed from a 63-year-old Caucasian female during a liver transplant. Patient history included primary biliary cirrhosis. Serology was positive for anti-mitochondrial antibody. |
| 31 | TLYMUNT01 | This library was constructed using RNA isolated from resting allogenic T-lymphocyte tissue removed from an adult (40-50-year-old) Caucasian male. |
| 32 | PANCNOT08 | This library was constructed using RNA isolated from pancreatic tissue removed from a 65-year-old Caucasian female during radical subtotal pancreatectomy. Pathology for the associated tumor tissue indicated an invasive grade 2 adenocarcinoma. Patient history included type II diabetes, osteoarthritis, cardiovascular disease, benign neoplasm in the large bowel, and a cataract. |
| 33 | KERANOT02 | This library was constructed using RNA isolated from epidermal breast keratinocytes (NHEK). NHEK (Clontech #CC-2501) is human breast keratinocyte cell line derived from a 30-year-old black female during breast-reduction surgery. |

Table 4 (cont.)

| Polynucleotide SEQ ID NO: | Library | Library Comment |
|---|---|---|
| 34 | BMARNOT03 | This library was constructed using RNA isolated from the left tibial bone marrow tissue of a 16-year-old Caucasian male during a partial left tibial osteotomy with free skin graft. Patient history included an abnormality of the red blood cells. Previous surgeries included bone and bone marrow biopsy, and soft tissue excision. |
| 35 | U937NOT01 | This library was constructed at Stratagene (STR937207), using RNA isolated from the U937 monocyte-like cell line. This line (ATCC CRL1593) was established from malignant cells obtained from the pleural effusion of a 37-year-old Caucasian male with diffuse histiocytic lymphoma. |
| 36 | BRSTNOT01 | This library was constructed using RNA isolated from the breast tissue of a 56-year-old Caucasian female who died in a motor vehicle accident. |
| 37 | BLADTUT04 | This library was constructed using RNA isolated from bladder tumor tissue removed from a 60-year-old Caucasian male during a radical cystectomy, prostatectomy, and vasectomy. Pathology indicated grade 3 transitional cell carcinoma in the left bladder wall. Carcinoma in-situ was identified in the dome and trigone. Family history included type I diabetes, a malignant neoplasm of the stomach, atherosclerotic coronary artery disease, and an acute myocardial infarction. |
| 38 | OVARNOT07 | This library was constructed using RNA isolated from left ovarian tissue removed from a 28-year-old Caucasian female during a vaginal hysterectomy and removal of the fallopian tubes and ovaries. The tissue was associated with multiple follicular cysts, endometrium in a weakly proliferative phase, and chronic cervicitis of the cervix with squamous metaplasia. Family history included benign hypertension, hyperlipidemia, and atherosclerotic coronary artery disease. |

# Table 5

| Program | Description | Reference | Parameter Threshold |
|---|---|---|---|
| ABI FACTURA | A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences. | Perkin-Elmer Applied Biosystems, Foster City, CA. | |
| ABI/PARACEL FDF | A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences. | Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA. | Mismatch <50% |
| ABI AutoAssembler | A program that assembles nucleic acid sequences. | Perkin-Elmer Applied Biosystems, Foster City, CA. | |
| BLAST | A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx. | Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25: 3389-3402. | *ESTs:* Probability value= 1.0E-8 or less<br>*Full Length sequences:* Probability value= 1.0E-10 or less |
| FASTA | A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises as least five functions: fasta, tfasta, fastx, tfastx, and ssearch. | Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad Sci. 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489. | *ESTs:* fasta E value=1.06E-6<br>*Assembled ESTs:* fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less<br>*Full Length sequences:* fastx score=100 or greater |
| BLIMPS | A BLocks IMProved Searcher that matches a sequence against those in BLOCKS and PRINTS databases to search for gene families, sequence homology, and structural fingerprint regions. | Henikoff, S and J.G. Henikoff, Nucl. Acid Res., 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424. | Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and Probability value= 1.0E-3 or less |
| PFAM | A Hidden Markov Models-based application useful for protein family search. | Krogh, A. et al. (1994) J. Mol. Biol., 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322. | Score=10-50 bits, depending on individual protein families |

# Table 5 cont.

| Program | Description | Reference | Parameter Threshold |
|---|---|---|---|
| ProfileScan | An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite. | Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25: 217-221. | Score= 4.0 or greater |
| Phred | A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability. | Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194. | |
| Phrap | A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences. | Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M. S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA. | Score= 120 or greater; Match length= 56 or greater |
| Consed | A graphical tool for viewing and editing Phrap assemblies | Gordon, D. et al. (1998) Genome Res. 8:195-202. | |
| SPScan | A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides. | Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12: 431-439. | Score=5 or greater |
| Motifs | A program that searches amino acid sequences for patterns that matched those defined in Prosite. | Bairoch et al. supra; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI. | |

What is claimed is:

1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, and fragments thereof.

2. A substantially purified variant having at least 90% amino acid sequence identity to the amino acid sequence of claim 1.

3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.

4. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 3.

5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.

6. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 3.

7. A method for detecting a polynucleotide, the method comprising the steps of:

(a) hybridizing the polynucleotide of claim 6 to at least one nucleic acid in a sample, thereby forming a hybridization complex; and

(b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide in the sample.

8. The method of claim 7 further comprising amplifying the polynucleotide prior to hybridization.

9. An isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID

NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, and fragments thereof.

10. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 9.

11. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 9.

12. An expression vector comprising at least a fragment of the polynucleotide of claim 3.

13. A host cell comprising the expression vector of claim 12.

14. A method for producing a polypeptide, the method comprising the steps of:

a) culturing the host cell of claim 13 under conditions suitable for the expression of the polypeptide; and

b) recovering the polypeptide from the host cell culture.

15. A pharmaceutical composition comprising the polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.

16. A purified antibody which specifically binds to the polypeptide of claim 1.

17. A purified agonist of the polypeptide of claim 1.

18. A purified antagonist of the polypeptide of claim 1.

19. A method for treating or preventing a disorder associated with decreased expression or activity of PROAP, the method comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 15.

20. A method for treating or preventing a disorder associated with increased expression or activity of PROAP, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 18.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 15/12, C07K 14/47, C12Q 1/68, A61K 38/17, C07K 16/18 — A3

(11) International Publication Number: WO 00/23589

(43) International Publication Date: 27 April 2000 (27.04.00)

(21) International Application Number: PCT/US99/24511

(22) International Filing Date: 19 October 1999 (19.10.99)

(30) Priority Data:

| | | |
|---|---|---|
| 60/172,216 | 20 October 1998 (20.10.98) | US |
| 60/118,559 | 4 February 1999 (04.02.99) | US |
| 60/172,229 | 11 February 1999 (11.02.99) | US |
| 60/154,336 | 22 April 1999 (22.04.99) | US |

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications

| | |
|---|---|
| US | 60/172,216 (CIP) |
| Filed on | 20 October 1998 (20.10.98) |
| US | 60/118,559 (CIP) |
| Filed on | 4 February 1999 (04.02.99) |
| US | 60/172,229 (CIP) |
| Filed on | 11 February 1999 (11.02.99) |
| US | 60/154,336 (CIP) |
| Filed on | 22 April 1999 (22.04.99) |

(71) Applicant *(for all designated States except US)*: INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive, #12, Mountain View, CA 94040 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue, #30, Mountain View, CA 94040 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). YANG, Junming [CN/US]; 7136 Clarendon Street, San Jose, CA 95129 (US). SHIH, Leo, L. [US/US]; Apartment B, 1081 Tanland Drive, Palo Alto, CA 94304 (US).

(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published**

*With international search report*

(88) Date of publication of the international search report: 28 September 2000 (28.09.00)

(54) Title: PROLIFERATION AND APOPTOSIS RELATED PROTEINS




(57) Abstract

The invention provides human proliferation and apoptosis related proteins (PROAP) and polynucleotides which identify and encode PROAP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of PROAP.

```
1    MSRTMARTRPGQLG--RVTGAGGWGSAAVC  1342011
1    MATPVPPPSPRHLRLLRLLSG-------LI  GI452276

29   RGRALRGREPALPSASFPDVAACPGSLDCA  1342011
25   LGAALNG-----ATARRPDATTCPGSLDCA  GI452276

59   LKRRARCPPGAHACGPCLQPFQEDQQGLCV  1342011
50   LKRRAKCPPGAHACGPCLQSFQEDQRGFCV  GI452276

89   PRMRRPPGGGRPQPRLEDEIDFLAQELA--  1342011
80   PRKHLSSGEGLPQPRLEEEIDSLAQELALK  GI452276

117  RKESGHS--TPPLPKDRQRLPEPA-TLGF  1342011
110  EKEAGHSRLTAQPLLERAQKLLEPAATLGF  GI452276

143  SARGQGLELGLPSTPGTPTPTPHTSLGSPV  1342011
140  SQWGQRLEPGLPSTHGTSSPIPHTSLSSRA  GI452276

173  SSDPVHMSPLEPRGGQGDGLALVLILAFCV  1342011
170  SSGPVQMSPLEPQGRHGNGLTLVLILAFCL  GI452276
```

FIGURE 1A

```
203 AGAAALSVASLCWCRLQREIRLTQKADYA- 1342011
200 ASSAALAVAALCWCRLQREIRLLTQKADYAA GI452276

232 TAKAPGSPAAPRISPGDQRLAQSAEMYHYQ 1342011
230 TAKGPTSPSTPRISPGDQRLAHSAEMYHYQ GI452276

262 HQRQQMLCLERHKEPPKELDTASSDEENED 1342011
260 HQRQQMLCLERHKEPPKELESASSDEENED GI452276

292 GDFTVYECPGLAPTGEMEVRNPLFDHAALS 1342011
290 GDFTVYECPGLAPTGEMEVRNPLFDHSTLS GI452276

322 APLPAPSSPPALP 1342011
320 APVPGPHSLPPLQ GI452276
```

FIGURE 1B

```
1    MAVNVYSTSVTSENLSRHDMLAWVNDSLHL  1880041
1    MAVNVYSTSVTSDNLSRHDMLAWINESLQL  GI 998357

31   NYTKIEQLCSGAAYCQFMDMLFPGCVHLRK  1880041
31   NLTKIEQLCSGAAYCQFMDMLFPGSIALKK  GI 998357

61   VKFQAKLEHEYIHNFKVLQAAFKKMGVDKI  1880041
61   VKFQAKLEHEYIQNFKTLQAGFKRMGVDKI  GI 998357

91   IPVEKLVKGKFQDNFEFIQWFKKFFDANYD  1880041
91   IPVDKLVKGKFQDNFEFVQWFKKFFDANYD  GI 998357

121  GKDYNPLLARQGQDVAPPPNPGDQIFNKSK  1880041
121  GKDYDPVAARQGQETAVAPSLVAPALNKPK  GI 998357

151  KLIGTAVPQRTSPTGPKNMQTSGRLSNVAP  1880041
151  KPLTSSSAAPQRPISTQRTAAAPK----AG  GI 998357
```

FIGURE 2A

09/807452
PCT/US99/24511

```
181 PCILRKNPPSARNGGHETDAQILELNQQLV 1880041
177 PGVVRKNP-----GVGNGDDEAAELMQQVN GI 998357

211 DLKLTVDGLEKERDFYFSKLRDIELICQEH 1880041
202 VLKLTVEDLEKERDFYFGKLRNIELICQEN GI 998357

241 ESENSPVISGIIGILYATEEGFAPPEDDEI 1880041
232 EGENDPVLQRIVDILYATDEGFVIPDEGG- GI 998357

271 EEHQQEDQDEY 1880041
261 ---PQEEQEEY GI 998357
```

FIGURE 2B

```
1    MGEDAAQAEKFQHPGSDMRQEKPSSPSPMP  3201881
1    MGEDAAQAEKFQHPNTDMLQEKPSSPSPMP  GI 455719

31   SSTPSPSLNLGNTEEAIRDNSQVNAVTVLT  3201881
31   SSTPSPSLNLGSTEEAIRDNSQVNAVTVHT  GI 455719

61   LLDKLVNMLDAVQENQHKMEQRQISLEGSV  3201881
61   LLDKLVNMLDAVRENQHNMEQRQINLEGSV  GI 455719

91   KGIQNDLTKLSKYQASTSNTVSKLLEKSRK  3201881
91   KGIQNDLTKLSKYQASTSNTVSKLLEKSRK  GI 455719

121  VSAHTRAVKERMDRQCAQVKRLENNHAQLL  3201881
121  VSAHTRAVRERLERQCVQVKRLENNHAQLL  GI 455719

151  RRNHFKVLIFQEENEIPASVFVKQPVSGAV  3201881
151  RRNHFKVLIFQEESEIPASVFVKEPVPSAA  GI 455719

181  EGKEELPDENKSLEETLHTVDLSSDDDLPH  3201881
181  EGKEELADENKSLEETLHNVDLSSDDELPR  GI 455719

211  DEEALEDSAEEKVGRSPRGREIKRS---RP  3201881
211  DEEALEDSAEEKME-ESRAEKIKRSSLKKV  GI 455719
```

FIGURE 3

```
1    MSFLLPKLTSKKEVDQAIKSTAEKVLVLRF  1438978
1    MSYMLPHLHNGWQVDQAILSEEDRVVVIRF  GI 2565275

31   GRDEDPVCLQLDDILSKTSSDLSKMAAIYL  1438978
31   GHDWDPTCMKMDEVLYSIAEKVKNFAVIYL  GI 2565275

61   VDVDQTAVYTQYFDISYIPSTV-FFFNGQH  1438978
61   VDITEVPDFNKMYELY-YDPCTVMFFFRNKH  GI 2565275

90   MKVDYG                          1438978
90   IMIDLGTGNNNKINWAMEDKQEMVDIIETV  GI 2565275

95                                   1438978
120  YRGARKGRGLVVSPKDYSTKYRY         GI 2565275
```

FIGURE 4

```
1   MAAPEERDLTQEQTEKLLQFQDLTGIESMD 2024773
1   M---EADGLTNEQTEKVLQFQDLTGIEDMN GI 3688609

31  QCRHTLEQHNWNIEAAVQDRLNEQEGVPSV 2024773
28  VCRDVLIRHQWDLEVAFQEQLNIREGRPTM GI 3688609

61  FNPPPS-------RPLQ----VNTADHR 2024773
58  FAASTDVRAPAVLNDRFLQQVFSANMPGGR GI 3688609

78  IYSYVVSRPQPRGLLGWGYYLIMLPFRFTY 2024773
88  TVSRVPSGPVPRSFTGIIGYVINFVFQY-F GI 3688609

108 YTILDIFRFALRFIRPDPRSR-VTDPVGDI 2024773
117 YSTLTSIVSAFVNLGGGNEARLVTDPLGDV GI 3688609

137 VSFMHSFEEKYGRAHPVFYQGTYSQALNDA 2024773
147 MKFIREYYERY-PEHPVFYQGTYAQALNDA GI 3688609

167 KRELRFLLVYLHGD--DHQDSDEFCRNTLC 2024773
176 KQELRFLIVYLHKDPAKNPDVESFCRNTLS GI 3688609

195 APEVISLINTRMLFWACSTNKPEGYRVSQA 2024773
206 ARSVIDYINTHTLLWGCDVATPEGYRVMQS GI 3688609

225 LRENTYPFLAMIMLKDRRMTVVGRLEGLIQ 2024773
236 ITVRSYPTMVMISLRANRMMIVGRFEGDCT GI 3688609
```

FIGURE 5A

```
255 PDDLINQLTFIMDANQTYLVSERLEERN 2024773
266 PEELRRRLQSVTNANEVWLSQARADRLERN GI 3688609

285 QTQVLRQQQDEAYLASLRADQEKERKKRE 2024773
296 FTQTLRRQQQDEAYEQSLLADEEKERQRQRE GI 3688609

315 RERKRRKEEEVQQQKLAEERRRQNLQEEKE 2024773
326 RDAVRQAEEAVEQARRRDVELRKEEIARQKI GI 3688609

345 RKLECLPPEPSPDDPESVKIIFKLPNDSRV 2024773
356 ELATLVPSEPAADAVGAIAVVFKLPSGTRL GI 3688609

375 ERRFHFSQSLTVIHDFLFSLKESPEKFQIE 2024773
386 ERRFNQTDSVLDVYHYLFCHPDSPDEPEIT GI 3688609

405 ANFPRRVLPCIPSEEWPNPP------T 2024773
416 TNFPRVLFSKANLDAAGETGTAKETLTKT GI 3688609

426 LQEAGLSHTEVLFVQDLTDE 2024773
446 LQAVGLKNREELFVNDL-EA GI 3688609
```

FIGURE 5B

```
1    MEYLSALNPSDLLRSVSNISSEFGRRVWTS  3869790
1    MEYLSAFNPNGLLRSVSTVSSELSRRVWNS  GI 3114594

31   APPPQRPFRVCDHKRTIRKGLTAATRQELI  3869790
31   APPPQRPFRVCDHKRTVRKGLTAASLQELI  GI 3114594

61   AKALETLLLNGVLTLVLEEDGTAVDSEDFF  3869790
61   DKVLETLLLRGVLTLVLEEDGTAVDSEDFF  GI 3114594

91   QLLEDDTCLMVLQSGQSWSPTRSGVLSYGI  3869790
91   QLLEDDTCLMVLEQGQSWSP-KSGMLSYGI  GI 3114594

121  GRERPKHSKDIARFTFDVYKQNPRDLFGSI  3869790
120  GREKPKHSKDIARITFDVYKQNPRDLFGSI  GI 3114594

151  NVKATFYGLYSMSCDFQGLGPKKVLRELLF  3869790
150  NVKATFYGLYSMSCDFQGVGPKRVLRELLF  GI 3114594

181  WTSTLLQGLGHMLLGISSTLRHAVEGAEQW  3869790
180  GTSSQLQGLGHMLLGISSTLRHVVEGADRW  GI 3114594

211  QQKG-RLHSY                      3869790
210  QWHGQRHLHS                      GI 3114594
```

FIGURE 6

**Docket No.: PF-0619 USN**

**DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe that I am the original, first and sole inventor (if only one name is listed below) of an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

PROLIFERATION AND APOPTOSIS RELATED PROTEINS

the specification of which:

/___/ is attached hereto.

/___/ was filed on _____ as application Serial No. _____ and if this box contains an X /___/, was amended on _____.

/ X / was filed as Patent Cooperation Treaty international application No. PCT/US99/24511 on October 19, 1999, if this box contains an X /_/, was amended on under Patent Cooperation Treaty Article 19 on _____ 2001, and if this box contains an X /_/, was amended on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge my duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim the benefit under Title 35, United States Code, §119 or §365(a)-(b) of any foreign application(s) for patent or inventor's certificate indicated below and of any Patent Cooperation Treaty international applications(s) designating at least one country other than the United States indicated below and have also identified below any foreign application(s) for patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application for said subject matter the priority of which is claimed:

**Docket No.: PF-0619 USN**

| Country | Number | Filing Date | Priority Claimed |
|---|---|---|---|
| _____ | _____ | _____ | /_/ Yes /_/ No |
| _____ | _____ | _____ | /_/ Yes /_/ No |

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

| Application Serial No. | Filed | Status (Pending, Abandoned, Patented) |
|---|---|---|
| 60/172,216 | October 20, 1998 | Expired |
| 60/118,559 | February 4, 1999 | Expired |
| 60/172,229 | February 11, 1999 | Expired |
| 60/154,336 | April 22, 1999 | Expired |

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code §112, I acknowledge my duty to disclose material information as defined in Title 37 Code of Federal Regulations, §1.56(a) which occurred between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

| Application Serial No. | Filed | Status (Pending, Abandoned, Patented) |
|---|---|---|
| | | |

I hereby appoint the following:

| | |
|---|---|
| Lucy J. Billings | Reg. No. 36,749 |
| Michael C. Cerrone | Reg. No. 39,132 |
| Diana Hamlet-Cox | Reg. No. 33,302 |
| Richard C. Ekstrom | Reg. No. 37,027 |
| Barrie D. Greene | Reg. No. 46,740 |
| Matthew R. Kaser | Reg. No. 44,817 |
| Lynn E. Murry | Reg. No. 42,918 |
| Shirley A. Recipon | Reg. No. 47,016 |
| Susan K. Sather | Reg. No. 44,316 |
| Michelle M. Stempien | Reg. No. 41,327 |
| David G. Streeter | Reg. No. 43,168 |
| Stephen Todd | Reg. No. 47,139 |
| Christopher Turner | Reg. No. 45,167 |
| P. Ben Wang | Reg. No. 41,420 |

respectively and individually, as my patent attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent

**Docket No.: PF-0619 USN**

and Trademark Office connected therewith. Please address all communications to:

**LEGAL DEPARTMENT**
**INCYTE GENOMICS, INC.**
**3160 PORTER DRIVE, PALO ALTO, CA 94304**

**TEL: 650-855-0555 FAX: 650-849-8886 or 650-845-4166**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

| | | |
|---|---|---|
| **Sole Inventor or First Joint Inventor:** | **Full name:** | **Y. TOM TANG** /00 |
| | **Signature:** | Y. Tom Tang |
| | **Date:** | February 27 **, 2001** |
| | **Citizenship** | ~~**People's Republic of China**~~ USA |
| | **Residence:** | **San Jose, California** CA |
| | **P.O. Address:** | **4230 Ranwick Court**<br>**San Jose, California 95118** |

| | | |
|---|---|---|
| **Second Joint Inventor:** | **Full name:** | **HENRY YUE** 200 |
| | **Signature:** | Henry Yue |
| | **Date:** | March 6 **, 2001** |
| | **Citizenship** | **United States of America** |
| | **Residence:** | **Sunnyvale, California** CA |
| | **P.O. Address:** | **826 Lois Avenue**<br>**Sunnyvale, California 94087** |

**Third Joint Inventor:**

**Full name:** JENNIFER L. HILLMAN 3 00

**Signature:**

**Date:** February 16 , 2001

**Citizenship** United States of America

**Residence:** Mountain View, California CA

**P.O. Address:** 230 Monroe Drive, #17
Mountain View, California
94040

**Fourth Joint Inventor:**

**Full name:** KARL J. GUEGLER 4 00

**Signature:**

**Date:** 02/02 , 2001

**Citizenship** Switzerland

**Residence:** Menlo Park, California CA

**P.O. Address:** 1048 Oakland Avenue
Menlo Park, California 94025

**Fifth Joint Inventor:**

**Full name:** NEIL C. CORLEY 5 00

**Signature:**

**Date:** MARCH 5 , 2001

**Citizenship** United States of America

**Residence:** Castro Valley, California CA

**P.O. Address:** 20426 Crow Creek Road
Castro Valley, California 94552

Docket No.: PF-0619 USN

**Sixth Joint Inventor:**

6 CD

| | |
|---|---|
| **Full name:** | **PREETI LAL** |
| **Signature:** | Preeti Lal |
| **Date:** | FEBRUARY 16 , 2001 |
| **Citizenship** | **India** |
| **Residence:** | **Santa Clara, California** CA |
| **P.O. Address:** | **P.O. Box 5142**<br>**Santa Clara, California 95056** |

**Seventh Joint Inventor:**

7 CD

| | |
|---|---|
| **Full name:** | **YALDA AZIMZAI** |
| **Signature:** | Yalda Azimzai |
| **Date:** | February 2nd , 2001 |
| **Citizenship** | **United States of America** |
| **Residence:** | **Castro Valley, California** CA |
| **P.O. Address:** | **5518 Boulder Canyon Drive**<br>**Castro Valley, California 94552** |

**Eighth Joint Inventor:**

8 CD

| | |
|---|---|
| **Full name:** | **MARIAH R. BAUGHN** |
| **Signature:** | Mariah R. Baughn |
| **Date:** | February 12 , 2001 |
| **Citizenship** | **United States of America** |
| **Residence:** | **San Leandro, California** CA |
| **P.O. Address:** | **14244 Santiago Road**<br>**San Leandro, California 94577** |

**Ninth Joint Inventor:**

| | |
|---|---|
| **Full name:** | **JUNMING YANG** 9th |
| **Signature:** | |
| **Date:** | February 16, 2001 |
| **Citizenship** | **China** |
| **Residence:** | ~~Menlo Park~~ San Jose, **California** CA |
| **P.O. Address:** | **7125 Bark Lane**<br>**San Jose, California 95129** |

**Tenth Joint Inventor:**

| | |
|---|---|
| **Full name:** | **LEO L. SHIH** 10th |
| **Signature:** | |
| **Date:** | March 12, **2001** |
| **Citizenship** | **United States of America** |
| **Residence:** | ~~Palo Alto,~~ East Palo Alto **California** CA |
| **P.O. Address:** | ~~**1081 Tanland Drive, Apt. B**~~<br>~~**Palo Alto, California 94303**~~<br>908 O'Connor St.<br>East Palo Alto, CA 94303 |

L. S.
3/12/2001

SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.
TANG, Y. Tom
YUE, Henry
HILLMAN, Jennifer L.
GUEGLER, Karl J.
CORLEY, Neil C.
LAL, Preeti
AZIMZAI, Yalda
BAUGHN, Mariah R.
JUNMING, Yang
SHIH, Leo L.

<120> PROLIFERATION AND APOPTOSIS RELATED PROTEINS

<130> PF-0619 PCT

<140> To Be Assigned
<141> Herewith

<150> 09/175,737; unassigned; 60/118,559; 09/249,740; unassigned; 60/154,336
<151> 1998-10-20; 1998-10-20; 1999-02-04; 1999-04-11; 1999-04-11; 1999-04-22

<160> 44

<170> PERL Program

<210> 1
<211> 334
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1342011CD1

<400> 1

```
Met Ser Arg Thr Met Ala Arg Thr Arg Pro Gly Gln Leu Gly Arg
  1               5                  10                  15
Val Thr Gly Ala Gly Gly Trp Gly Ser Ala Ala Val Cys Arg Gly
             20                  25                  30
Arg Ala Leu Arg Gly Arg Glu Pro Ala Leu Pro Ser Ala Ser Phe
         35                  40                  45
Pro Asp Val Ala Ala Cys Pro Gly Ser Leu Asp Cys Ala Leu Lys
     50                  55                  60
Arg Arg Ala Arg Cys Pro Pro Gly Ala His Ala Cys Gly Pro Cys
 65                  70                  75
Leu Gln Pro Phe Gln Glu Asp Gln Gln Gly Leu Cys Val Pro Arg
             80                  85                  90
Met Arg Arg Pro Pro Gly Gly Gly Arg Pro Gln Pro Arg Leu Glu
         95                 100                 105
```

```
Asp Glu Ile Asp Phe Leu Ala Gln Glu Leu Ala Arg Lys Glu Ser
                110                 115                 120
Gly His Ser Thr Pro Pro Leu Pro Lys Asp Arg Gln Arg Leu Pro
                125                 130                 135
Glu Pro Ala Thr Leu Gly Phe Ser Ala Arg Gly Gln Gly Leu Glu
                140                 145                 150
Leu Gly Leu Pro Ser Thr Pro Gly Thr Pro Thr Pro Thr Pro His
                155                 160                 165
Thr Ser Leu Gly Ser Pro Val Ser Ser Asp Pro Val His Met Ser
                170                 175                 180
Pro Leu Glu Pro Arg Gly Gly Gln Gly Asp Gly Leu Ala Leu Val
                185                 190                 195
Leu Ile Leu Ala Phe Cys Val Ala Gly Ala Ala Ala Leu Ser Val
                200                 205                 210
Ala Ser Leu Cys Trp Cys Arg Leu Gln Arg Glu Ile Arg Leu Thr
                215                 220                 225
Gln Lys Ala Asp Tyr Ala Thr Ala Lys Ala Pro Gly Ser Pro Ala
                230                 235                 240
Ala Pro Arg Ile Ser Pro Gly Asp Gln Arg Leu Ala Gln Ser Ala
                245                 250                 255
Glu Met Tyr His Tyr Gln His Gln Arg Gln Gln Met Leu Cys Leu
                260                 265                 270
Glu Arg His Lys Glu Pro Pro Lys Glu Leu Asp Thr Ala Ser Ser
                275                 280                 285
Asp Glu Glu Asn Glu Asp Gly Asp Phe Thr Val Tyr Glu Cys Pro
                290                 295                 300
Gly Leu Ala Pro Thr Gly Glu Met Glu Val Arg Asn Pro Leu Phe
                305                 310                 315
Asp His Ala Ala Leu Ser Ala Pro Leu Pro Ala Pro Ser Ser Pro
                320                 325                 330
Pro Ala Leu Pro
```

<210> 2
<211> 281
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1880041CD1

<400> 2

```
Met Ala Val Asn Val Tyr Ser Thr Ser Val Thr Ser Glu Asn Leu
  1               5                  10                  15
Ser Arg His Asp Met Leu Ala Trp Val Asn Asp Ser Leu His Leu
                20                  25                  30
Asn Tyr Thr Lys Ile Glu Gln Leu Cys Ser Gly Ala Ala Tyr Cys
                35                  40                  45
Gln Phe Met Asp Met Leu Phe Pro Gly Cys Val His Leu Arg Lys
                50                  55                  60
Val Lys Phe Gln Ala Lys Leu Glu His Glu Tyr Ile His Asn Phe
                65                  70                  75
Lys Val Leu Gln Ala Ala Phe Lys Lys Met Gly Val Asp Lys Ile
                80                  85                  90
```

```
Ile Pro Val Glu Lys Leu Val Lys Gly Lys Phe Gln Asp Asn Phe
                 95                  100                 105
Glu Phe Ile Gln Trp Phe Lys Lys Phe Phe Asp Ala Asn Tyr Asp
                110                 115                 120
Gly Lys Asp Tyr Asn Pro Leu Leu Ala Arg Gln Gly Gln Asp Val
                125                 130                 135
Ala Pro Pro Pro Asn Pro Gly Asp Gln Ile Phe Asn Lys Ser Lys
                140                 145                 150
Lys Leu Ile Gly Thr Ala Val Pro Gln Arg Thr Ser Pro Thr Gly
                155                 160                 165
Pro Lys Asn Met Gln Thr Ser Gly Arg Leu Ser Asn Val Ala Pro
                170                 175                 180
Pro Cys Ile Leu Arg Lys Asn Pro Pro Ser Ala Arg Asn Gly Gly
                185                 190                 195
His Glu Thr Asp Ala Gln Ile Leu Glu Leu Asn Gln Gln Leu Val
                200                 205                 210
Asp Leu Lys Leu Thr Val Asp Gly Leu Glu Lys Glu Arg Asp Phe
                215                 220                 225
Tyr Phe Ser Lys Leu Arg Asp Ile Glu Leu Ile Cys Gln Glu His
                230                 235                 240
Glu Ser Glu Asn Ser Pro Val Ile Ser Gly Ile Ile Gly Ile Leu
                245                 250                 255
Tyr Ala Thr Glu Glu Gly Phe Ala Pro Pro Glu Asp Asp Glu Ile
                260                 265                 270
Glu Glu His Gln Gln Glu Asp Gln Asp Glu Tyr
                275                 280
```

<210> 3
<211> 237
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3201881CD1

<400> 3

```
Met Gly Glu Asp Ala Ala Gln Ala Glu Lys Phe Gln His Pro Gly
  1               5                  10                  15
Ser Asp Met Arg Gln Glu Lys Pro Ser Ser Pro Ser Pro Met Pro
                 20                  25                  30
Ser Ser Thr Pro Ser Pro Ser Leu Asn Leu Gly Asn Thr Glu Glu
                 35                  40                  45
Ala Ile Arg Asp Asn Ser Gln Val Asn Ala Val Thr Val Leu Thr
                 50                  55                  60
Leu Leu Asp Lys Leu Val Asn Met Leu Asp Ala Val Gln Glu Asn
                 65                  70                  75
Gln His Lys Met Glu Gln Arg Gln Ile Ser Leu Glu Gly Ser Val
                 80                  85                  90
Lys Gly Ile Gln Asn Asp Leu Thr Lys Leu Ser Lys Tyr Gln Ala
                 95                 100                 105
Ser Thr Ser Asn Thr Val Ser Lys Leu Leu Glu Lys Ser Arg Lys
                110                 115                 120
Val Ser Ala His Thr Arg Ala Val Lys Glu Arg Met Asp Arg Gln
```

```
                125                 130                 135
Cys Ala Gln Val Lys Arg Leu Glu Asn Asn His Ala Gln Leu Leu
                140                 145                 150
Arg Arg Asn His Phe Lys Val Leu Ile Phe Gln Glu Glu Asn Glu
                155                 160                 165
Ile Pro Ala Ser Val Phe Val Lys Gln Pro Val Ser Gly Ala Val
                170                 175                 180
Glu Gly Lys Glu Glu Leu Pro Asp Glu Asn Lys Ser Leu Glu Glu
                185                 190                 195
Thr Leu His Thr Val Asp Leu Ser Ser Asp Asp Asp Leu Pro His
                200                 205                 210
Asp Glu Glu Ala Leu Glu Asp Ser Ala Glu Glu Lys Val Gly Arg
                215                 220                 225
Ser Pro Arg Gly Arg Glu Ile Lys Arg Ser Arg Pro
                230                 235
```

<210> 4
<211> 941
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 939000CD1

<400> 4

```
Met Asn Lys Lys Lys Lys Pro Phe Leu Gly Met Pro Ala Pro Leu
  1                 5                  10                  15
Gly Tyr Val Pro Gly Leu Gly Arg Gly Ala Thr Gly Phe Thr Thr
                 20                  25                  30
Arg Ser Asp Ile Gly Pro Ala Arg Asp Ala Asn Asp Pro Val Asp
                 35                  40                  45
Asp Arg His Ala Pro Pro Gly Lys Arg Thr Val Gly Asp Gln Met
                 50                  55                  60
Lys Lys Asn Gln Ala Ala Asp Asp Asp Asp Glu Asp Leu Asn Asp
                 65                  70                  75
Thr Asn Tyr Asp Glu Phe Asn Gly Tyr Ala Gly Ser Leu Phe Ser
                 80                  85                  90
Ser Gly Pro Tyr Glu Lys Asp Asp Glu Glu Ala Asp Ala Ile Tyr
                 95                 100                 105
Ala Ala Leu Asp Lys Arg Met Asp Glu Arg Arg Lys Glu Arg Arg
                110                 115                 120
Glu Gln Arg Glu Lys Glu Glu Ile Glu Lys Tyr Arg Met Glu Arg
                125                 130                 135
Pro Lys Ile Gln Gln Gln Phe Ser Asp Leu Lys Arg Lys Leu Ala
                140                 145                 150
Glu Val Thr Glu Glu Glu Trp Leu Ser Ile Pro Glu Val Gly Asp
                155                 160                 165
Ala Arg Asn Lys Arg Gln Arg Asn Pro Arg Tyr Glu Lys Leu Thr
                170                 175                 180
Pro Val Pro Asp Ser Phe Phe Ala Lys His Leu Gln Thr Gly Glu
                185                 190                 195
Asn His Thr Ser Val Asp Pro Arg Gln Thr Gln Phe Gly Gly Leu
                200                 205                 210
```

```
Asn Thr Pro Tyr Pro Gly Gly Leu Asn Thr Pro Tyr Pro Gly Gly
                215                 220                 225
Met Thr Pro Gly Leu Met Thr Pro Gly Thr Gly Glu Leu Asp Met
                230                 235                 240
Arg Lys Ile Gly Gln Ala Arg Asn Thr Leu Met Asp Met Arg Leu
                245                 250                 255
Ser Gln Val Ser Asp Ser Val Ser Gly Gln Thr Val Val Asp Pro
                260                 265                 270
Lys Gly Tyr Leu Thr Asp Leu Asn Ser Met Ile Pro Thr His Gly
                275                 280                 285
Gly Asp Ile Asn Asp Ile Lys Lys Ala Arg Leu Leu Leu Lys Ser
                290                 295                 300
Val Arg Glu Thr Asn Pro His His Pro Pro Ala Trp Ile Ala Ser
                305                 310                 315
Ala Arg Leu Glu Glu Val Thr Gly Lys Leu Gln Val Ala Arg Asn
                320                 325                 330
Leu Ile Met Lys Gly Thr Glu Met Cys Pro Lys Ser Glu Asp Val
                335                 340                 345
Trp Leu Glu Ala Ala Arg Leu Gln Pro Gly Asp Thr Ala Lys Ala
                350                 355                 360
Val Val Ala Gln Ala Val Arg His Leu Pro Gln Ser Val Arg Ile
                365                 370                 375
Tyr Ile Arg Ala Ala Glu Leu Glu Thr Asp Ile Arg Ala Lys Lys
                380                 385                 390
Arg Val Leu Arg Lys Ala Leu Glu His Val Pro Asn Ser Val Arg
                395                 400                 405
Leu Trp Lys Ala Ala Val Glu Leu Glu Glu Pro Glu Asp Ala Arg
                410                 415                 420
Ile Met Leu Ser Arg Ala Val Glu Cys Cys Pro Thr Ser Val Glu
                425                 430                 435
Leu Trp Leu Ala Leu Ala Arg Leu Glu Thr Tyr Glu Asn Ala Arg
                440                 445                 450
Lys Val Leu Asn Lys Ala Arg Glu Asn Ile Pro Thr Asp Arg His
                455                 460                 465
Ile Trp Ile Thr Ala Ala Lys Leu Glu Glu Ala Asn Gly Asn Thr
                470                 475                 480
Gln Met Val Glu Lys Ile Ile Asp Arg Ala Ile Thr Ser Leu Arg
                485                 490                 495
Ala Asn Gly Val Glu Ile Asn Arg Glu Gln Trp Ile Gln Asp Ala
                500                 505                 510
Glu Glu Cys Asp Arg Ala Gly Ser Val Ala Thr Cys Gln Ala Val
                515                 520                 525
Met Arg Ala Val Ile Gly Ile Gly Ile Glu Glu Glu Asp Arg Lys
                530                 535                 540
His Thr Trp Met Glu Asp Ala Asp Ser Cys Val Ala His Asn Ala
                545                 550                 555
Leu Glu Cys Ala Arg Ala Ile Tyr Ala Tyr Ala Leu Gln Val Phe
                560                 565                 570
Pro Ser Lys Lys Ser Val Trp Leu Arg Ala Ala Tyr Phe Glu Lys
                575                 580                 585
Asn His Gly Thr Arg Glu Ser Leu Glu Ala Leu Leu Gln Arg Ala
                590                 595                 600
Val Ala His Cys Pro Lys Ala Glu Val Leu Trp Leu Met Gly Ala
                605                 610                 615
Lys Ser Lys Trp Leu Ala Gly Asp Val Pro Ala Ala Arg Ser Ile
```

```
                620                 625                 630
Leu Ala Leu Ala Phe Gln Ala Asn Pro Asn Ser Glu Glu Ile Trp
                635                 640                 645
Leu Ala Ala Val Lys Leu Glu Ser Glu Asn Asp Glu Tyr Glu Arg
                650                 655                 660
Ala Arg Arg Leu Leu Ala Lys Ala Arg Ser Ser Ala Pro Thr Ala
                665                 670                 675
Arg Val Phe Met Lys Ser Val Lys Leu Glu Trp Val Gln Asp Asn
                680                 685                 690
Ile Arg Ala Ala Gln Asp Leu Cys Glu Glu Ala Leu Arg His Tyr
                695                 700                 705
Glu Asp Phe Pro Lys Leu Trp Met Met Lys Gly Gln Ile Glu Glu
                710                 715                 720
Gln Lys Glu Met Met Glu Lys Ala Arg Glu Ala Tyr Asn Gln Gly
                725                 730                 735
Leu Lys Lys Cys Pro His Ser Thr Pro Leu Trp Leu Leu Leu Ser
                740                 745                 750
Arg Leu Glu Glu Lys Ile Gly Gln Leu Thr Arg Ala Arg Ala Ile
                755                 760                 765
Leu Glu Lys Ser Arg Leu Lys Asn Pro Lys Asn Pro Gly Leu Trp
                770                 775                 780
Leu Glu Ser Val Arg Leu Glu Tyr Arg Ala Gly Leu Lys Asn Ile
                785                 790                 795
Ala Asn Thr Leu Met Ala Lys Ala Leu Gln Glu Cys Pro Asn Ser
                800                 805                 810
Gly Ile Leu Trp Ser Glu Ala Ile Phe Leu Glu Ala Arg Pro Gln
                815                 820                 825
Arg Arg Thr Lys Ser Val Asp Ala Leu Lys Lys Cys Glu His Asp
                830                 835                 840
Pro His Val Leu Leu Ala Val Ala Lys Leu Phe Trp Ser Gln Arg
                845                 850                 855
Lys Ile Thr Lys Ala Arg Glu Trp Phe His Arg Thr Val Lys Ile
                860                 865                 870
Asp Ser Asp Leu Gly Asp Ala Trp Ala Phe Phe Tyr Lys Phe Glu
                875                 880                 885
Leu Gln His Gly Thr Glu Glu Gln Gln Glu Glu Val Arg Lys Arg
                890                 895                 900
Cys Glu Ser Ala Glu Pro Arg His Gly Glu Leu Trp Cys Ala Val
                905                 910                 915
Ser Lys Asp Ile Ala Asn Trp Gln Lys Lys Ile Gly Asp Ile Leu
                920                 925                 930
Arg Leu Val Ala Gly Arg Ile Lys Asn Thr Phe
                935                 940
```

<210> 5
<211> 918
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2125677CD1

<400> 5

```
Met Thr Ala Arg Glu Glu Ala Ser Leu Arg Thr Leu Glu Gly Arg
 1               5                  10                  15
Arg Arg Ala Thr Leu Leu Ser Ala Arg Gln Gly Met Met Ser Ala
            20                  25                  30
Arg Gly Asp Phe Leu Asn Tyr Ala Leu Ser Leu Met Arg Ser His
        35                  40                  45
Asn Asp Glu His Ser Asp Val Leu Pro Val Leu Asp Val Cys Ser
    50                  55                  60
Leu Lys His Val Ala Tyr Val Phe Gln Ala Leu Ile Tyr Trp Ile
65                  70                  75
Lys Ala Met Asn Gln Gln Thr Thr Leu Asp Thr Pro Gln Leu Glu
                80                  85                  90
Arg Lys Arg Thr Arg Glu Leu Leu Glu Leu Gly Ile Asp Asn Glu
            95                  100                 105
Asp Ser Glu His Glu Asn Asp Asp Asp Thr Asn Gln Ser Ala Thr
        110                 115                 120
Leu Asn Asp Lys Asp Asp Asp Ser Leu Pro Ala Glu Thr Gly Gln
    125                 130                 135
Asn His Pro Phe Phe Arg Arg Ser Asp Ser Met Thr Phe Leu Gly
140                 145                 150
Cys Ile Pro Pro Asn Pro Phe Glu Val Pro Leu Ala Glu Ala Ile
155                 160                 165
Pro Leu Ala Asp Gln Pro His Leu Leu Gln Pro Asn Ala Arg Lys
                170                 175                 180
Glu Asp Leu Phe Gly Arg Pro Ser Gln Gly Leu Tyr Ser Ser Ser
            185                 190                 195
Ala Ser Ser Gly Lys Cys Leu Met Glu Val Thr Val Asp Arg Asn
        200                 205                 210
Cys Leu Glu Val Leu Pro Thr Lys Met Ser Tyr Ala Ala Asn Leu
    215                 220                 225
Lys Asn Val Met Asn Met Gln Asn Arg Gln Lys Lys Glu Gly Glu
230                 235                 240
Glu Gln Pro Val Leu Pro Glu Glu Thr Glu Ser Ser Lys Pro Gly
245                 250                 255
Pro Ser Ala His Asp Leu Ala Ala Gln Leu Lys Ser Ser Leu Leu
            260                 265                 270
Ala Glu Ile Gly Leu Thr Glu Ser Glu Gly Pro Pro Leu Thr Ser
        275                 280                 285
Phe Arg Pro Gln Cys Ser Phe Met Gly Met Val Ile Ser His Asp
    290                 295                 300
Met Leu Leu Gly Arg Trp Arg Leu Ser Leu Glu Leu Phe Gly Arg
305                 310                 315
Val Phe Met Glu Asp Val Gly Ala Glu Pro Gly Ser Ile Leu Thr
                320                 325                 330
Glu Leu Gly Gly Phe Glu Val Lys Glu Ser Lys Phe Arg Arg Glu
            335                 340                 345
Met Glu Lys Leu Arg Asn Gln Gln Ser Arg Asp Leu Ser Leu Glu
        350                 355                 360
Val Lys Val Asp Arg Asp Arg Asp Leu Leu Ile Gln Gln Thr Met
    365                 370                 375
Arg Gln Leu Asn Asn His Phe Gly Arg Arg Cys Ala Thr Thr Pro
380                 385                 390
Met Ala Val His Arg Val Lys Val Thr Phe Lys Asp Glu Pro Gly
395                 400                 405
```

Glu Gly Ser Gly Val Ala Arg Ser Phe Tyr Thr Ala Ile Ala Gln
410 415 420
Ala Phe Leu Ser Asn Glu Lys Leu Pro Asn Leu Glu Cys Ile Gln
425 430 435
Asn Ala Asn Lys Gly Thr His Thr Ser Leu Met Gln Arg Leu Arg
440 445 450
Asn Arg Gly Glu Arg Asp Arg Glu Arg Glu Arg Glu Arg Glu Met
455 460 465
Arg Arg Ser Ser Gly Leu Arg Ala Gly Ser Arg Arg Asp Arg Asp
470 475 480
Arg Asp Phe Arg Arg Gln Leu Ser Ile Asp Thr Arg Pro Phe Arg
485 490 495
Pro Ala Ser Glu Gly Asn Pro Ser Asp Asp Pro Glu Pro Leu Pro
500 505 510
Ala His Arg Gln Ala Leu Gly Glu Arg Leu Tyr Pro Arg Val Gln
515 520 525
Ala Met Gln Pro Ala Phe Ala Ser Lys Ile Thr Gly Met Leu Leu
530 535 540
Glu Leu Ser Pro Ala Gln Leu Leu Leu Leu Leu Ala Ser Glu Asp
545 550 555
Ser Leu Arg Ala Arg Val Asp Glu Ala Met Glu Leu Ile Ile Ala
560 565 570
His Gly Arg Glu Asn Gly Ala Asp Ser Ile Leu Asp Leu Gly Leu
575 580 585
Val Asp Ser Ser Glu Lys Val Gln Gln Glu Asn Arg Lys Arg His
590 595 600
Gly Ser Ser Arg Ser Val Val Asp Met Asp Leu Asp Asp Thr Asp
605 610 615
Asp Gly Asp Asp Asn Ala Pro Leu Phe Tyr Gln Pro Gly Lys Arg
620 625 630
Gly Phe Tyr Thr Pro Arg Pro Gly Lys Asn Thr Glu Ala Arg Leu
635 640 645
Asn Cys Phe Arg Asn Ile Gly Arg Ile Leu Gly Leu Cys Leu Leu
650 655 660
Gln Asn Glu Leu Cys Pro Ile Thr Leu Asn Arg His Val Ile Lys
665 670 675
Val Leu Leu Gly Arg Lys Val Asn Trp His Asp Phe Ala Phe Phe
680 685 690
Asp Pro Val Met Tyr Glu Ser Leu Arg Gln Leu Ile Leu Ala Ser
695 700 705
Gln Ser Ser Asp Ala Asp Ala Val Phe Ser Ala Met Asp Leu Ala
710 715 720
Phe Ala Ile Asp Leu Cys Lys Glu Glu Gly Gly Gly Gln Val Glu
725 730 735
Leu Ile Pro Asn Gly Val Asn Ile Pro Val Thr Pro Gln Asn Val
740 745 750
Tyr Glu Tyr Val Arg Lys Tyr Ala Glu His Arg Met Leu Val Val
755 760 765
Ala Glu Gln Pro Leu His Ala Met Arg Lys Gly Leu Leu Asp Val
770 775 780
Leu Pro Lys Asn Ser Leu Glu Asp Leu Thr Ala Glu Asp Phe Arg
785 790 795
Leu Leu Val Asn Gly Cys Gly Glu Val Asn Val Gln Met Leu Ile
800 805 810
Ser Phe Thr Ser Phe Asn Asp Glu Ser Gly Glu Asn Ala Glu Lys

```
                815                 820                 825
Leu Leu Gln Phe Lys Arg Trp Phe Trp Ser Ile Val Glu Lys Met
                830                 835                 840
Ser Met Thr Glu Arg Gln Asp Leu Val Tyr Phe Trp Thr Ser Ser
                845                 850                 855
Pro Ser Leu Pro Ala Ser Glu Glu Gly Phe Gln Pro Met Pro Ser
                860                 865                 870
Ile Thr Ile Arg Pro Pro Asp Asp Gln His Leu Pro Thr Ala Asn
                875                 880                 885
Thr Cys Ile Ser Arg Leu Tyr Val Pro Leu Tyr Ser Ser Lys Gln
                890                 895                 900
Ile Leu Lys Gln Lys Leu Leu Leu Ala Ile Lys Thr Lys Asn Phe
                905                 910                 915
Gly Phe Val
```

<210> 6
<211> 324
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2603810CD1

```
<400> 6
Met Gly Pro Trp Gly Glu Pro Glu Leu Leu Val Trp Arg Pro Glu
  1               5                  10                  15
Ala Val Ala Ser Glu Pro Pro Val Pro Val Gly Leu Glu Val Lys
                20                  25                  30
Leu Gly Ala Leu Val Leu Leu Leu Val Leu Thr Leu Leu Cys Ser
                35                  40                  45
Leu Val Pro Ile Cys Val Leu Arg Arg Pro Gly Ala Asn His Glu
                50                  55                  60
Gly Ser Ala Ser Arg Gln Lys Ala Leu Ser Leu Val Ser Cys Phe
                65                  70                  75
Ala Gly Gly Val Phe Leu Ala Thr Cys Leu Leu Asp Leu Leu Pro
                80                  85                  90
Asp Tyr Leu Ala Ala Ile Asp Glu Ala Leu Ala Ala Leu His Val
                95                 100                 105
Thr Leu Gln Phe Pro Leu Gln Glu Phe Ile Leu Ala Met Gly Phe
               110                 115                 120
Phe Leu Val Leu Val Met Glu Gln Ile Thr Leu Ala Tyr Lys Glu
               125                 130                 135
Gln Ser Gly Pro Ser Pro Leu Glu Glu Thr Arg Ala Leu Leu Gly
               140                 145                 150
Thr Val Asn Gly Gly Pro Gln His Trp His Asp Gly Pro Gly Val
               155                 160                 165
Pro Gln Ala Ser Gly Ala Pro Ala Thr Pro Ser Ala Leu Arg Ala
               170                 175                 180
Cys Val Leu Val Phe Ser Leu Ala Leu His Ser Val Phe Glu Gly
               185                 190                 195
Leu Ala Val Gly Leu Gln Arg Asp Arg Ala Arg Ala Met Glu Leu
               200                 205                 210
Cys Leu Ala Leu Leu Leu His Lys Gly Ile Leu Ala Val Ser Leu
```

```
                215                 220                 225
Ser Leu Arg Leu Leu Gln Ser His Leu Arg Ala Gln Val Val Ala
                230                 235                 240
Gly Cys Gly Ile Leu Phe Ser Cys Met Thr Pro Leu Gly Ile Gly
                245                 250                 255
Leu Gly Ala Ala Leu Ala Glu Ser Ala Gly Pro Leu His Gln Leu
                260                 265                 270
Ala Gln Ser Val Leu Glu Gly Met Ala Ala Gly Thr Phe Leu Tyr
                275                 280                 285
Ile Thr Phe Leu Glu Ile Leu Pro Gln Glu Leu Ala Ser Ser Glu
                290                 295                 300
Gln Arg Ile Leu Lys Val Ile Leu Leu Leu Ala Gly Phe Ala Leu
                305                 310                 315
Leu Thr Gly Leu Leu Phe Ile Gln Ile
                320
```

<210> 7
<211> 185
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2715761CD1

<400> 7

```
Met Thr Thr Pro Asn Lys Thr Pro Pro Gly Ala Asp Pro Lys Gln
  1               5                  10                  15
Leu Glu Arg Thr Gly Thr Val Arg Glu Ile Gly Ser Gln Ala Val
                20                  25                  30
Trp Ser Leu Ser Ser Cys Lys Pro Gly Phe Gly Val Asp Gln Leu
                35                  40                  45
Arg Asp Asp Asn Leu Glu Thr Tyr Trp Gln Ser Asp Gly Ser Gln
                50                  55                  60
Pro His Leu Val Asn Ile Gln Phe Arg Arg Lys Thr Thr Val Lys
                65                  70                  75
Thr Leu Cys Ile Tyr Ala Asp Tyr Lys Ser Asp Glu Ser Tyr Thr
                80                  85                  90
Pro Ser Lys Ile Ser Val Arg Val Gly Asn Asn Phe His Asn Leu
                95                 100                 105
Gln Glu Ile Arg Gln Leu Glu Leu Val Glu Pro Ser Gly Trp Ile
               110                 115                 120
His Val Pro Leu Thr Asp Asn His Lys Lys Pro Thr Arg Thr Phe
               125                 130                 135
Met Ile Gln Ile Ala Val Leu Ala Asn His Gln Asn Gly Arg Asp
               140                 145                 150
Thr His Met Arg Gln Ile Lys Ile Tyr Thr Pro Val Glu Glu Ser
               155                 160                 165
Ser Ile Gly Lys Phe Pro Arg Cys Thr Thr Ile Asp Phe Met Met
               170                 175                 180
Tyr Arg Ser Ile Arg
               185
```

<210> 8
<211> 445
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3255641CD1

<400> 8

```
Met Leu Ala Ser Tyr Gly Leu Ala Tyr Ser Leu Met Lys Phe Phe
  1               5                  10                  15
Thr Gly Pro Met Ser Asp Phe Lys Asn Val Gly Leu Val Phe Val
             20                  25                  30
Asn Ser Lys Arg Asp Arg Thr Lys Ala Val Leu Cys Met Val Val
             35                  40                  45
Ala Gly Ala Ile Ala Ala Val Phe His Thr Leu Ile Ala Tyr Ser
             50                  55                  60
Asp Leu Gly Tyr Tyr Ile Ile Asn Lys Leu His His Val Asp Glu
             65                  70                  75
Ser Val Gly Ser Lys Thr Arg Arg Ala Phe Leu Tyr Leu Ala Ala
             80                  85                  90
Phe Pro Phe Met Asp Ala Met Ala Trp Thr His Ala Gly Ile Leu
             95                 100                 105
Leu Lys His Lys Tyr Ser Phe Leu Val Gly Cys Ala Ser Ile Ser
            110                 115                 120
Asp Val Ile Ala Gln Val Val Phe Val Ala Ile Leu Leu His Ser
            125                 130                 135
His Leu Glu Cys Arg Glu Pro Leu Leu Ile Pro Ile Leu Ser Leu
            140                 145                 150
Tyr Met Gly Ala Leu Val Arg Cys Thr Thr Leu Cys Leu Gly Tyr
            155                 160                 165
Tyr Lys Asn Ile His Asp Ile Ile Pro Asp Arg Ser Gly Pro Glu
            170                 175                 180
Leu Gly Gly Asp Ala Thr Ile Arg Lys Met Leu Ser Phe Trp Trp
            185                 190                 195
Pro Leu Ala Leu Ile Leu Ala Thr Gln Arg Ile Ser Arg Pro Ile
            200                 205                 210
Val Asn Leu Phe Val Ser Arg Asp Leu Gly Gly Ser Ser Ala Ala
            215                 220                 225
Thr Glu Ala Val Ala Ile Leu Thr Ala Thr Tyr Pro Val Gly His
            230                 235                 240
Met Pro Tyr Gly Trp Leu Thr Glu Ile Arg Ala Val Tyr Pro Ala
            245                 250                 255
Phe Asp Lys Asn Asn Pro Ser Asn Lys Leu Val Ser Thr Ser Asn
            260                 265                 270
Thr Val Thr Ala Ala His Ile Lys Lys Phe Thr Phe Val Cys Met
            275                 280                 285
Ala Leu Ser Leu Thr Leu Cys Phe Val Met Phe Trp Thr Pro Asn
            290                 295                 300
Val Ser Glu Lys Ile Leu Ile Asp Ile Ile Gly Val Asp Phe Ala
            305                 310                 315
Phe Ala Glu Leu Cys Val Val Pro Leu Arg Ile Phe Ser Phe Phe
            320                 325                 330
Pro Val Pro Val Thr Val Arg Ala His Leu Thr Gly Trp Leu Met
```

```
                335                 340                 345
Thr Leu Lys Lys Thr Phe Val Leu Ala Pro Ser Ser Val Leu Arg
                350                 355                 360
Ile Ile Val Leu Ile Ala Ser Leu Val Val Leu Pro Tyr Leu Gly
                365                 370                 375
Val His Gly Ala Thr Leu Gly Val Gly Ser Leu Leu Ala Gly Phe
                380                 385                 390
Val Gly Glu Ser Thr Met Val Ala Ile Ala Ala Cys Tyr Val Tyr
                395                 400                 405
Arg Lys Gln Lys Lys Lys Met Glu Asn Glu Ser Ala Thr Glu Gly
                410                 415                 420
Glu Asp Ser Ala Met Thr Asp Met Pro Pro Thr Glu Glu Val Thr
                425                 430                 435
Asp Ile Val Glu Met Arg Glu Glu Asn Glu
                440                 445


<210> 9
<211> 73
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3620391CD1

<400> 9
Met Pro Arg Glu Arg Arg Glu Arg Asp Ala Lys Glu Arg Asp Thr
  1               5                  10                  15
Met Lys Glu Asp Gly Gly Ala Glu Phe Ser Ala Arg Ser Arg Lys
                20                  25                  30
Arg Lys Ala Asn Val Thr Val Phe Cys Arg Ile Gln Met Lys Lys
                35                  40                  45
Trp Pro Lys Ser Thr Gly Arg Arg Trp Thr Ser Val Gly Ala Arg
                50                  55                  60
Leu Gly Arg Met Met Gln Ser Val Gln Ala Pro Ala Pro
                65                  70


<210> 10
<211> 288
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3969860CD1

<400> 10
Met Ala Ala Leu Phe Gln Glu Ala Ser Ser Cys Pro Val Cys Ser
  1               5                  10                  15
Asp Tyr Leu Glu Lys Pro Met Ser Leu Glu Cys Gly Cys Ala Val
                20                  25                  30
Cys Leu Lys Cys Ile Asn Ser Leu Gln Lys Glu Pro His Gly Glu
                35                  40                  45
```

```
Asp Leu Leu Cys Cys Cys Ser Ser Met Val Ser Arg Lys Asn Lys
                  50                  55                  60
Ile Arg Arg Asn Arg Gln Leu Glu Arg Leu Ala Ser His Ile Lys
                  65                  70                  75
Glu Leu Glu Pro Lys Leu Lys Lys Ile Leu Gln Met Asn Pro Arg
                  80                  85                  90
Met Arg Lys Phe Gln Val Asp Met Thr Leu Asp Ala Asn Thr Ala
                  95                 100                 105
Asn Asn Phe Leu Leu Ile Ser Asp Asp Leu Arg Ser Val Arg Ser
                 110                 115                 120
Gly Arg Ile Arg Gln Asn Arg Gln Asp Leu Ala Glu Arg Phe Asp
                 125                 130                 135
Val Ser Val Cys Ile Leu Gly Ser Pro Arg Phe Thr Cys Gly Arg
                 140                 145                 150
His Cys Trp Glu Val Asp Val Gly Thr Ser Thr Glu Trp Asp Leu
                 155                 160                 165
Gly Val Cys Arg Glu Ser Val His Arg Lys Gly Arg Ile Gln Leu
                 170                 175                 180
Thr Thr Glu Leu Gly Phe Trp Thr Val Ser Leu Arg Asp Gly Gly
                 185                 190                 195
Arg Leu Ser Ala Ser Thr Val Pro Leu Thr Phe Leu Phe Val Asp
                 200                 205                 210
Arg Lys Leu Gln Arg Val Gly Ile Phe Leu Asp Met Gly Met Gln
                 215                 220                 225
Asn Val Ser Phe Phe Asp Ala Glu Ser Gly Ser His Val Tyr Thr
                 230                 235                 240
Phe Arg Ser Val Ser Ala Glu Glu Pro Leu Arg Pro Phe Leu Ala
                 245                 250                 255
Pro Ser Val Pro Pro Asn Gly Asp Gln Gly Val Leu Ser Ile Cys
                 260                 265                 270

Pro Leu Met Asn Ser Gly Thr Thr Asp Ala Pro Val Arg Pro Gly
                 275                 280                 285
Glu Ala Lys


<210> 11
<211> 98
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 4286006CD1

<400> 11
Met Ala Lys Phe Gly Val His Arg Ile Leu Leu Leu Ala Ile Ser
  1               5                  10                  15
Leu Thr Lys Cys Leu Glu Ser Thr Lys Leu Leu Ala Asp Leu Lys
                 20                  25                  30
Lys Cys Gly Asp Leu Glu Cys Glu Ala Leu Ile Asn Arg Val Ser
                 35                  40                  45
Ala Met Arg Asp Tyr Arg Gly Pro Asp Cys Arg Tyr Leu Asn Phe
                 50                  55                  60
Thr Lys Gly Glu Glu Ile Ser Val Tyr Val Lys Leu Ala Gly Asp
```

```
                 65                  70                  75
Arg Glu Asp Leu Trp Ala Gly Ser Lys Gly Lys Glu Phe Gly Tyr
                 80                  85                  90
Phe Pro Arg Asp Ala Val Gln Ile
                 95
```

<210> 12
<211> 549
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 4325626CD1

<400> 12

```
Met Asp Val Val Glu Val Ala Gly Ser Trp Trp Ala Gln Glu Arg
  1               5                  10                  15
Glu Asp Ile Ile Met Lys Tyr Glu Lys Gly His Arg Ala Gly Leu
                 20                  25                  30
Pro Glu Asp Lys Gly Pro Lys Pro Phe Arg Ser Tyr Asn Asn Asn
                 35                  40                  45
Val Asp His Leu Gly Ile Val His Glu Thr Glu Leu Pro Pro Leu
                 50                  55                  60
Thr Ala Arg Glu Ala Lys Gln Ile Arg Arg Glu Ile Ser Arg Lys
                 65                  70                  75
Ser Lys Trp Val Asp Met Leu Gly Asp Trp Glu Lys Tyr Lys Ser
                 80                  85                  90
Ser Arg Lys Leu Ile Asp Arg Ala Tyr Lys Gly Met Pro Met Asn
                 95                 100                 105
Ile Arg Gly Pro Met Trp Ser Val Leu Leu Asn Thr Glu Glu Met
                110                 115                 120
Lys Leu Lys Asn Pro Gly Arg Tyr Gln Ile Met Lys Glu Lys Gly
                125                 130                 135
Lys Arg Ser Ser Glu His Ile Gln Arg Ile Asp Arg Asp Val Ser
                140                 145                 150
Gly Thr Leu Arg Lys His Ile Phe Phe Arg Asp Arg Tyr Gly Thr
                155                 160                 165
Lys Gln Arg Glu Leu Leu His Ile Leu Leu Ala Tyr Glu Glu Tyr
                170                 175                 180
Asn Pro Glu Val Gly Tyr Cys Arg Asp Leu Ser His Ile Ala Ala
                185                 190                 195
Leu Phe Leu Leu Tyr Leu Pro Glu Glu Asp Ala Phe Trp Ala Leu
                200                 205                 210
Val Gln Leu Leu Ala Ser Glu Arg His Ser Leu Gln Gly Phe His
                215                 220                 225
Ser Pro Asn Gly Gly Thr Val Gln Gly Leu Gln Asp Gln Gln Glu
                230                 235                 240
His Val Val Ala Thr Ser Gln Pro Lys Thr Met Gly His Gln Asp
                245                 250                 255
Lys Lys Asp Leu Cys Gly Gln Cys Ser Pro Leu Gly Cys Leu Ile
                260                 265                 270
Arg Ile Leu Ile Asp Gly Ile Ser Leu Gly Leu Thr Leu Arg Leu
                275                 280                 285
Trp Asp Val Tyr Leu Val Glu Gly Glu Gln Ala Leu Met Pro Ile
```

```
                290                 295                 300
Thr Arg Ile Ala Phe Lys Val Gln Gln Lys Arg Leu Thr Lys Thr
                305                 310                 315
Ser Arg Cys Gly Pro Trp Ala Arg Phe Cys Asn Arg Phe Val Asp
                320                 325                 330
Thr Trp Ala Arg Asp Glu Asp Thr Val Leu Lys His Leu Arg Ala
                335                 340                 345
Ser Met Lys Lys Leu Thr Arg Lys Gln Gly Asp Leu Pro Pro Pro
                350                 355                 360
Ala Lys Pro Glu Gln Gly Ser Ser Ala Ser Arg Pro Val Pro Ala
                365                 370                 375
Ser Arg Gly Gly Lys Thr Leu Cys Lys Gly Asp Arg Gln Ala Pro
                380                 385                 390
Pro Gly Pro Pro Ala Arg Phe Pro Arg Pro Ile Trp Ser Ala Ser
                395                 400                 405
Pro Pro Arg Ala Pro Arg Ser Ser Thr Pro Cys Pro Gly Gly Ala
                410                 415                 420
Val Arg Glu Asp Thr Tyr Pro Val Gly Thr Gln Gly Val Pro Ser
                425                 430                 435
Pro Ala Leu Ala Gln Gly Gly Pro Gln Gly Ser Trp Arg Phe Leu
                440                 445                 450
Gln Trp Asn Ser Met Pro Arg Leu Pro Thr Asp Leu Asp Val Glu
                455                 460                 465
Gly Pro Trp Phe Arg His Tyr Asp Phe Arg Gln Ser Cys Trp Val
                470                 475                 480
Arg Ala Ile Ser Gln Glu Asp Gln Leu Ala Pro Cys Trp Gln Ala
                485                 490                 495
Glu His Pro Ala Glu Arg Val Arg Ser Ala Phe Ala Ala Pro Ser
                500                 505                 510
Thr Asp Ser Asp Gln Gly Thr Pro Phe Arg Ala Arg Asp Glu Gln
                515                 520                 525
Pro Cys Ala Pro Thr Ser Gly Pro Cys Leu Cys Gly Leu His Leu
                530                 535                 540
Glu Ser Ser Gln Phe Pro Pro Gly Phe
                545
```

<210> 13
<211> 95
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1438978CD1

<400> 13

```
Met Ser Phe Leu Leu Pro Lys Leu Thr Ser Lys Lys Glu Val Asp
  1                 5                  10                  15
Gln Ala Ile Lys Ser Thr Ala Glu Lys Val Leu Val Leu Arg Phe
                 20                  25                  30
Gly Arg Asp Glu Asp Pro Val Cys Leu Gln Leu Asp Asp Ile Leu
                 35                  40                  45
Ser Lys Thr Ser Ser Asp Leu Ser Lys Met Ala Ala Ile Tyr Leu
                 50                  55                  60
```

```
Val Asp Val Asp Gln Thr Ala Val Tyr Thr Gln Tyr Phe Asp Ile
                  65                  70                  75
Ser Tyr Ile Pro Ser Thr Val Phe Phe Phe Asn Gly Gln His Met
                  80                  85                  90
Lys Val Asp Tyr Gly
                  95
```

<210> 14
<211> 445
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2024773CD1

<400> 14

```
Met Ala Ala Pro Glu Glu Arg Asp Leu Thr Gln Glu Gln Thr Glu
  1               5                  10                  15
Lys Leu Leu Gln Phe Gln Asp Leu Thr Gly Ile Glu Ser Met Asp
                 20                  25                  30
Gln Cys Arg His Thr Leu Glu Gln His Asn Trp Asn Ile Glu Ala
                 35                  40                  45
Ala Val Gln Asp Arg Leu Asn Glu Gln Glu Gly Val Pro Ser Val
                 50                  55                  60
Phe Asn Pro Pro Pro Ser Arg Pro Leu Gln Val Asn Thr Ala Asp
                 65                  70                  75
His Arg Ile Tyr Ser Tyr Val Val Ser Arg Pro Gln Pro Arg Gly
                 80                  85                  90
Leu Leu Gly Trp Gly Tyr Tyr Leu Ile Met Leu Pro Phe Arg Phe
                 95                 100                 105
Thr Tyr Tyr Thr Ile Leu Asp Ile Phe Arg Phe Ala Leu Arg Phe
                110                 115                 120
Ile Arg Pro Asp Pro Arg Ser Arg Val Thr Asp Pro Val Gly Asp
                125                 130                 135
Ile Val Ser Phe Met His Ser Phe Glu Glu Lys Tyr Gly Arg Ala
                140                 145                 150
His Pro Val Phe Tyr Gln Gly Thr Tyr Ser Gln Ala Leu Asn Asp
                155                 160                 165
Ala Lys Arg Glu Leu Arg Phe Leu Leu Val Tyr Leu His Gly Asp
                170                 175                 180
Asp His Gln Asp Ser Asp Glu Phe Cys Arg Asn Thr Leu Cys Ala
                185                 190                 195
Pro Glu Val Ile Ser Leu Ile Asn Thr Arg Met Leu Phe Trp Ala
                200                 205                 210
Cys Ser Thr Asn Lys Pro Glu Gly Tyr Arg Val Ser Gln Ala Leu
                215                 220                 225
Arg Glu Asn Thr Tyr Pro Phe Leu Ala Met Ile Met Leu Lys Asp
                230                 235                 240
Arg Arg Met Thr Val Val Gly Arg Leu Glu Gly Leu Ile Gln Pro
                245                 250                 255
Asp Asp Leu Ile Asn Gln Leu Thr Phe Ile Met Asp Ala Asn Gln
                260                 265                 270
Thr Tyr Leu Val Ser Glu Arg Leu Glu Arg Glu Glu Arg Asn Gln
                275                 280                 285
```

```
Thr Gln Val Leu Arg Gln Gln Gln Asp Glu Ala Tyr Leu Ala Ser
                290                 295                 300
Leu Arg Ala Asp Gln Glu Lys Glu Arg Lys Lys Arg Glu Glu Arg
                305                 310                 315
Glu Arg Lys Arg Arg Lys Glu Glu Glu Val Gln Gln Gln Lys Leu
                320                 325                 330
Ala Glu Glu Arg Arg Arg Gln Asn Leu Gln Glu Glu Lys Glu Arg
                335                 340                 345
Lys Leu Glu Cys Leu Pro Pro Glu Pro Ser Pro Asp Asp Pro Glu
                350                 355                 360
Ser Val Lys Ile Ile Phe Lys Leu Pro Asn Asp Ser Arg Val Glu
                365                 370                 375
Arg Arg Phe His Phe Ser Gln Ser Leu Thr Val Ile His Asp Phe
                380                 385                 390
Leu Phe Ser Leu Lys Glu Ser Pro Glu Lys Phe Gln Ile Glu Ala
                395                 400                 405
Asn Phe Pro Arg Arg Val Leu Pro Cys Ile Pro Ser Glu Glu Trp
                410                 415                 420
Pro Asn Pro Pro Thr Leu Gln Glu Ala Gly Leu Ser His Thr Glu
                425                 430                 435
Val Leu Phe Val Gln Asp Leu Thr Asp Glu
                440                 445


<210> 15
<211> 219
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3869790CD1

<400> 15
Met Glu Tyr Leu Ser Ala Leu Asn Pro Ser Asp Leu Leu Arg Ser
  1               5                  10                  15
Val Ser Asn Ile Ser Ser Glu Phe Gly Arg Arg Val Trp Thr Ser
                20                  25                  30
Ala Pro Pro Pro Gln Arg Pro Phe Arg Val Cys Asp His Lys Arg
                35                  40                  45
Thr Ile Arg Lys Gly Leu Thr Ala Ala Thr Arg Gln Glu Leu Leu
                50                  55                  60
Ala Lys Ala Leu Glu Thr Leu Leu Leu Asn Gly Val Leu Thr Leu
                65                  70                  75
Val Leu Glu Glu Asp Gly Thr Ala Val Asp Ser Glu Asp Phe Phe
                80                  85                  90
Gln Leu Leu Glu Asp Asp Thr Cys Leu Met Val Leu Gln Ser Gly
                95                 100                 105
Gln Ser Trp Ser Pro Thr Arg Ser Gly Val Leu Ser Tyr Gly Leu
                110                 115                 120
Gly Arg Glu Arg Pro Lys His Ser Lys Asp Ile Ala Arg Phe Thr
                125                 130                 135
Phe Asp Val Tyr Lys Gln Asn Pro Arg Asp Leu Phe Gly Ser Leu
                140                 145                 150
Asn Val Lys Ala Thr Phe Tyr Gly Leu Tyr Ser Met Ser Cys Asp
```

```
                155                 160                 165
Phe Gln Gly Leu Gly Pro Lys Lys Val Leu Arg Glu Leu Leu Arg
                170                 175                 180
Trp Thr Ser Thr Leu Leu Gln Gly Leu Gly His Met Leu Leu Gly
                185                 190                 195
Ile Ser Ser Thr Leu Arg His Ala Val Glu Gly Ala Glu Gln Trp
                200                 205                 210
Gln Gln Lys Gly Arg Leu His Ser Tyr
                215
```

<210> 16
<211> 439
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 001273CD1

<400> 16

```
Met Ala Ala Ala Arg Cys Trp Arg Pro Leu Leu Arg Gly Pro Arg
  1                 5                  10                  15
Leu Ser Leu His Thr Ala Ala Asn Ala Ala Ala Thr Ala Thr Glu
                 20                  25                  30
Thr Thr Cys Gln Asp Val Ala Ala Thr Pro Val Ala Arg Tyr Pro
                 35                  40                  45
Pro Ile Val Ala Ser Met Thr Ala Asp Ser Lys Ala Ala Arg Leu
                 50                  55                  60
Arg Arg Ile Glu Arg Trp Gln Ala Thr Val His Ala Ala Glu Ser
                 65                  70                  75
Val Asp Glu Lys Leu Arg Ile Leu Thr Lys Met Gln Phe Met Lys
                 80                  85                  90
Tyr Met Val Tyr Pro Gln Thr Phe Ala Leu Asn Ala Asp Arg Trp
                 95                 100                 105
Tyr Gln Tyr Phe Thr Lys Thr Val Phe Leu Ser Gly Leu Pro Pro
                110                 115                 120
Arg Pro Ser Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro
                125                 130                 135
Ala Leu Asp Leu Ala Ala Leu Arg Ala Val Ala Cys Asp Cys Leu
                140                 145                 150
Leu Gln Glu His Phe Tyr Leu Arg Arg Arg Arg Arg Val His Arg
                155                 160                 165
Tyr Glu Glu Ser Glu Val Ile Ser Leu Pro Phe Leu Asp Gln Leu
                170                 175                 180
Val Ser Thr Leu Val Gly Leu Leu Ser Pro His Asn Pro Ala Leu
                185                 190                 195
Ala Ala Ala Ala Leu Asp Tyr Arg Cys Pro Val His Phe Tyr Trp
                200                 205                 210
Val Arg Gly Glu Glu Ile Ile Pro Arg Gly His Arg Arg Gly Arg
                215                 220                 225
Ile Asp Asp Leu Arg Tyr Gln Ile Asp Asp Lys Pro Asn Asn Gln
                230                 235                 240
Ile Arg Ile Ser Lys Gln Leu Ala Glu Phe Val Pro Leu Asp Tyr
                245                 250                 255
Ser Val Pro Ile Glu Ile Pro Thr Ile Lys Cys Lys Pro Asp Lys
```

```
                260                 265                 270
Leu Pro Leu Phe Lys Arg Gln Tyr Glu Asn His Ile Phe Val Gly
                275                 280                 285
Ser Lys Thr Ala Asp Pro Cys Cys Tyr Gly His Thr Gln Phe His
                290                 295                 300
Leu Leu Pro Asp Lys Leu Arg Arg Glu Arg Leu Leu Arg Gln Asn
                305                 310                 315
Cys Ala Asp Gln Ile Glu Val Val Phe Arg Ala Asn Ala Ile Ala
                320                 325                 330
Ser Leu Phe Ala Trp Thr Gly Ala Gln Ala Met Tyr Gln Gly Phe
                335                 340                 345
Trp Ser Glu Ala Asp Val Thr Arg Pro Phe Val Ser Gln Ala Val
                350                 355                 360
Ile Thr Asp Gly Lys Tyr Phe Ser Phe Phe Cys Tyr Gln Leu Asn
                365                 370                 375
Thr Leu Ala Leu Thr Thr Gln Ala Asp Gln Asn Asn Pro Arg Lys
                380                 385                 390
Asn Ile Cys Trp Gly Thr Gln Ser Lys Pro Leu Tyr Glu Thr Ile
                395                 400                 405
Glu Asp Asn Asp Val Lys Gly Phe Asn Asp Asp Val Leu Leu Gln
                410                 415                 420
Ile Val His Phe Leu Leu Asn Arg Pro Lys Glu Glu Lys Ser Gln
                425                 430                 435
Leu Leu Glu Asn
```

<210> 17
<211> 526
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 411831CD1

<400> 17

```
Met Ala Ser Gly Pro His Ser Thr Ala Thr Ala Ala Ala Ala Ala
  1                 5                  10                  15
Ser Ser Ala Ala Pro Ser Ala Gly Gly Ser Ser Ser Gly Thr Thr
                 20                  25                  30
Thr Thr Thr Thr Thr Thr Thr Gly Gly Ile Leu Ile Gly Asp Arg
                 35                  40                  45
Leu Tyr Ser Glu Val Ser Leu Thr Ile Asp His Ser Leu Ile Pro
                 50                  55                  60
Glu Glu Arg Leu Ser Pro Thr Pro Ser Met Gln Asp Gly Leu Asp
                 65                  70                  75
Leu Pro Ser Glu Thr Asp Leu Arg Ile Leu Gly Cys Glu Leu Ile
                 80                  85                  90
Gln Ala Ala Gly Ile Leu Leu Arg Leu Pro Gln Val Ala Met Ala
                 95                 100                 105
Thr Gly Gln Val Leu Phe His Arg Phe Phe Tyr Ser Lys Ser Phe
                110                 115                 120
Val Lys His Ser Phe Glu Ile Val Ala Met Ala Cys Ile Asn Leu
                125                 130                 135
Ala Ser Lys Ile Glu Glu Ala Pro Arg Arg Ile Arg Asp Val Ile
```

```
                  140                 145                 150
Asn Val Phe His His Leu Arg Gln Leu Arg Gly Lys Arg Thr Pro
                  155                 160                 165
Ser Pro Leu Ile Leu Asp Gln Asn Tyr Ile Asn Thr Lys Asn Gln
                  170                 175                 180
Val Ile Lys Ala Glu Arg Arg Val Leu Lys Glu Leu Gly Phe Cys
                  185                 190                 195
Val His Val Lys His Pro His Lys Ile Ile Val Met Tyr Leu Gln
                  200                 205                 210
Val Leu Glu Cys Glu Arg Asn Gln Thr Leu Val Gln Thr Ala Trp
                  215                 220                 225
Asn Tyr Met Asn Asp Ser Leu Arg Thr Asn Val Phe Val Arg Phe
                  230                 235                 240
Gln Pro Glu Thr Ile Ala Cys Ala Cys Ile Tyr Leu Ala Ala Arg
                  245                 250                 255
Ala Leu Gln Ile Pro Leu Pro Thr Arg Pro His Trp Phe Leu Leu
                  260                 265                 270
Phe Gly Thr Thr Glu Glu Glu Ile Gln Glu Ile Cys Ile Glu Thr
                  275                 280                 285
Leu Arg Leu Tyr Thr Arg Lys Lys Pro Asn Tyr Glu Leu Leu Glu
                  290                 295                 300
Lys Glu Val Glu Lys Arg Lys Val Ala Leu Gln Glu Ala Lys Leu
                  305                 310                 315
Lys Ala Lys Gly Leu Asn Pro Asp Gly Thr Pro Ala Leu Ser Thr
                  320                 325                 330
Leu Gly Gly Phe Ser Pro Ala Ser Lys Pro Ser Ser Pro Arg Glu
                  335                 340                 345
Val Lys Ala Glu Glu Lys Ser Pro Ile Ser Ile Asn Val Lys Thr
                  350                 355                 360
Val Lys Lys Glu Pro Glu Asp Arg Gln Gln Ala Ser Lys Ser Pro
                  365                 370                 375
Tyr Asn Gly Val Arg Lys Asp Ser Lys Arg Ser Arg Asn Ser Arg
                  380                 385                 390
Ser Ala Ser Arg Ser Arg Ser Arg Thr Arg Ser Arg Ser Arg Ser
                  395                 400                 405
His Thr Pro Arg Arg His Tyr Asn Asn Arg Arg Ser Arg Ser Gly
                  410                 415                 420
Thr Tyr Ser Ser Arg Ser Arg Ser Arg Ser Arg Ser Arg Ser His Ser Glu
                  425                 430                 435
Ser Pro Arg Arg His His Asn His Gly Ser Pro His Leu Lys Ala
                  440                 445                 450
Lys His Thr Arg Asp Asp Leu Lys Ser Ser Asn Arg His Gly His
                  455                 460                 465
Lys Arg Lys Lys Ser Arg Ser Arg Ser Gln Ser Lys Ser Arg Asp
                  470                 475                 480
His Ser Asp Ala Ala Lys Lys His Arg His Glu Arg Gly His His
                  485                 490                 495
Arg Asp Arg Arg Glu Arg Ser Arg Ser Phe Glu Arg Ser His Lys
                  500                 505                 510
Ser Lys His His Gly Gly Ser Arg Ser Gly His Gly Arg His Arg
                  515                 520                 525
Arg
```

<210> 18

<211> 298
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1520835CD1

<400> 18

```
Met Gly Pro Lys Asp Ser Ala Lys Cys Leu His Arg Gly Pro Gln
  1               5                  10                  15
Pro Ser His Trp Ala Ala Gly Asp Gly Pro Thr Gln Glu Arg Cys
             20                  25                  30
Gly Pro Arg Ser Leu Gly Ser Pro Val Leu Gly Leu Asp Thr Cys
             35                  40                  45
Arg Ala Trp Asp His Val Asp Gly Gln Ile Leu Gly Gln Leu Arg
             50                  55                  60
Pro Leu Thr Glu Glu Glu Glu Glu Glu Gly Ala Gly Ala Thr Leu
             65                  70                  75
Ser Arg Gly Pro Ala Phe Pro Gly Met Gly Ser Glu Glu Leu Arg
             80                  85                  90
Leu Ala Ser Phe Tyr Asp Trp Pro Leu Thr Ala Glu Val Pro Pro
             95                 100                 105
Glu Leu Leu Ala Ala Ala Gly Phe Phe His Thr Gly His Gln Asp
            110                 115                 120
Lys Val Arg Cys Phe Phe Cys Tyr Gly Gly Leu Gln Ser Trp Lys
            125                 130                 135
Arg Gly Asp Asp Pro Trp Thr Glu His Ala Lys Trp Phe Pro Ser
            140                 145                 150
Cys Gln Phe Leu Leu Arg Ser Lys Gly Arg Asp Phe Val His Ser
            155                 160                 165
Val Gln Glu Thr His Ser Gln Leu Leu Gly Ser Trp Asp Pro Trp
            170                 175                 180
Glu Glu Pro Glu Asp Ala Ala Pro Val Ala Pro Ser Val Pro Ala
            185                 190                 195
Ser Gly Tyr Pro Glu Leu Pro Thr Pro Arg Arg Glu Val Gln Ser
            200                 205                 210
Glu Ser Ala Gln Glu Pro Gly Gly Val Ser Pro Ala Glu Ala Gln
            215                 220                 225
Arg Ala Trp Trp Val Leu Glu Pro Pro Gly Ala Arg Asp Val Glu
            230                 235                 240
Ala Gln Leu Arg Arg Leu Gln Glu Glu Arg Thr Cys Lys Val Cys
            245                 250                 255
Leu Asp Arg Ala Val Ser Ile Val Phe Val Pro Cys Gly His Leu
            260                 265                 270
Val Cys Ala Glu Cys Ala Pro Gly Leu Gln Leu Cys Pro Ile Cys
            275                 280                 285
Arg Ala Pro Val Arg Ser Arg Val Arg Thr Phe Leu Ser
            290                 295
```

<210> 19
<211> 249
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1902803CD1

<400> 19
Met Ala Ala Gly Met Tyr Leu Glu His Tyr Leu Asp Ser Ile Glu
1 5 10 15
Asn Leu Pro Phe Glu Leu Gln Arg Asn Phe Gln Leu Met Arg Asp
20 25 30
Leu Asp Gln Arg Thr Glu Asp Leu Lys Ala Glu Ile Asp Lys Leu
35 40 45
Ala Thr Glu Tyr Met Ser Ser Ala Arg Ser Leu Ser Ser Glu Glu
50 55 60
Lys Leu Ala Leu Leu Lys Gln Ile Gln Glu Ala Tyr Gly Lys Cys
65 70 75
Lys Glu Phe Gly Asp Asp Lys Val Gln Leu Ala Met Gln Thr Tyr
80 85 90
Glu Met Val Asp Lys His Ile Arg Arg Leu Asp Thr Asp Leu Ala
95 100 105
Arg Phe Glu Ala Asp Leu Lys Glu Lys Gln Ile Glu Ser Ser Asp
110 115 120
Tyr Asp Ser Ser Ser Ser Lys Gly Lys Lys Lys Gly Arg Thr Gln
125 130 135
Lys Glu Lys Lys Ala Ala Arg Ala Arg Ser Lys Gly Lys Asn Ser
140 145 150
Asp Glu Glu Ala Pro Lys Thr Ala Gln Lys Lys Leu Lys Leu Val
155 160 165
Arg Thr Ser Pro Glu Tyr Gly Met Pro Ser Val Thr Phe Gly Ser
170 175 180
Val His Pro Ser Asp Val Leu Asp Met Pro Val Asp Pro Asn Glu
185 190 195
Pro Thr Tyr Cys Leu Cys His Gln Val Ser Tyr Gly Glu Met Ile
200 205 210
Gly Cys Asp Asn Pro Asp Cys Ser Ile Glu Trp Phe His Phe Ala
215 220 225
Cys Val Gly Leu Thr Thr Lys Pro Arg Gly Lys Trp Phe Cys Pro
230 235 240
Arg Cys Ser Gln Glu Arg Lys Lys Lys
245

<210> 20
<211> 1748
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1342011CB1

<400> 20
cgggtcgacc cacgcgtccg ggggacaag ccagaggctg gaggagcagc atcccttcca 60
ggctgcacac ttgtcagtgc cgggttctgg ggagaaccgc acgggaagga gaggtcgctg 120
gcggcatcgt ttgctgctcc ccagagacag acctgggccc ttccctctgg gactcccaat 180
ctggacgggg ttcctggctt gctgtggggc atgttgaggc cggaggctgg gcttgtgggg 240

ctgcacggcc ctgcccagga gaactcagca ctgcctggac ggtgaggctc agcttctgag 300
ctgagggctc tatcaggcct ggaagtggac cctggggagg ggtggggcag ggtagttctg 360
ataagtccta ggactgttcg cttccgggtt ctgagccctg gcgtcaggga ggaagggcat 420
gtccagaaca atggccagaa ccaggcccgg ccagctcggg cgggtgacgg gggcgggtgg 480
ctggggcagc gctgccgtgt gcaggggccg agccctgcgg ggccgtgagc cggccctgcc 540
ttctgcttcc ttcccagatg tagccgcctg tcccgggagc ctggactgtg ccctgaagag 600
gcgggcaagg tgtcctcctg gtgcacatgc ctgtgggccc tgccttcagc ccttccagga 660
ggaccagcaa gggctctgtg tgcccaggat gcgccggcct ccaggcgggg gccggcccca 720
gcccagactg gaagatgaga ttgacttcct ggcccaggag cttgcccgga aggagtctgg 780
acactcaact ccgcccctac ccaaggaccg acagcggctc ccggagcctg ccacccctgg 840
cttctcggca cgggggcagg ggctggagct gggcctcccc tccactccag gaacccccac 900
gcccacgccc cacacctccc tgggctcccc tgtgtcatcc gacccggtgc acatgtcgcc 960
cctggagccc cggggagggc aaggcgacgg cctcgccctt gtgctgatcc tggcgttctg 1020
tgtggccggt gcagccgccc tctccgtagc ctccctctgc tggtgcaggc tgcagcgtga 1080
gatccgcctg actcagaagg ccgactacgc cactgcgaag gcccctggct cacctgcagc 1140
tccccggatc tcgcctgggg accagcggct ggcacagagc gcggagatgt accactacca 1200
gcaccaacgg caacagatgc tgtgcctgga gcggcataaa gagccaccca aggagctgga 1260
cacggcctcc tcggatgagg agaatgagga cggagacttc acggtgtacg agtgcccggg 1320
cctggccccg accggggaaa tggaggtgcg caaccctctg ttcgaccacg ccgcactgtc 1380
cgcgcccctg ccggccccca gctcaccgcc tgcactgcca tgacctggag gcagacagac 1440
gcccacctgc tccccgacct cgaggccccc ggggaggggc agggcctgga gcttcccact 1500
aaaaacatgt tttgatgctg tgtgcttttg gctgggcctc gggctccagg ccctgggacc 1560
ccttgccagg gagacccccg aacctttgtg ccaggacacc tcctggtccc ctgcacctct 1620
cctgttcggt ttagacccca aaactggagg gggcatggag aaccgtagag cgcaggaacg 1680
ggtgggtaat tctagagaca aaagccaatt aaagtccatt tcagacctgc aaaaaaaaaa 1740
aaaaaagg 1748

<210> 21
<211> 1016
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1880041CB1

<400> 21
ccgcagtctc tgtgcgttga agccggagac cgcggcggcc tcagcgagga ccctccgccc 60
cggagccgcc ggccggagcc gcagcctctg ccgcagcgcc cccgccacct gtcccctccc 120
cctccgcctc cgccggagcc gcctcgtgca ctctggggta tggccgtcaa tgtgtactcc 180
acatctgtga ccagtgaaaa tctgagtcgc catgatatgc ttgcatgggt caacgactcc 240
ctgcacctca actataccaa gatagaacag ctttgttcag gggcagccta ctgccagttc 300
atggacatgc tcttccccgg ctgtgtgcac ttgaggaaag tgaagttcca ggccaaacta 360
gagcatgaat acatccacaa cttcaaggtg ctgcaagcag ctttcaagaa gatgggtgtt 420
gacaaaatca ttcctgtaga gaaattagtg aaaggaaaat tccaagataa ttttgagttt 480
attcagtggt ttaagaaatt ctttgacgca aactatgatg gaaaggatta caaccctctg 540
ctggcgcggc agggccagga cgtagcgcca cctcctaacc caggtgatca gatcttcaac 600
aaatccaaga aactcattgg cacagcagtt ccacagagga cgtcccccac aggcccaaaa 660
aacatgcaga cctctggccg gctgagcaat gtggcccccc cctgcattct ccggaagaat 720
cctccatcag cccgaaatgg cggccatgag actgatgccc aaattcttga actcaaccaa 780
cagctggtgg acttgaagct gacagtggat gggctggaga aggaacgtga cttctacttc 840
agcaaacttc gtgacatcga gctcatctgc caggagcatg aaagtgaaaa cagccctgtt 900
atctcaggca tcattggcat cctctatgcc acagaggaag gattcgcacc ccctgaggac 960
gatgagattg aagagcatca acaagaagac caggacgagt actgagggcg gccgca 1016

<210> 22
<211> 1145
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3201881CB1

<400> 22
tgtgcccaga acgcggttag gaagtgtgtg catacgtctg aaccctaaat ggttctcagt 60
tctgtaaact tctcctccca ctgggtggag tagggccttt aagagcagct ggaatgcagt 120
tccctgatc agcgtaccag ttgttgcctg tctgaacctc tgccagtcct ggagactggt 180
gccctgagct ccaaccagcg ggcctcatcc tacaccctca ccaccgcaac ttctcacccg 240
agcaagaagc agctcccaga gagaaagaac gttcccacct gcctagccat gggagaggac 300
gctgcacagg ccgaaaagtt ccagcaccct gggtctgaca tgcggcagga aaagccctcg 360
agccccagcc cgatgccttc ctccacacca agccccagcc tgaacctagg gaacacagag 420
gaggccatcc gggacaactc acaggtgaac gcagtcacgg tgctcacgct cctggacaag 480
ctggtgaaca tgctagacgc tgtgcaggag aaccagcaca agatggagca gcgacagatc 540
agtttggagg gctccgtgaa gggcatccag aatgacctca ccaagctctc caagtaccag 600
gcctccacca gcaacacggt gagcaagctg ctggagaagt cccgcaaggt cagcgcccac 660
acgcgcgcgg tcaaagagcg catggatagg cagtgcgcac aggtgaagcg gctggagaac 720
aaccacgccc agctcctccg acgcaaccat ttcaaagtgc tcatcttcca ggaggaaaat 780
gagatccctg ccagcgtgtt tgtgaaacag cccgtttccg gtgccgtgga agggaaggag 840
gagcttccgg atgaaaacaa atccctggag gaaaccctgc acaccgtgga cctctcctca 900
gatgatgatt tgccccacga tgaggaggcc ctggaagaca gtgccgagga aaaggttgga 960
agaagtaggg gcagagaaat taaaagatcc cggccgtgaa ggaagttgga tagcctcaaa 1020
gaaagctttt tttttgccag gaactttggg gaaaaaggtt gaacaagtct gggggacaaa 1080
gttcctatct tgttaggaga aggggagagg agtttttaga atcttcttca agtcaaatct 1140
accag 1145

<210> 23
<211> 3084
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 939000CB1

<400> 23
cggctcgagg cgggtgacgc gacgacggcg acactttgct acggagtgca ttcggacgtc 60
gaagcctaga gtctctgcgt ctttccctct tccgctgcct cattcctttc cttcctagcc 120
ttggtcgtcg ccgccaccat gaacaagaag aagaaaccgt tcctagggat gcccgcgccc 180
ctcggctacg tgccgggggct gggccggggc gccactggct tcaccacgcg gtcagacatt 240
gggcccgccc gtgatgcaaa tgaccctgtg gatgatcgcc atgcaccccc aggcaagaga 300
accgttgggg accagatgaa gaaaaatcag gctgctgacg atgacgacga ggatctaaat 360
gacaccaatt acgatgagtt taatggctat gctgggagcc tcttctcaag tggaccctac 420
gagaaagatg atgaggaagc agatgctatc tatgcagccc tggataaaag gatggatgaa 480
agaagaaaag aaagacggga gcaaagggag aaagaagaaa tagagaaata tcgtatggaa 540
cgccccaaaa tccaacagca gttctcagac ctcaagagga agttggcaga agtcacagaa 600
gaagagtggc tgagcatccc cgaggttggc gatgccagaa ataaacgtca gcggaaccca 660
cgctatgaga agctgacccc tgttcctgac agtttctttg ccaaacattt acagaccgga 720
gagaaccata cctcagtgga tccccgacaa actcaatttg gaggtcttaa cacaccctat 780

```
ccaggtggac taaacactcc atacccaggt ggaatgacgc caggactgat gacacctggc 840
acaggtgagc tggacatgag gaagattggc caagcgagga acactctgat ggacatgagg 900
ctgagccagg tgtctgactc cgtgagtgga cagaccgtcg ttgaccccaa aggctacctg 960
acggatttaa attccatgat cccgacacac ggaggagaca tcaatgatat caagaaggcg 1020
cgactgctcc tcaagtctgt tcgggagacg aaccctcatc acccgccagc ctggattgca 1080
tcagcccgcc tggaagaagt cactgggaag ctacaagtag ctcggaacct tatcatgaag 1140
gggacggaga tgtgcccaaa gagtgaagat gtctggctgg aagcagccag gttgcagcct 1200
ggggacacag ccaaggccgt ggtagcccaa gctgtccgtc atctcccaca gtctgtcagg 1260
atttacatca gagccgcaga gctggaaacg gacattcgtg caaagaagcg ggttcttcgg 1320
aaagccctcg agcatgttcc aaactcggtt cgcttgtgga aagcagccgt tgagctggaa 1380
gaacctgaag atgctagaat catgctgagc cgagctgtgg agtgctgccc caccagcgtg 1440
gagctctggc ttgctctggc aaggctggag acctatgaaa atgcccgcaa ggtcttgaac 1500
aaggcgcggg agaacattcc tacagaccga catatctgga tcacggctgc taagctggag 1560
gaagccaatg ggaacacgca gatggtggag aagatcatcg accgagccat cacctcgctg 1620
cgggccaacg gtgtggagat caaccgtgag cagtggatcc aggatgccga ggaatgtgac 1680
agggctggga gtgtggccac ctgccaggcc gtcatgcgtg ccgtgattgg gattgggatt 1740
gaggaggaag atcggaagca tacctggatg gaggatgctg acagttgtgt agcccacaat 1800
gccctggagt gtgcacgagc catctacgcc tacgccctgc aggtgttccc cagcaagaag 1860
agtgtgtggc tgcgcgccgc gtacttcgag aagaaccatg gcactcggga gtccctggaa 1920
gcactcctgc agagggctgt ggcccactgc cccaaagcag aggtgctgtg gctcatgggc 1980
gccaagtcca agtggctggc aggggatgtg cctgcagcaa ggagcatcct ggccctggcc 2040
ttccagccca accccaacag tgaggagatc tggctggcag ccgtgaagct ggagtccgag 2100
aatgatgagt acgagcgggc ccggaggctg ctggccaagg cgcggagcag tgccccacc 2160
gcccgggtgt tcatgaagtc tgtgaagctg gagtgggtgc aagacaacat cagggcagcc 2220
caagatctgt gcgaggaggc cctgcggcac tatgaggact tccccaagct gtggatgatg 2280
aaggggcaga tcgaggagca gaaggagatg atggagaagg cgcgggaagc ctataaccag 2340
gggttgaaga agtgtcccca ctccacaccc ctgtggcttt tgctctctcg gctggaggag 2400
aagattgggc agcttactcg agcacgggcc attttggaaa agtctcgtct gaagaaccca 2460
aagaaccctg ggctgtggtt ggagtccgtg cggctggagt accgtgcggg gctgaagaac 2520
atcgcaaata cactcatggc caaggcgctg caggagtgcc ccaactccgg tatcctgtgg 2580
tctgaggcca tcttcctcga ggcaaggccc cagaggagga ccaagagcgt ggatgccctg 2640
aagaagtgtg agcatgaccc ccatgtgctc ctggccgtgg ccaagctgtt ttggagtcag 2700
cggaagatca ccaaggccag ggagtggttc caccgcactg tgaagattga ctcggacctg 2760
ggggatgcct gggccttctt ctacaagttt gagctgcagc atggcactga ggagcagcag 2820
gaggaggtga ggaagcgctg tgagagtgca gagcctcggc atggggagct gtggtgcgcc 2880
gtgtccaagg acatcgccaa ctggcagaag aagatcgggg acatccttag gctggtggcc 2940
ggccgcatca agaacacctt ctgattgagc ggttgccatg gccggtctcc gtggggcagg 3000
gttgggccgc atgtggaagg gctctgagct gtgtcctcct tcattaaaag tttttatgtc 3060
tcgtgtcaga aaaaaaaaaa aaaa                                      3084
```

<210> 24
<211> 3315
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2125677CB1

<400> 24

```
acttattccc acttggaact ggatggtcag tattatggat tctactgaag ctcaattacg  60
ttatggttct gcattagcat ctgctggtga tcctggacat ccaaagcatc ctcttcacga 120
ttctcagaat tcagcgagaa gagagaggat gactgcgcga gaagaagcta gcttacgaac 180
acttgaaggc agacgacgtg ccaccttgct tagcgcccgt caaggaatga tgtctgcacg 240
```

aggagacttc ctaaattatg ctctgtctct aatgcggtct cataatgatg agcatttctga 300
tgttcttcca gttttggatg tttgctcatt gaagcatgtg gcatatgttt ttcaagcact 360
tatatactgg attaaggcaa tgaatcagca gacaacattg gatacacctc aactagaacg 420
caaaaggacg cgagaactct tggaactggg tattgataat gaagattcag aacatgaaaa 480
tgatgatgac accaatcaaa gtgctacttt gaatgataag gatgatgact ctcttctcgc 540
agaaactggc caaaaccatc catttttccg acgttcagac tccatgacat tcctgggtg 600
tatacccca aatccatttg aagtgcctct ggctgaagcc atcccctgg ctgatcagcc 660
acatctgttg cagccaaatg ctagaaagga ggatcttttt ggccgtccaa gtcagggtct 720
ttattcttca tctgccagta gtgggaaatg tttaatggag gttacagtgg atagaaactg 780
cctagaggtt cttccaacaa aaatgtctta tgctgccaat ctgaaaaatg taatgaacat 840
gcaaaaccgg caaaaaaaag aaggggaaga acagcccgtg ctgccagaag aaactgagag 900
ttcaaaacca gggccatctg ctcatgatct tgctgcacaa ttaaaaagta gcttactagc 960
agaaatagga cttactgaaa gtgaagggcc acctctcaca tctttcaggc cacagtgtag 1020
ctttatggga atggttattt cccatgatat gctgctagga cgttggcgcc tttctttaga 1080
actgttcggc agggtattca tggaagatgt tggagcagaa cctggatcaa tcctaactga 1140
attgggtggt tttgaggtaa aagaatcaaa attccgcaga gaaatggaaa aactgagaaa 1200
ccagcagtca agagatttgt cactagaggt aaaggttgat cgggatcgag atctttctcat 1260
tcagcagact atgaggcagc ttaacaatca ctttggtcga agatgtgcta ctacaccaat 1320
ggctgtacac agagtaaaag tcacatttaa ggatgagcca ggagagggca gtggtgtagc 1380
acgaagtttt tatacagcca ttgcacaagc atttttatca aatgaaaaat tgccaaatct 1440
agagtgtatc caaaatgcca acaaaggcac ccacacaagt ttaatgcaga gattaaggaa 1500
ccgaggagag agagaccggg aaagggagag agaaagggaa atgaggagga gtagtggttt 1560
gcgagcaggt tctcggaggg accgggatag agactttaga agacagcttt ccatcgacac 1620
taggccctt agaccagcct ctgaagggaa tcctagcgat gatcctgagc ctttgccagc 1680
acatcggcag gcacttggag agaggcttta tcctcgtgta caagcaatgc aaccagcatt 1740
tgcaagtaaa atcactggca tgttgttgga attatcccca gctcagctgc ttctccttct 1800
agcaagtgag gattctctga gagcaagagt ggatgaggcc atggaactca ttattgcaca 1860
tggacgggaa aatggagctg atagtatcct ggatcttgga ttagtagact cctcagaaaa 1920
ggtacagcag gaaaaccgaa agcgccatgg ctctagtcga agtgtagtag atatggattt 1980
agatgataca gatgatggtg atgacaatgc ccctttgttt taccaacctg ggaaaagagg 2040
attttatact ccaaggcctg gcaagaacac agaagcaagg ttgaattgtt tcagaaacat 2100
tggcaggatt cttggactat gtctgttaca gaatgaacta tgtcctatca cattgaatag 2160
acatgtaatt aaagtattgc ttggtagaaa agtcaattgg catgattttg ctttttttga 2220
tcctgtaatg tatgagagtt tgcggcaact aatcctcgcg tctcagagtt cagatgctga 2280
tgctgttttc tcagcaatgg atttggcatt tgcaattgac ctgtgtaaag aagaaggtgg 2340
aggacaggtt gaactcattc ctaatggtgt aaatatacca gtcactccac agaatgtata 2400
tgagtatgtg cggaaatacg cagaacacag aatgttggta gttgcagaac agcccttaca 2460
tgcaatgagg aaaggtctac tagatgtgct tccaaaaaat tcattagaag atttaacggc 2520
agaagatttt aggcttttgg taaatggctg cggtgaagtc aatgtgcaaa tgctgatcag 2580
ttttacctct ttcaatgatg aatcaggaga aaatgctgag aagcttctgc agttcaagcg 2640
ttggttctgg tcaatagtag agaagatgag catgacagaa cgacaagatc ttgtttactt 2700
ttggacatca agcccatcac tgccagccag tgaagaagga ttccagccta tgccctcaat 2760
cacaataaga ccaccagatg accaacatct tcctactgca aatacttgca ttttctcgact 2820
ttacgtccca ctctattcct ctaaacagat tctcaaacag aaattgttac tcgccattaa 2880
gaccaagaat tttggttttg tgtagagtat aaaaagtgtg tattgctgtg taatattact 2940
agcaaatttt gtagattttt ttccatttgt ctataaaagt ttatggaagt taatgctgtc 3000
atacccccct ggtggtacct taaagagata aaatgcagac attccttgct gagtttatag 3060
cttaaaggcc taaggagcac tagcaacatt tggctatatt ggtttgctag tcaccaactt 3120
ctgggtctaa ccccagccaa agatgacagc agaacaacat aatttacact gtgatttatc 3180
tttttgctga gggggaaaaa atgtaaatgt tctgaaaatt cactgctgcc tttgtggaaa 3240
ctgtttcagc aaaggttctt gtatagaggg aatagggaat ttcaaaataa aaaattaagt 3300
atgaaaaaaa aaaaa 3315

<210> 25

<211> 1677
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2603810CB1

<400> 25
tgggagggggg cgggaattcc cgactctagg ccggaagcgc gcggagacca tgtagtgaga 60
ccctcgcgag gtctgagagt cactggagct accagaagca tcatggggcc ctgggagag 120
ccagagctcc tggtgtggcg ccccgaggcg gtagcttcag agcctccagt gcctgtgggg 180
ctggaggtga agttgggggc cctggtgctg ctgctggtgc tcaccctcct ctgcagcctg 240
gtgcccatct gtgtgctgcg ccggccagga gctaaccatg aaggctcagc ttcccgccag 300
aaagccctga gcctagtaag ctgtttcgcg gggggcgtct ttttggccac ttgtctcctg 360
gacctgctgc ctgactacct ggctgccata gatgaggccc tggcagcctt gcacgtgacg 420
ctccagttcc cactgcaaga gttcatcctg gccatgggct tcttcctggt cctggtgatg 480
gagcagatca cactggctta caaggagcag tcagggccgt cacctctgga ggaaacaagg 540
gctctgctgg gaacagtgaa tggtgggccg cagcattggc atgatgggcc aggggtccca 600
caggcgagtg gagccccagc aacccccctca gccttgcgtg cctgtgtact ggtgttctcc 660
ctggccctcc actccgtgtt cgaggggctg gcggtagggc tgcagcgaga ccgggctcgg 720
gccatggagc tgtgcctggc tttgctgctc cacaagggca tcctggctgt cagcctgtcc 780
ctgcggctgt tgcagagcca ccttagggca caggtggtgg ctggctgtgg gatcctcttc 840
tcatgcatga cacctctagg catcgggctg ggtgcagctc tggcagagtc ggcaggacct 900
ctgcaccagc tggcccagtc tgtgctagag ggcatggcag ctggcacctt tctctatatc 960
accttttctgg aaatcctgcc ccaggagctg gccagttctg agcaaaggat cctcaaggtc 1020
attctgctcc tagcaggctt tgccctgctc actggcctgc tcttcatcca aatctagggg 1080
gcttcaagag aggggcaggg gagattgatg atcaggtgcc cctgttctcc cttccctccc 1140
ccagttgtgg ggaataggaa ggaaagggga agggaaatac tgaggaccaa aaagttctct 1200
gggagctaaa gatagagcct ttggggctat ctgactaatg agagggaagt gggcagacaa 1260
gaggctggcc ccagtcccaa ggaacaagag atggtcaagt cgctagagac atatcagggg 1320
acattaggat tggggaagac acttgactgc tagaatcaga ggttggacac tatacataag 1380
gacaggctca catgggaggc tggaggtggg tacccagctg ctgtggaacg ggtatggaga 1440
ggtcataaac ctagagtcag tgtcctgttg gtcctagccc atttcagcac cctgccactt 1500
ggagtggacc cctcctactc ttcttagcgc ctaccctcat acctatctcc ctcctcccat 1560
ctcctagggg actggcgcca aatggtctct ccctgccaat tttggtaatc tctctggcct 1620
ctccagtcct gcttactccc ctatttttaa agtgccaaac aatccccttc ctctttc 1677

<210> 26
<211> 997
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2715761CB1

<400> 26
gcgacccttg ttcaacgccg ttggcgaaca gctgctggag gtgccgagaa tctgagtttc 60
ggcaagcagc caggtctgga aactaatatt ttaaaaatga ctacaccaaa caagacacct 120
cctggtgctg accccaagca gttggaaagg actggaacag tacgggaaat tgggtcacaa 180
gctgtttggt cactctcatc ttgcaaacca ggatttggag tggatcagtt acgagatgac 240
aatctagaaa cttattggca atcagatggt tcccagcctc atttagtgaa catccaattc 300
agaagaaaaa caacagtgaa gacattatgt atttatgcag actacaaatc tgatgaaagc 360

tatactccaa gcaagatctc agtcagagta ggaaataatt ttcacaacct tcaagaaatt 420
cggcaacttg agttggtgga accaagtggc tggattcatg ttcccttaac tgacaatcat 480
aagaagccaa ctcgtacatt catgatacag attgctgttc tagccaatca ccagaatgga 540
agagacaccc atatgagaca aattaaaata tacacaccag tagaagagag ctccattggt 600
aaatttccta gatgtacaac tatagatttc atgatgtatc gttcaataag gtgactttaa 660
aatgagacga aaatcattaa acgtatcttt gttttatcct gtatttaaat aatatatcat 720
gtacctttat tgaacaaggc atccgttata tctaattttg tatatgttta aaaatatttt 780
attgtaactt tgacaaataa atttggggtc atattatctt tattttcttt aacatgtaat 840
aaagctcaca tattttacat tactaaaaat ggatttgaag ccaatcattt tatttccct 900
tgtatcaaaa gaaaagagtt ccttgtatca aaagaaaaga gttgaactga aaatttcagt 960
atatacacaa ttataatagc taggtgatta tttcatt 997

<210> 27
<211> 1481
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3255641CB1

<400> 27
ctgatccggt tcttggtgcc cctgggcatc accaacatag ccatcgactt cggggagcag 60
gccttgaacc ggggcattgc tgctgtcaag gaggatgcag tcgagatgct ggccagctac 120
gggctggcgt actcctcat gaagttcttc acgggtccca tgagtgactt caaaaatgtg 180
ggcctggtgt ttgtgaacag caagagagac aggaccaaag ccgtcctgtg tatggtggtg 240
gcaggggcca tcgctgccgt ctttcacaca ctgatagctt atagtgattt aggatactac 300
attatcaata aactgcacca tgtggacgag tcggtgggga gcaagacgag aagggccttc 360
ctgtacctcg ccgcctttcc tttcatggac gcaatggcat ggacccatgc tggcattctc 420
ttaaaacaca aatacagttt cctggtggga tgtgcctcaa tctcagatgt catagctcag 480
gttgtttttg tagccatttt gcttcacagt cacctggaat gccgggagcc cctgctcatc 540
ccgatcctct ccttgtacat gggcgcactt gtgcgctgca ccaccctgtg cctgggctac 600
tacaagaaca ttcacgacat catccctgac agaagtggcc cggagctggg gggagatgca 660
acaataagaa agatgctgag cttctggtgg cctttggctc taatttctggc cacacagaga 720
atcagtcggc ctattgtcaa cctctttgtt tcccgggacc ttggtggcag ttctgcagcc 780
acagaggcag tggcgatttt gacagccaca taccctgtgg gtcacatgcc atacggctgg 840
ttgacggaaa tccgtgctgt gtatcctgct ttcgacaaga ataaccccag caacaaactg 900
gtgagcacga gcaacacagt cacggcagcc cacatcaaga agttcacctt cgtctgcatg 960
gctctgtcac tcacgctctg tttcgtgatg ttttggacac ccaacgtgtc tgagaaaatc 1020
ttgatagaca tcatcggagt ggactttgcc tttgcagaac tctgtgttgt tcctttgcgg 1080
atcttctcct tcttcccagt tccagtcaca gtgagggcgc atctcaccgg gtggctgatg 1140
acactgaaga aaaccttcgt ccttgccccc agctctgtgc tgcggatcat cgtcctcatc 1200
gccagcctcg tggtcctacc ctacctgggg gtgcacggtg cgaccctggg cgtgggctcc 1260
ctcctggcgg gctttgtggg agaatccacc atggtcgcca tcgctgcgtg ctatgtctac 1320
cggaagcaga aaaagaagat ggagaatgag tcggccacgg agggggaaga ctctgccatg 1380
acagacatgc ctccgacaga ggaggtgaca gacatcgtgg aaatgagaga ggagaatgaa 1440
taaggcacgg gacgccatgg gcactgcagg gacagtcagt c 1481

<210> 28
<211> 303
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3620391CB1

<400> 28
tctagagccg ccgcctgccg ggtctggagc gcgccgtccg ccgcggacaa gaccctggcc 60
tcacgccgga gcagccccat catgccgagg gagcgcaggg agcgggatgc gaaggagcgg 120
gacaccatga aggaggacgg cggcgcggag ttctcggctc gctccaggaa gaggaaggca 180
aacgtgaccg ttttttgcag gatccagatg aagaaatggc caaaatcgac aggacggcga 240
tggaccagtg tgggagccag acttgggaga atgatgcagt ctgtgcaggc ccctgctccc 300
tga 303

<210> 29
<211> 1452
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3969860CB1

<400> 29
gcgctctaat gttaccactc tgcatcctgt tctaggcttt tctggctttg tctgcccgga 60
tgcccagtgc cctgagaagg agctacatgc cacgggctgg aggctagagc ctgtggcacc 120
atgatttgcc tccgatggag gtggctgaat taggcttccc agagactgca gtgtcccaat 180
ccaggatctg tctatgtgct gtattgtgtg gccactggga ctttgcagac atgatggtga 240
taaggagcct gagtggacat ggctgcactc ttccaagaag caagcagctg tcccgtctgc 300
tcagactatc tggaaaaacc aatgtccctg gagtgtggat gcgccgtctg cctcaagtgc 360
attaattcac tgcagaagga gccccatggg gaggatctac tttgctgttg ctcttccatg 420
gtctctcgga agaacaaaat caggcgcaat cggcagctag agaggctggc ttcccacatc 480
aaggaactgg agcccaagct gaagaagata ctgcagatga acccaaggat gcggaagttc 540
caagtggata tgaccttgga tgccaacaca gccaacaact tcctcctcat ttctgacgac 600
ctcaggagcg tccgaagtgg gcgcatcaga cagaatcggc aagaccttgc cgagagattt 660
gacgtgtccg tttgcatcct gggctcccct cgctttacct gtggccgcca ctgctgggag 720
gtggacgtgg gaacaagcac agaatgggac ctgggagtct gcagagaatc tgttcaccgc 780
aaagggagga tccagctgac cacagagctt ggattctgga ctgtgagttt gagggatgga 840
ggccgcctct ctgccagcac ggtgccgctg actttcctct tcgtagaccg caagttacag 900
cgagtgggga tttttctgga tatgggcatg cagaacgttt ccttttttga tgctgaaagt 960
ggttcccatg tctatacatt caggagcgta tctgctgagg agccattgcg cccatttttg 1020
gctccttcag ttccacctaa tggtgatcaa ggtgtcttga gcatctgtcc tttgatgaac 1080
tcaggcacta ctgatgctcc agtccgtcct ggggaggcca aataagccct cactccaaaa 1140
aaacaaaaaa cagggtaaga aaattacttg ggtgggtaga cttaggaacg ctctacttcg 1200
taaaagcatt atacaaagtc acgggagaaa aatatgggac atttcttgat tgtacttaat 1260
ctaatttgat tagattatag agtcctaagt attaattatt gccaccatca aactcattga 1320
gtcctatggt tcacatcttg tttcctatag aaatgtcctg tattctggga tcaatttcca 1380
aatgctttac ttttttattt ctgcaagttc aaattaatgt attatagaag ttatgagtta 1440
aatagaagag ta 1452

<210> 30
<211> 495
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 4286006CB1

<400> 30
gtttgtctct caagttaaac caacaagccg atagaaaaag gtagttatca agagattttt 60
aaaacttcaa ccctttttct cttatagtta gtgaagagag tagaatatct ccagttttgg 120
ctgacatctc tacaacctga acaattggct taaacttcac ttgggattcc cggttgcttg 180
ttttagcatg gcgaaatttg gcgttcacag aatccttctt ctggctattt ctctgacaaa 240
gtgtctggag agtacaaaac tgctggcaga ccttaaaaaa tgtggtgact tggaatgtga 300
agctttaata aacagagtct cagccatgag agattataga ggacctgact gccgatacct 360
gaacttcact aagggagaag agatatctgt ttatgttaaa cttgcaggag atagggaaga 420
tttgtgggca ggaagtaaag gaaaggagtt tggatatttt cccagagatg cagtccagat 480
ttgagagggt gtcag 495

<210> 31
<211> 1993
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 4325626CB1

<400> 31
gccgcgtacg gtgtgacctt tagacaattc tgtctcacag gatggacgtg gtagaggtcg 60
cgggcagttg gtgggcacaa gagcgagagg acatcattat gaaatacgaa aagggacacc 120
gagctgggct gccagaggac aaggggccta agccttttcg aagctacaac aacaacgtcg 180
atcatttggg gattgtacat gagacggagc tgcctcctct gactgcgcgg gaggcgaagc 240
aaattcggcg ggagatcagc cgaaagagca agtgggtgga tatgctggga gactgggaga 300
aatacaaaag cagcagaaag ctcatagatc gagcgtacaa gggaatgccc atgaacatcc 360
ggggcccgat gtggtcagtc ctcctgaaca ctgaggaaat gaagttgaaa aaccccggaa 420
gataccagat catgaaggag aagggcaaga ggtcatctga gcacatccag cgcatcgacc 480
gggacgtaag cgggacatta aggaagcata tattcttcag ggatcgatac ggaaccaagc 540
agcgggaact actccacatc ctcctggcat atgaggagta taaccccgag gtgggctact 600
gcagggacct gagccacatc gccgccttgt tcctcctcta tcttcctgag gaggatgcat 660
tctgggcact ggtgcagctg ctggccagtg agaggcactc cctgcaggga tttcacagcc 720
caaatggcgg gaccgtccag gggctccaag accaacagga gcatgtggta gccacgtcac 780
aacccaagac catggggcat caggacaaga aagatctatg tgggcagtgt tccccgttag 840
gctgcctcat ccggatattg attgacggga tctctctcgg gctcacccta cgcctgtggg 900
acgtgtatct ggtagaaggc gaacaggcgt tgatgccgat aacaagaatc gcctttaagg 960
ttcagcagaa gcgcctcacg aagacgtcca ggtgtggccc gtgggcacgt ttttgcaacc 1020
ggttcgttga tacctgggcc agggatgagg acactgtgct caagcatctt agggcctcta 1080
tgaagaaact aacaagaaag cagggggacc tgccaccccc agccaaaccc gagcaagggt 1140
cgtcggcatc caggcctgtg ccggcttcac gtggcgggaa gaccctctgc aagggggaca 1200
ggcaggcccc tccaggccca ccagcccggt tcccgcggcc catttggtca gcttccccgc 1260
cacgggcacc tcgttcttcc acaccctgtc ctggtggggc tgtccgggaa gacacctacc 1320
ctgtgggcac tcagggtgtg cccagcccgg cctggctcta gggaggacct cagggttcct 1380
ggagattcct gcagtggaac tccatgcccc gcctcccaac ggacctggac gtagagggcc 1440
cttggttccg ccattatgat ttcagacaga gctgctgggt ccgtgccata tcccaggagg 1500
accagctggc cccctgctgg caggctgaac accctgcgga gcgggtgaga tcggctttcg 1560
ctgcacccag cactgattcc gaccagggca ccccttcag agctagggac gaacagccgt 1620
gtgctcccac ctcagggcct tgcctctgcg gcctccactt ggaaagttct cagttcctc 1680
caggcttcta gaagcatctg ggccagggct catggctgga taatttccct aggcttaaca 1740

acccaagcaa gttcgcatcc tcgttttatt tttggttaaa cttatgaaaa tgtattaaga 1800
aagagtgcag ctcgagagag attcagagat ggaacacacc agaccccaga tcacaaagcc 1860
aaccatgccc agcccctccc agcaccccca gccccacgac catcgttctg aattctgacg 1920
acaccgtgag cctgcctttg tacttcaaac tcatggaagg ataaccacct tcatgttttg 1980
aaataaatgg gtc 1993

<210> 32
<211> 728
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1438978CB1

<400> 32
aagctcttcc attgggctgt tgagtggtgg ccgaccgacg gccaggagtt tcttttctgc 60
gcttgtgcgt tttctgttcg gtttccttcc cgctagcggg gccacgaggg ttgctaggca 120
acagccctg ggtgacttgg tcttagggtc ctgtccggct tggggctgat gaaaggagct 180
gtccgcgccc gggctcttcc gagaagtggt tgctgacagc cacaaagtga aagggagtga 240
ggcggcgtgg acgagtaagg agtgacagtg aggattcaca tttgggttat ttcaagatga 300
gcttcctact gcccaagctg actagcaaaa aggaagtaga ccaggcgata aaaagtactg 360
ctgagaaggt gttggttctc aggtttggga gagatgaaga tcctgtctgt ctgcagctag 420
atgatattct ttctaagacc tcttctgact taagtaaaat ggctgctata tacctggtag 480
atgtggacca aactgcagtt tatacacagt attttgacat cagttatatt ccatctactg 540
tctttttctt caatgggcag catatgaaag tggattatgg gtaagtgcag ttgatctgaa 600
gttaattgca accttgtaag tttccttggt aagcattttc agtagcttgc ctatttccat 660
gtgatgttgg ctctgtgagt cttatatcag tactgtttcc tcaattgacg cactctctaa 720
tttttttat 728

<210> 33
<211> 1452
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2024773CB1

<400> 33
gtcaggagcg tagaggcggc ggcaaaatgg cggcgcctga ggagcgggat ctaacccagg 60
agcagacaga gaagctgctg cagtttcagg atctcactgg catcgaatct atggatcagt 120
gtcgccatac cttggaacag cataactgga acatagaggc tgctgtacag gacagattga 180
atgagcaaga gggcgtacct agtgttttca acccacctcc atcacgaccc ctgcaggtta 240
atacagctga ccacaggatc tacagctatg ttgtctcaag acctcaacca agggggctgc 300
ttggatgggg ttattacttg ataatgcttc cattccggtt tacctattac acgatacttg 360
atatatttag gtttgctctt cgttttatac ggcctgaccc tcgcagccgg gtcactgacc 420
ccgttgggga cattgtttca tttatgcact cttttgaaga gaaatatggg agggcacacc 480
ctgtcttcta ccagggaacg tacagccagg cacttaacga tgccaaaagg gagcttcgct 540
ttcttttggt ttatcttcat ggagatgatc accaggactc tgatgagttt tgtcgcaaca 600
cactctgtgc acctgaagtt atttcactaa taaacactag gatgctcttc tgggcatgct 660
ctacaaacaa acctgaggga tacagggtct cacaggcttt acgagagaac acctatccat 720
tcctggccat gattatgctg aaggatcgaa ggatgactgt ggtgggacgg ctagaaggcc 780

tcattcaacc tgatgacctc attaaccaac tgacatttat catggatgct aaccagactt 840
acctggtgtc agaacgccta gaaagggaag aaagaaacca gacccaagtg ctgagacaac 900
agcaggatga ggcctacctg gcctctctca gagctgacca ggagaaagaa agaaagaaac 960
gggaggagcg ggagcgtaag cggcggaagg aggaggaggt gcaacagcaa aagttggcag 1020
aggagagacg gcggcagaat ttacaggagg aaaaggaaag gaagttggaa tgcctgcccc 1080
ctgaaccttc ccctgatgac cctgaaagtg tcaagatcat cttcaaatta cctaatgatt 1140
ctcgagtaga gagacgattc cacttttcac agtctctaac agtaatccac gacttcttat 1200
tctccttgaa ggaaagccca gaaaagtttc agattgaagc caatttccc aggcgagtgc 1260
tgccctgcat cccttcagag gagtggccca atcccctac gctacaggag gccggactca 1320
gccacacaga agttcttttt gttcaggacc taactgacga atgacatttt tttcttcctg 1380
tcccctccta ccccagtccc taaaagaaat ggggaaaaaa gaaaacaaca gcaagtcaaa 1440
aaaaaaaaaa aa 1452

<210> 34
<211> 1229
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3869790CB1

<400> 34
ccaggcttga ctcattccca ccttgtcctg ggctgagatc ccaggtttgt aacagaaaac 60
accactaaag ccccagcaca ggagagaacc acccagccca gaagttccag ggaaggaact 120
ctccggtcca ccatggagta cctctcagct ctgaacccca gtgacttact caggtcagta 180
tctaatataa gctcggagtt tggacggagg gtctggacct cagctccacc accccagcga 240
cctttccgtg tctgtgatca caagcggacc atccggaaag gcctgacagc tgccacccgc 300
caggagctgc tagccaaagc attggagacc ctactgctga atggagtgct aaccctggtg 360
ctagaggagg atggaactgc agtggacagt gaggacttct tccagctgct ggaggatgac 420
acgtgcctga tggtgttgca gtctggtcag agctggagcc ctacaaggag tggagtgctg 480
tcatatggcc tgggacggga gaggcccaag cacagcaagg acatcgcccg attcaccttt 540
gacgtgtaca agcaaaaccc tcgagacctc tttggcagcc tgaatgtcaa agccacattc 600
tacgggctct actctatgag ttgtgacttt caaggacttg gcccaaagaa agtactcagg 660
gagctccttc gttggacctc cacactgctg caaggcctgg gccatatgtt gctgggaatt 720
tcctccaccc ttcgtcatgc agtggagggg gctgagcagt ggcagcagaa gggccgcctc 780
cattcctact aaggggctct gagcttctgc ccccagaatc attccaaccg acccactgca 840
aagactatga cagcatcaaa tttcaggacc tgcagacagt acaggctaga taacccaccc 900
aatttcccca ctgtcctctg atcccctcgt gacagaacct ttcagcataa cgcctcacat 960
cccaagtcta tacccttacc tgaagaatgc tgttctttcc tagccacctt tctagcctcc 1020
cacttgccct gaaaggccaa gatcaagatg tcccccaggc atcttgatcc cagcctgact 1080
gctgctacat ctaatcccct accaatgcct cctgtcccta aactccccag catactgatg 1140
acagccctct ctgactttac cttgagatct gtcttcatac ccttccccta aaactaacaa 1200
aaacatttcc aataaaaata tcagaatac 1229

<210> 35
<211> 1455
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 001273CB1

<400> 35
tggaatcgcg ggcaaagatg gcggcggcca ggtgttggag gcctttgcta cgcggtccga 60
ggctttcatt gcacaccgcg gctaatgccg ccgccacggc tacagaaacg acctgccaag 120
acgtcgcggc gaccccgtc gcgcggtacc cgccgattgt ggcctccatg acagccgaca 180
gcaaagctgc acggctgcgg cggatcgagc gctggcaggc gacggtgcac gctgcggagt 240
cggtagacga gaagctgcga atcctcacca agatgcagtt tatgaagtac atggtttacc 300
cgcagacctt cgcgctgaat gccgaccgct ggtaccagta cttcaccaag accgtgttcc 360
tgtcgggtct gccgccgcgc cccagcgagc ccgagcccga gcccgaaccc gaacctgaac 420
ctgcgctgga cctcgcggcg ctgcgtgcgg tcgcctgcga ctgcctgctg caggagcact 480
tctacctgcg gcgcaggcgg cgcgtgcacc gttacgagga gagcgaggtc atatctttgc 540
ccttcctgga tcagctggtg tcaaccctcg tgggcctcct cagcccacac aaccggccc 600
tggccgctgc cgccctcgat tatagatgcc cagttcattt ttactgggtg cgtggtgaag 660
aaattattcc tcgtggtcat cgaagaggtc gaattgatga cttgcgatac cagatagatg 720
ataaaccaaa caaccagatt cgaatatcca agcaactcgc agagtttgtg ccattggatt 780
attctgttcc tatagaaatc cccactataa aatgtaaacc agacaaactt ccattattca 840
aacggcagta tgaaaaccac atatttgttg gctcaaaaac tgcagatcct tgctgttacg 900
gtcacaccca gtttcatctg ttacctgaca aattaagaag ggaaaggctt ttgagacaaa 960
actgtgctga tcagatagaa gttgttttta gagctaatgc tattgcaagc ctttttgctt 1020
ggactggagc acaagctatg tatcaaggat tctggagtga agcagatgtt actcgacctt 1080
ttgtctccca ggctgtgatc acagatggaa aatacttttc ctttttctgc taccagctaa 1140
atactttggc actgactaca caagctgatc aaaataaccc tcgtaaaaat atatgttggg 1200
gtacacaaag taagcctctt tatgaaacaa ttgaggataa tgatgtgaaa ggttttaatg 1260
atgatgttct acttcagata gttcactttc tactgaatag accaaaagaa gaaaaatcac 1320
agctgttgga aaactgaaaa agcatatttg attgagaact gtgggaatat ttaaatttta 1380
ctgaaggaac aataatgatg agatttgtaa ctgtcaacta ttaaatacat tgatttttga 1440
gacaaaaaaa aaaaa 1455

<210> 36
<211> 2099
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 411831CB1

<400> 36
gaacgctggt tagtcttgtt tcgggttccg gctgcgttgg gcttgcgtgc ggctcgctaa 60
gactatggcg tccgggcctc attcgacagc tactgctgcc gcagccgcct catcggccgc 120
cccaagcgcg ggcggctcca gctccgggac gacgaccacg acgacgacca cgacgggagg 180
gatcctgatc ggcgatcgcc tgtactcgga agtttcactt accatcgacc actctctgat 240
tccggaggag aggctctcgc ccacccatc catgcaggat gggctcgacc tgcccagtga 300
gacggactta cgcatcctgg gctgcgagct catccaggcc gccggcattc tcctccggct 360
gccgcaggtg gcgatggcaa cggggcaggt gttgttttcat cgttttttct actccaaatc 420
tttcgtcaaa cacagtttcg agattgttgc tatggcttgt attaatcttg catcaaaaat 480
cgaagaagca cctagaagaa taagagatgt gattaatgta ttccaccacc tccgccagtt 540
aagaggaaaa aggactccaa gccccctgat ccttgatcag aactacatta acaccaaaaa 600
tcaagttatc aaagcagaga ggagggtgct aaaggagttg ggatttttgtg ttcatgtcaa 660
gcatcctcat aagatcattg ttatgtattt acaagtctta gaatgtgaac gtaatcaaac 720
cctggttcaa actgcctgga attacatgaa tgacagtctt cgaaccaatg tgtttgttcg 780
atttcaacca gagactatag catgtgcttg catctacctt gcagctagag cacttcagat 840
tccgttgcca actcgtcccc attggtttct tctttttggt aactacagaag aggaaatcca 900
ggaaatctgc atagaaacac ttaggcttta taccagaaaa aagccaaact atgaattact 960
ggaaaaagaa gtagaaaaaa gaaaagtagc cttacaagaa gccaaattaa aagcaaaggg 1020

attgaatccg gatggaactc cagcccttc aaccctgggt ggatttctc cagcctccaa 1080
gccatcatca ccaagagaag taaaagctga agagaaatca ccaatctcca ttaatgtgaa 1140
gacagtcaaa aaagaacctg aggatagaca acaggcttcc aaaagccctt acaatggtgt 1200
aagaaaagac agcaagagaa gtagaaatag cagaagtgca agtcgatcga ggtcaagaac 1260
acgatcacgt tctagatcac atactccaag aagacactat aataataggc ggagtcgatc 1320
tggaacatac agctcgagat caagaagcag gtcccgcagt cacagtgaaa gccctcgaag 1380
acatcataat catggttctc ctcaccttaa ggccaagcat accagagatg atttaaaaag 1440
ttcaaacaga catggtcata aaaggaaaaa atctcgttct cgatctcaga gcaagtctcg 1500
ggatcactca gatgcagcca agaaacacag gcatgaaagg ggacatcata gggacaggcg 1560
tgaacgatct cgctcctttg agaggtccca taaaagcaag caccatggtg gcagtcgctc 1620
aggacatggc aggcacaggc gctgactttc tcttcctttg agcctgcatc agttcttggt 1680
tttgcctatc tacagtgtga tgtatggact caatcaaaaa cattaaacgc aaactgatta 1740
ggatttgatt tcttgaaacc ctctaggtct ctagaacact gaggacagtt tcttttgaaa 1800
agaactatgt taatttttt gcacattaaa atgccctagc agtatctaat taaaaaccat 1860
ggtcaggttc aattgtactt tattatagtt gtgtattgtt tattgctata agaactggag 1920
cgtgaattct gtaaaaatgt atcttatttt tatacagata aaattgcaga cactgttcta 1980
tttaagtggt tatttgttta aatgatggtg aatactttct taacactggt ttgtctgcat 2040
gtgtaaagat ttttacaagg aaataaaata caaatcttgt tttttctaaa aaaaaaaaa 2099

<210> 37
<211> 1363
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1520835CB1

<400> 37
gaccccagag gccaccctgg ccacttccag aaagctgtgg gccctgggat actcccctcc 60
cagggtgtct ggtggcaggc ctgtgcctat ccctgctgtc cccagggtgg gccccggggg 120
tcaggagctc cagaagggcc agctgggcat attctgagat tggccatcag cccccatttc 180
tgctgcaaac ctggtcagag ccagtgttcc ctccatgggg cctaaagaca gtgccaagtg 240
cctgcaccgt ggaccacagc cgagccactg ggcagccggt gatggtccca cgcaggagcg 300
ctgtggaccc cgctctctgg gcagccctgt cctaggccctg gacacctgca gagcctggga 360
ccacgtggat gggcagatcc tgggccagct gcggcccctg acagaggagg aagaggagga 420
gggcgccggg gccaccttgt ccaggggccc tgccttcccc ggcatgggct ctgaggagtt 480
gcgtctggcc tccttctatg actggccgct gactgctgag gtgccacccg agctgctggc 540
tgctgccggc ttcttccaca caggccatca ggacaaggtg aggtgcttct tctgctatgg 600
gggcctgcag agctggaagc gcggggacga ccccctggacg gagcatgcca agtggttccc 660
cagctgtcag ttcctgctcc ggtcaaaagg aagagacttt gtccacagtg tgcaggagac 720
tcactcccag ctgctgggct cctgggaccc gtgggaagaa ccggaagacg cagcccctgt 780
ggcccctcc gtccctgcct ctgggtaccc tgagctgccc acacccagga gagaggtcca 840
gtctgaaagt gcccaggagc caggaggggt cagtccagcc gaggcccaga gggcgtggtg 900
ggttcttgag ccccaggag ccagggatgt ggaggcgcag ctgcggcggc tgcaggagga 960
gaggacgtgc aaggtgtgcc tggaccgcgc cgtgtccatc gtctttgtgc cgtgcggcca 1020
cctggtctgt gctgagtgtg ccccggcct gcagctgtgc ccatctgca gagccccgt 1080
ccgcagccgc gtgcgcacct tcctgtccta ggccaggtgc catggccggc caggtgggct 1140
gcagagtggg ctcccctgcc ctctctgcct gttctggact gtgttctggg cctgctgagg 1200
atggcagagc tggtgtccat ccagcactga ccagccctga ttccccgacc accgcccagg 1260
gtggagaagg aggcccttgc ttggcgtggg ggatggctta actgtacctg tttggatgct 1320
tctgaataga aataaagtgg gttttccctg gaaaaaaaaa aaa 1363

<210> 38
<211> 1465
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1902803CB1

<400> 38
gggttaaata caaagcaagg agaatgaaaa ggacccctcc tctgaaatac agcaccggcc 60
tcagcatgga ggcaaaagga cagtgggcaa gaccacgtcc ctccgaaggg agatggctgc 120
ggggatgtat ttggaacatt atctggacag tattgaaaac cttccctttg aattacagag 180
aaactttcag ctcatgaggg acctagacca aagaacagag gacctgaagg ctgaaattga 240
caagttggcc actgagtata tgagtagtgc ccgcagcctg agctccgagg aaaaattggc 300
ccttctcaaa cagatccagg aagcctatgg caagtgcaag gaattttggtg acgacaaggt 360
gcagcttgcc atgcagacct atgagatggt ggacaaacac attcggcggc tggacacaga 420
cctggcccgt tttgaggctg atctcaagga gaaacagatt gagtcaagtg actatgacag 480
ctctttccagc aaaggcaaaa agaaaggccg gactcaaaag gagaagaaag ctgctcgtgc 540
tcgttccaaa gggaaaaact cggatgaaga agcccccaag actgcccaga agaagttaaa 600
gctcgtgcgc acaagtcctg agtatgggat gccctcagtg accttggca gtgtccaccc 660
ctctgatgtg ttggatatgc ctgtggatcc caacgaaccc acctattgcc tttgtcacca 720
ggtctcctat ggagagatga ttggctgtga caaccctgat tgttccattg agtggttcca 780
ttttgcctgt gtgggctga caaccaagcc tcgggggaaa tggttttgcc cacgctgctc 840
ccaagaacgg aagaagaaat agataagggc cttggattcc aacacagttt cttccacatc 900
ccctgacttg ggctagtggg cagaggaatg cctgtgctgg ggccaggggt tcagggagga 960
gtggatggca cagtgctgtc atcccttctc ctcccctctc cccactcccg gtgctgaggc 1020
tgcatcagac cctggtaggg aggggtgccg cagccactaa cggtatgtgc tctccttcag 1080
ccctctccct tcggagggac gtggtcttgc ccactgtcct tttgcctcca tgctgaggtc 1140
ggtgctgtat ttcagaggga gggtcctttt cattctcctt gctttgtatt taaggactgg 1200
ggcatagcat gggggcagtc ccccagacct cttcattccc cctcctgtgg tgagggctag 1260
gtgtgatcaa cacttttctt ctccattccc ttcctgcttt tttcatggtg ggggatccac 1320
caggtcatct aggctctggc cctagttgaa ggggcacccc ttcctctgtg ccaagaggat 1380
tcatcctggg agaggggca aggtggaatg cagataactc acatgtaaaa ggaacttggg 1440
taggtaaata aaagctatac atgtt 1465

<210> 39
<211> 332
<212> PRT
<213> Mus musculus

<300>
<308> GenBank ID No: g452276

<400> 39
Met Ala Thr Pro Val Pro Pro Pro Ser Pro Arg His Leu Arg Leu
1 5 10 15
Leu Arg Leu Leu Leu Ser Gly Leu Ile Leu Gly Ala Ala Leu Asn
20 25 30
Gly Ala Thr Ala Arg Arg Pro Asp Ala Thr Thr Cys Pro Gly Ser

```
                 35                  40                  45
Leu Asp Cys Ala Leu Lys Arg Arg Ala Lys Cys Pro Pro Gly Ala
                 50                  55                  60
His Ala Cys Gly Pro Cys Leu Gln Ser Phe Gln Glu Asp Gln Arg
                 65                  70                  75
Gly Phe Cys Val Pro Arg Lys His Leu Ser Ser Gly Glu Gly Leu
                 80                  85                  90
Pro Gln Pro Arg Leu Glu Glu Glu Ile Asp Ser Leu Ala Gln Glu
                 95                 100                 105
Leu Ala Leu Lys Glu Lys Glu Ala Gly His Ser Arg Leu Thr Ala
                110                 115                 120
Gln Pro Leu Leu Glu Arg Ala Gln Lys Leu Leu Glu Pro Ala Ala
                125                 130                 135
Thr Leu Gly Phe Ser Gln Trp Gly Gln Arg Leu Glu Pro Gly Leu
                140                 145                 150
Pro Ser Thr His Gly Thr Ser Ser Pro Ile Pro His Thr Ser Leu
                155                 160                 165
Ser Ser Arg Ala Ser Ser Gly Pro Val Gln Met Ser Pro Leu Glu
                170                 175                 180
Pro Gln Gly Arg His Gly Asn Gly Leu Thr Leu Val Leu Ile Leu
                185                 190                 195
Ala Phe Cys Leu Ala Ser Ser Ala Ala Leu Ala Val Ala Ala Leu
                200                 205                 210
Cys Trp Cys Arg Leu Gln Arg Glu Ile Arg Leu Thr Gln Lys Ala
                215                 220                 225
Asp Tyr Ala Ala Thr Ala Lys Gly Pro Thr Ser Pro Ser Thr Pro
                230                 235                 240
Arg Ile Ser Pro Gly Asp Gln Arg Leu Ala His Ser Ala Glu Met
                245                 250                 255
Tyr His Tyr Gln His Gln Arg Gln Gln Met Leu Cys Leu Glu Arg
                260                 265                 270
His Lys Glu Pro Pro Lys Glu Leu Glu Ser Ala Ser Ser Asp Glu
                275                 280                 285
Glu Asn Glu Asp Gly Asp Phe Thr Val Tyr Glu Cys Pro Gly Leu
                290                 295                 300
Ala Pro Thr Gly Glu Met Glu Val Arg Asn Pro Leu Phe Asp His
                305                 310                 315

Ser Thr Leu Ser Ala Pro Val Pro Gly Pro His Ser Leu Pro Pro
                320                 325                 330
Leu Gln


<210> 40
<211> 268
<212> PRT
<213> Homo sapiens


<300>
<308> GenBank ID No: g998357

<400> 40
Met Ala Val Asn Val Tyr Ser Thr Ser Val Thr Ser Asp Asn Leu
  1               5                  10                  15
```

```
Ser Arg His Asp Met Leu Ala Trp Ile Asn Glu Ser Leu Gln Leu
                  20                  25                  30
Asn Leu Thr Lys Ile Glu Gln Leu Cys Ser Gly Ala Ala Tyr Cys
                  35                  40                  45
Gln Phe Met Asp Met Leu Phe Pro Gly Ser Ile Ala Leu Lys Lys
                  50                  55                  60
Val Lys Phe Gln Ala Lys Leu Glu His Glu Tyr Ile Gln Asn Phe
                  65                  70                  75
Lys Ile Leu Gln Ala Gly Phe Lys Arg Met Gly Val Asp Lys Ile
                  80                  85                  90
Ile Pro Val Asp Lys Leu Val Lys Gly Lys Phe Gln Asp Asn Phe
                  95                 100                 105
Glu Phe Val Gln Trp Phe Lys Lys Phe Phe Asp Ala Asn Tyr Asp
                 110                 115                 120
Gly Lys Asp Tyr Asp Pro Val Ala Ala Arg Gln Gly Gln Glu Thr
                 125                 130                 135
Ala Val Ala Pro Ser Leu Val Ala Pro Ala Leu Asn Lys Pro Lys
                 140                 145                 150
Lys Pro Leu Thr Ser Ser Ser Ala Ala Pro Gln Arg Pro Ile Ser
                 155                 160                 165
Thr Gln Arg Thr Ala Ala Ala Pro Lys Ala Gly Pro Gly Val Val
                 170                 175                 180
Arg Lys Asn Pro Gly Val Gly Asn Gly Asp Asp Glu Ala Ala Glu
                 185                 190                 195
Leu Met Gln Gln Val Asn Val Leu Lys Leu Thr Val Glu Asp Leu
                 200                 205                 210
Glu Lys Glu Arg Asp Phe Tyr Phe Gly Lys Leu Arg Asn Ile Glu
                 215                 220                 225
Leu Ile Cys Gln Glu Asn Glu Gly Glu Asn Asp Pro Val Leu Gln
                 230                 235                 240
Arg Ile Val Asp Ile Leu Tyr Ala Thr Asp Glu Gly Phe Val Ile
                 245                 250                 255
Pro Asp Glu Gly Gly Pro Gln Glu Glu Gln Glu Glu Tyr
                 260                 265
```

<210> 41
<211> 418
<212> PRT
<213> Mus musculus

<300>
<308> GenBank ID No: g455719

<400> 41

```
Met Gly Glu Asp Ala Ala Gln Ala Glu Lys Phe Gln His Pro Asn
  1               5                  10                  15
Thr Asp Met Leu Gln Glu Lys Pro Ser Ser Pro Ser Pro Met Pro
                 20                  25                  30
Ser Ser Thr Pro Ser Pro Ser Leu Asn Leu Gly Ser Thr Glu Glu
                 35                  40                  45
Ala Ile Arg Asp Asn Ser Gln Val Asn Ala Val Thr Val His Thr
                 50                  55                  60
```

```
Leu Leu Asp Lys Leu Val Asn Met Leu Asp Ala Val Arg Glu Asn
                65                  70                  75
Gln His Asn Met Glu Gln Arg Gln Ile Asn Leu Glu Gly Ser Val
                80                  85                  90
Lys Gly Ile Gln Asn Asp Leu Thr Lys Leu Ser Lys Tyr Gln Ala
                95                 100                 105
Ser Thr Ser Asn Thr Val Ser Lys Leu Leu Glu Lys Ser Arg Lys
               110                 115                 120
Val Ser Ala His Thr Arg Ala Val Arg Glu Arg Leu Glu Arg Gln
               125                 130                 135
Cys Val Gln Val Lys Arg Leu Glu Asn Asn His Ala Gln Leu Leu
               140                 145                 150
Arg Arg Asn His Phe Lys Val Leu Ile Phe Gln Glu Glu Ser Glu
               155                 160                 165
Ile Pro Ala Ser Val Phe Val Lys Glu Pro Val Pro Ser Ala Ala
               170                 175                 180
Glu Gly Lys Glu Glu Leu Ala Asp Glu Asn Lys Ser Leu Glu Glu
               185                 190                 195
Thr Leu His Asn Val Asp Leu Ser Ser Asp Asp Glu Leu Pro Arg
               200                 205                 210
Asp Glu Glu Ala Leu Glu Asp Ser Ala Glu Glu Lys Met Glu Glu
               215                 220                 225
Ser Arg Ala Glu Lys Ile Lys Arg Ser Ser Leu Lys Lys Val Asp
               230                 235                 240
Ser Leu Lys Lys Ala Phe Ser Arg Gln Asn Ile Glu Lys Lys Met
               245                 250                 255
Asn Lys Leu Gly Thr Lys Ile Val Ser Val Glu Arg Arg Glu Lys
               260                 265                 270
Ile Lys Lys Ser Leu Thr Pro Asn His Gln Lys Ala Ser Ser Gly
               275                 280                 285
Lys Ser Ser Pro Phe Lys Val Ser Pro Leu Ser Phe Gly Arg Lys
               290                 295                 300
Lys Val Arg Glu Gly Glu Ser Ser Val Glu Asn Glu Thr Lys Leu
               305                 310                 315
Glu Asp Gln Met Gln Glu Asp Arg Glu Glu Gly Ser Phe Thr Glu
               320                 325                 330
Gly Leu Ser Glu Ala Ser Leu Pro Ser Gly Leu Met Glu Gly Ser
               335                 340                 345
Ala Glu Asp Ala Glu Lys Ser Ala Arg Arg Gly Asn Asn Ser Ala
               350                 355                 360
Val Gly Ser Asn Ala Asp Leu Thr Ile Glu Glu Asp Glu Glu Glu
               365                 370                 375
Glu Pro Val Ala Leu Gln Gln Ala Gln Gln Val Arg Tyr Glu Ser
               380                 385                 390
Gly Tyr Met Leu Asn Ser Glu Glu Met Glu Glu Pro Ser Glu Lys
               395                 400                 405
Gln Val Gln Pro Ala Val Leu His Val Asp Gln Thr Ala
               410                 415
```

<210> 42
<211> 142
<212> PRT
<213> Homo sapiens

<300>
<308> GenBank ID No: g2565275

<400> 42
Met Ser Tyr Met Leu Pro His Leu His Asn Gly Trp Gln Val Asp
1 5 10 15
Gln Ala Ile Leu Ser Glu Glu Asp Arg Val Val Val Ile Arg Phe
20 25 30
Gly His Asp Trp Asp Pro Thr Cys Met Lys Met Asp Glu Val Leu
35 40 45
Tyr Ser Ile Ala Glu Lys Val Lys Asn Phe Ala Val Ile Tyr Leu
50 55 60
Val Asp Ile Thr Glu Val Pro Asp Phe Asn Lys Met Tyr Glu Leu
65 70 75
Tyr Asp Pro Cys Thr Val Met Phe Phe Phe Arg Asn Lys His Ile
80 85 90
Met Ile Asp Leu Gly Thr Gly Asn Asn Asn Lys Ile Asn Trp Ala
95 100 105
Met Glu Asp Lys Gln Glu Met Val Asp Ile Ile Glu Thr Val Tyr
110 115 120
Arg Gly Ala Arg Lys Gly Arg Gly Leu Val Val Ser Pro Lys Asp
125 130 135
Tyr Ser Thr Lys Tyr Arg Tyr
140

<210> 43
<211> 464
<212> PRT
<213> Drosophila melanogaster

<300>
<308> GenBank ID NO: g3688609

<400> 43
Met Glu Ala Asp Gly Leu Thr Asn Glu Gln Thr Glu Lys Val Leu
1 5 10 15
Gln Phe Gln Asp Leu Thr Gly Ile Glu Asp Met Asn Val Cys Arg
20 25 30
Asp Val Leu Ile Arg His Gln Trp Asp Leu Glu Val Ala Phe Gln
35 40 45
Glu Gln Leu Asn Ile Arg Glu Gly Arg Pro Thr Met Phe Ala Ala
50 55 60
Ser Thr Asp Val Arg Ala Pro Ala Val Leu Asn Asp Arg Phe Leu
65 70 75
Gln Gln Val Phe Ser Ala Asn Met Pro Gly Gly Arg Thr Val Ser
80 85 90
Arg Val Pro Ser Gly Pro Val Pro Arg Ser Phe Thr Gly Ile Ile
95 100 105
Gly Tyr Val Ile Asn Phe Val Phe Gln Tyr Phe Tyr Ser Thr Leu
110 115 120
Thr Ser Ile Val Ser Ala Phe Val Asn Leu Gly Gly Gly Asn Glu
125 130 135

```
Ala Arg Leu Val Thr Asp Pro Leu Gly Asp Val Met Lys Phe Ile
                140                 145                 150
Arg Glu Tyr Tyr Glu Arg Tyr Pro Glu His Pro Val Phe Tyr Gln
                155                 160                 165
Gly Thr Tyr Ala Gln Ala Leu Asn Asp Ala Lys Gln Glu Leu Arg
                170                 175                 180
Phe Leu Ile Val Tyr Leu His Lys Asp Pro Ala Lys Asn Pro Asp
                185                 190                 195
Val Glu Ser Phe Cys Arg Asn Thr Leu Ser Ala Arg Ser Val Ile
                200                 205                 210
Asp Tyr Ile Asn Thr His Thr Leu Leu Trp Gly Cys Asp Val Ala
                215                 220                 225
Thr Pro Glu Gly Tyr Arg Val Met Gln Ser Ile Thr Val Arg Ser
                230                 235                 240
Tyr Pro Thr Met Val Met Ile Ser Leu Arg Ala Asn Arg Met Met
                245                 250                 255
Ile Val Gly Arg Phe Glu Gly Asp Cys Thr Pro Glu Glu Leu Leu
                260                 265                 270
Arg Arg Leu Gln Ser Val Thr Asn Ala Asn Glu Val Trp Leu Ser
                275                 280                 285
Gln Ala Arg Ala Asp Arg Leu Glu Arg Asn Phe Thr Gln Thr Leu
                290                 295                 300
Arg Arg Gln Gln Asp Glu Ala Tyr Glu Gln Ser Leu Leu Ala Asp
                305                 310                 315
Glu Glu Lys Glu Arg Gln Arg Gln Arg Glu Arg Asp Ala Val Arg
                320                 325                 330
Gln Ala Glu Glu Ala Val Glu Gln Ala Arg Arg Asp Val Glu Leu
                335                 340                 345
Arg Lys Glu Glu Ile Ala Arg Gln Lys Ile Glu Leu Ala Thr Leu
                350                 355                 360

Val Pro Ser Glu Pro Ala Ala Asp Ala Val Gly Ala Ile Ala Val
                365                 370                 375
Val Phe Lys Leu Pro Ser Gly Thr Arg Leu Glu Arg Arg Phe Asn
                380                 385                 390
Gln Thr Asp Ser Val Leu Asp Val Tyr His Tyr Leu Phe Cys His
                395                 400                 405
Pro Asp Ser Pro Asp Glu Phe Glu Ile Thr Thr Asn Phe Pro Lys
                410                 415                 420
Arg Val Leu Phe Ser Lys Ala Asn Leu Asp Ala Ala Gly Glu Thr
                425                 430                 435
Gly Thr Ala Lys Glu Thr Leu Thr Lys Thr Leu Gln Ala Val Gly
                440                 445                 450
Leu Lys Asn Arg Glu Leu Leu Phe Val Asn Asp Leu Glu Ala
                455                 460
```

<210> 44
<211> 219
<212> PRT
<213> Mus musculus

<300>
<308> GenBank ID No: g3114594

<400> 44

```
Met Glu Tyr Leu Ser Ala Phe Asn Pro Asn Gly Leu Leu Arg Ser
 1               5                  10                  15
Val Ser Thr Val Ser Ser Glu Leu Ser Arg Arg Val Trp Asn Ser
            20                  25                  30
Ala Pro Pro Pro Gln Arg Pro Phe Arg Val Cys Asp His Lys Arg
        35                  40                  45
Thr Val Arg Lys Gly Leu Thr Ala Ala Ser Leu Gln Glu Leu Leu
    50                  55                  60
Asp Lys Val Leu Glu Thr Leu Leu Leu Arg Gly Val Leu Thr Leu
65                  70                  75
Val Leu Glu Glu Asp Gly Thr Ala Val Asp Ser Glu Asp Phe Phe
                80                  85                  90
Gln Leu Leu Glu Asp Asp Thr Cys Leu Met Val Leu Glu Gln Gly
            95                  100                 105
Gln Ser Trp Ser Pro Lys Ser Gly Met Leu Ser Tyr Gly Leu Gly
        110                 115                 120
Arg Glu Lys Pro Lys His Ser Lys Asp Ile Ala Arg Ile Thr Phe
    125                 130                 135
Asp Val Tyr Lys Gln Asn Pro Arg Asp Leu Phe Gly Ser Leu Asn
140                 145                 150
Val Lys Ala Thr Phe Tyr Gly Leu Tyr Ser Met Ser Cys Asp Phe
155                 160                 165
Gln Gly Val Gly Pro Lys Arg Val Leu Arg Glu Leu Leu Arg Gly
            170                 175                 180
Thr Ser Ser Gln Leu Gln Gly Leu Gly His Met Leu Leu Gly Ile
        185                 190                 195
Ser Ser Thr Leu Arg His Val Val Glu Gly Ala Asp Arg Trp Gln
    200                 205                 210
Trp His Gly Gln Arg His Leu His Ser
215
```